Digitale Bibliotheek
Sluiten Bladeren door artikelen uit een tijdschrift
 
Zoeken naar met titel:
ABCDEFGHIJKLMNOPQRSTUVWXYZ

 
   volgende >>
     Tijdschrift beschrijving
       Alle jaargangen van het bijbehorende tijdschrift
         Alle afleveringen van het bijbehorende jaargang
                                       Alle artikelen van de bijbehorende aflevering
 
                             2104 gevonden resultaten
nr titel auteur tijdschrift jaar jaarg. afl. pagina('s) type
1 A Bayesian Dynamic Model of Asthma in the Real Life Amzal, B.
 2013
 16 7 p. A594-A595
nvt p.
 artikel
2 A Bayesian Multiple Treatment Comparison of Duloxetine, Pregabalin, Gabapentin, Amitriptyline, and Their Combinations for Painful Peripheral Neuropathy Based on Pain Reduction Reported in Clinical Trails Chinthammit, C.
 2013
 16 7 p. A432-A433
nvt p.
 artikel
3 Abiraterone Acetate Versus Enzalutamide for Metastatic Castration-Resistant Prostate Cancer Post Chemotherapy: Cost Effectiveness Analysis He, J.
 2013
 16 7 p. A411-
1 p.
 artikel
4 Abiraterone and Enzalutamide for the Treatment of Metastatic Castration-Resistant Prostate Cancer (mCRPC) Post Chemotherapy: An Indirect Comparison and Budget Impact Analysis Li, T.
 2013
 16 7 p. A394-
1 p.
 artikel
5 A Budgetary Impact Analysis Model for Everolimus in the Treatment of ER+ HER2- Metastatic Breast Cancer in England and Wales Taylor, M.
 2013
 16 7 p. A399-
1 p.
 artikel
6 A Budget Impact Analysis (BIA) of Transcatheter Aortic Valve Implantation (TAVI) in High-Risk Patients with Syntomatic Severe Valve Stenosis (SSVS) Under the Brazilian Public Health Care System (SUS) Perspective Paladini, L.
 2013
 16 7 p. A704-
1 p.
 artikel
7 A Budget Impact Analysis to Estimate the Economic Impact of Drug Eluting Balloon for the Treatment of Peripheral Vascular Disease Corbo, M.
 2013
 16 7 p. A518-A519
nvt p.
 artikel
8 A Budget Impact and Cost-Effectiveness Analysis of Blood Glucose Monitoring System in One Italian Region Colombo, G.L.
 2013
 16 7 p. A439-
1 p.
 artikel
9 A Budget Impact Model for Novoseven for the Management of Bleeding Episodes in Patients with Haemophilia a Treated with Inhibitors Kaskens, L.
 2013
 16 7 p. A379-
1 p.
 artikel
10 A Case Study of FDA Practices and Its Influence on Regulatory and Reimbursement Decisions for Darunavir Rubinstein, J.
 2013
 16 7 p. A365-
1 p.
 artikel
11 Acceptability of Indirect Evidence to Support Drug Reimbursement in Australia O’Leary, B.A.
 2013
 16 7 p. A469-A470
nvt p.
 artikel
12 Acceptance of Surrogate Endpoints by HTA Agencies in Europe Es-Skali, I.J.
 2013
 16 7 p. A484-
1 p.
 artikel
13 Accessibility of Orphan Drugs in France, United Kingdom and Germany: Different Approaches with Regard to HTA and Prices Grandfils, N.
 2013
 16 7 p. A457-
1 p.
 artikel
14 Accessing the Pharmaceutical Markets of Brazil, Russia, India and China Faria-Billinton, E.C.
 2013
 16 7 p. A476-
1 p.
 artikel
15 Access to Medicines Index: Measuring How Well Countries Provide Access to Medicines Shankar, R.
 2013
 16 7 p. A681-A682
nvt p.
 artikel
16 A Choice of Business for the Pharmaceutical Industry “Seguro Popular” in Mexico Vilchis, S.
 2013
 16 7 p. A492-
1 p.
 artikel
17 A Community-Based, Case-Control Study Evaluating Mortality Reduction from Gastric Cancer by Endoscopic Screening in Japan Hamashima, C.
 2013
 16 7 p. A395-
1 p.
 artikel
18 A Comparative Study of the Role of Disease Severity in Drug Reimbursement Decision Making in Belgium, France, the Netherlands and Sweden Franken, M.
 2013
 16 7 p. A474-
1 p.
 artikel
19 A Comparative Study on the Cost of Antibiotics for the Years 2011-2012 in Three General Hospitals of Greece Gkogkozotou, V.K.
 2013
 16 7 p. A351-
1 p.
 artikel
20 A Comparison of Coverage and Reimbursement Decisions in Germany (AMNOG) and Scotland (SMC) Charokopou, M.
 2013
 16 7 p. A475-A476
nvt p.
 artikel
21 A Comparison of Demographic and Clinical Variables of Down Syndrome Patients in Utah and the United States Jiao, T.
 2013
 16 7 p. A629-A630
nvt p.
 artikel
22 A Comparison of German Benefit Assessments by G-Ba, IQWiG and Manufacturers Eheberg, D.
 2013
 16 7 p. A484-
1 p.
 artikel
23 A Comparison of Methodologies for Estimating Survival in Patients Treated with Second-generation Tyrosine-kinase Inhibitors (TKIs) for Chronic Myeloid Leukaemia (CML) Pennington, B.
 2013
 16 7 p. A326-A327
nvt p.
 artikel
24 A Comparison of the Economic Burden and Health Care Utilizations of Veteran Patients Diagnosed with Diabetes in the United States Xie, L.
 2013
 16 7 p. A435-
1 p.
 artikel
25 A Comparison of the Economic Burden and Health Care Utilizations of Veteran Patients Diagnosed with Hypertension in the United States Wang, L.
 2013
 16 7 p. A522-
1 p.
 artikel
26 A Comparison of the Relative Weights of Health Domains on Global Retrospective and Experienced Health and Well-Being Joore, M.A.
 2013
 16 7 p. A601-
1 p.
 artikel
27 A Comprehensive Review of Epidemiology and Economic Studies for Patients Diagnosed with Non-Psychotic Major Depressive Disorder Greene, N.
 2013
 16 7 p. A694-
1 p.
 artikel
28 A Cost Analysis of Medication for Patients with Type 2 Diabetes Mellitus (T2DM) – How This Varies According to Body Mass Index (BMI) Status, Age, Gender and Co-Morbidity Queally, M.B.
 2013
 16 7 p. A437-
1 p.
 artikel
29 A Cost-Analysis of Stereotactic Radiotherapy in Lung Cancer Perrier, L.
 2013
 16 7 p. A401-
1 p.
 artikel
30 A Cost-Consequence Analysis of Different Protease Inhibitors Schemes for HIV Treatment from the Colombian Health Care System Perspective Rueda, J.D.
 2013
 16 7 p. A713-
1 p.
 artikel
31 A Cost-Effectiveness Analyses of Using Sunitinib (SU) in First Line of Metastatic Renal Cancer in Romanian Jurisdiction Berghea, F.
 2013
 16 7 p. A411-A412
nvt p.
 artikel
32 A Cost-Effectiveness Analysis of Axitinib and Sorafenib for 2nd Line Treatment of Advanced Renal Cell Carcinoma After Failure of Cytokines in the United States Stillman, I.O.
 2013
 16 7 p. A410-
1 p.
 artikel
33 A Cost-Effectiveness Analysis of Cisplatin Plus Pemetrexed Doublet Induction Treatment Followed by Pemetrexed Maintenance Compared with Bevacizumab Plus Cisplatin Plus Gemcitabine Triplet Induction Treatment Followed by Bevacizumab Maintenance for Non-Squamous NSCLC in Sweden Bryden, P.A.
 2013
 16 7 p. A410-
1 p.
 artikel
34 A Cost-Effectiveness Analysis of Ingenol Mebutate Gel for the Treatment of Actinic Keratosis: A Scottish Perspective Tolley, K.
 2013
 16 7 p. A506-
1 p.
 artikel
35 A Cost-Effectiveness Analysis of Linezolid Versus Vancomycin for Ventilator-Associated Pneumonia Patients in Costa Rica Garita, M.
 2013
 16 7 p. A353-A354
nvt p.
 artikel
36 A Cost–Effectiveness And Budget Impact Analysis of Different Biologic Treatments for Psoriasis in Colombia Ariza, J.G.
 2013
 16 7 p. A696-
1 p.
 artikel
37 A Cost-Effectiveness Model Comparing Sub-Cutaneous Biologic Treatment for Severe Plaque Psoriasis in Mexico Valencia, A.
 2013
 16 7 p. A726-
1 p.
 artikel
38 A Cost of a Childbirth with in vitro Fertilization in Poland Góra, K.
 2013
 16 7 p. A332-A333
nvt p.
 artikel
39 A Cost-Of-Illness Analysis of Hepatitis C in Greece Athanasakis, K.
 2013
 16 7 p. A496-
1 p.
 artikel
40 A Cost-Utility Analysis of Everolimus Plus Exemestane for the Treatment of ER+ HER2- Metastatic Breast Cancer in the United Kingdom Taylor, M.
 2013
 16 7 p. A416-
1 p.
 artikel
41 A Cost-Utility Analysis of Lighterlife Total as a Treatment for Obesity in the United Kingdom Lewis, L.
 2013
 16 7 p. A385-
1 p.
 artikel
42 A Cost-Utility Analysis of Ranibizumab in Age-Related Macular Degeneration Based on Real-Life Observational Data in France de Pouvourville, G.
 2013
 16 7 p. A507-
1 p.
 artikel
43 A Critical Appraisal of Cost-Effectiveness Analyses of Human Papillomavirus Testing in Cervical Screening: Making Appropriate Comparisons and Usefully Interpreting Results O’Mahony, J.
 2013
 16 7 p. A410-
1 p.
 artikel
44 Active-Implantable Cardiac Devices: Is There Room for Cost Savings in Portuguese Hospitals? Pelicano-Romano, J.
 2013
 16 7 p. A529-
1 p.
 artikel
45 Acute Asthma Characteristics and Asthma Control in Latin America Montealegre-Golcher, F.J.
 2013
 16 7 p. A723-
1 p.
 artikel
46 Acute Exposure of Bisphenol-A from Electronic Gadgets Does Not Induce Oxidative Stress in the Rat Brain Kumar, N.
 2013
 16 7 p. A692-
1 p.
 artikel
47 Added Value and Future Adoption of a New Medical Imaging Technology for Interventional Cardiology Meeks, M.D.M.E.
 2013
 16 7 p. A540-
1 p.
 artikel
48 Adding a Reminder Short Message Service (SMS) Before and Tablet Computer During Clinic Improves Electronic Patient Reported Outcome Measures (ePROMS) Collection Roberts, N.
 2013
 16 7 p. A337-
1 p.
 artikel
49 Additional Clinical Benefit for Patient Relevant Endpoints: Investment Disincentives by AMNOG in the Example of Parkinson’s Disease Walzer, S.
 2013
 16 7 p. A627-A628
nvt p.
 artikel
50 Additional Investments, Added Value, Real World Evidence and Additional Clinical Benefit in the Context of Subgroups of Special Interest Walzer, S.
 2013
 16 7 p. A423-
1 p.
 artikel
51 Addressing Childhood-Obesity in Mexico: Savings on Health Care Expenditures from Regulating Food and Beverage Sales in Basic Education Schools Guajardo, V.
 2013
 16 7 p. A666-
1 p.
 artikel
52 Addressing Heterogeneity in Baseline Risk of COPD Exacerbations Using Meta-regression Cope, S.
 2013
 16 7 p. A327-
1 p.
 artikel
53 A Decision Analytic Markov Model to Evaluate the Health Outcomes of Sofosbuvir for Previously Untreated Patients and Those Without Treatment Options with Chronic Hepatitis C Virus Genotype 2 Infection Younossi, Z.M.
 2013
 16 7 p. A341-
1 p.
 artikel
54 A De Novo Economic Model to Assess the Cost and Quality of Life Consequences of an Intervention for Levodopa Induced Dyskinesia Amongst Patients with Parkinson’s Disease Bhattacharyya, S.
 2013
 16 7 p. A590-A591
nvt p.
 artikel
55 A Deterministic Model to Evaluate the Costs for Surgical Procedures: The Win-Win Model Velleca, M.
 2013
 16 7 p. A468-
1 p.
 artikel
56 Adherence and Resource Use Among Patients Treated with Biologics. Findings from the Beetle Study (Biological Drugs: Evaluation of Economics, Treatments, and Labeling in Real-World Setting) Degli Esposti, L.
 2013
 16 7 p. A323-
1 p.
 artikel
57 Adherence by Spanish Retinologists to the Guidance for the Management of Patients with Wet Age-Related Macular Degeneration Colomé, A.
 2013
 16 7 p. A511-A512
nvt p.
 artikel
58 Adherence Interventions to Improve Adherence to Antiretroviral Therapy in Low Income Settings: An Individual Patient Data Network Meta-Analysis Mills, E.J.
 2013
 16 7 p. A361-
1 p.
 artikel
59 Adherence Rates for Intravenous Chemotherapy Regimens to Treat Colon Cancer Seal, B.
 2013
 16 7 p. A418-
1 p.
 artikel
60 Adherence, Switching, and Discontinuation During the 12 Weeks Following Antidepressant Initiation in Patients with Depressive Disorder: Results of a Prospective, Longitudinal Study Lenderking, W.R.
 2013
 16 7 p. A550-
1 p.
 artikel
61 Adherence to Antiretroviral Therapy Among HIV-Infected Patients Attending to a University Infectious Diseases Clinic in Venezuela Bastardo, Y.M.
 2013
 16 7 p. A361-
1 p.
 artikel
62 Adherence to Disease-Specific Recommendations for Pharmacoeconomic Studies in Rheumatoid Arthritis Makady, A.
 2013
 16 7 p. A586-
1 p.
 artikel
63 Adherence to Treatment and Persistency in Patients Treated with VKA in France, Italy, Germany, Spain and the United Kingdom Carrasco, J.
 2013
 16 7 p. A516-
1 p.
 artikel
64 Adherence to Warfarin Treatment in Brazil: Systematic Review of the Literature Feijo, L.F.
 2013
 16 7 p. A536-A537
nvt p.
 artikel
65 A Discrete Choice Experiment to Evaluate Blood Glucose Meter Preferences in People with Type 1 and Type 2 Diabetes in the United Kingdom Perard, R.
 2013
 16 7 p. A447-
1 p.
 artikel
66 A Disease Model of Metastatic Colorectal Cancer Including Multiple Treatment Lines van Rooijen, E.M.
 2013
 16 7 p. A425-A426
nvt p.
 artikel
67 Adjunctive Therapy with Pregabalin in Generalized Anxiety Disorder Patients with Partial Response to Ssri Treatment: A Cost-Consequences Analysis in Medical Practice in Spain Carrasco, J.L.
 2013
 16 7 p. A547-
1 p.
 artikel
68 Adjusting for Treatment Switching in Clinical Trials When Only Summary Data Are Available – An Evaluation of Potential Methods Boucher, R.
 2013
 16 7 p. A610-A611
nvt p.
 artikel
69 Adrenal Insufficiency: Burden of Disease and Cost of Illness Chauhan, R.
 2013
 16 7 p. A436-
1 p.
 artikel
70 Adrenal Insufficiency: Burden of Disease in France in 2011 Bourguignon, S.
 2013
 16 7 p. A381-
1 p.
 artikel
71 Advanced Budget Notification (ABN): Is There a Win:Win for Manufacturers and Payers Given the Current Austerity Measures Across the EU Mallinson, M.
 2013
 16 7 p. A467-
1 p.
 artikel
72 Ações De Farmacovigilância: Relato De Notificações De Medicamentos À Agência Nacional De Vigilância Sanitária (ANVISA) – Brasil Costa Paulo, P.T.
 2013
 16 7 p. A672-
1 p.
 artikel
73 A Evolução Da Rede Brasileira De Avaliação E Tecnologia Em Saúde Gonçalves, L.
 2013
 16 7 p. A700-
1 p.
 artikel
74 Affordability of Antihypertensive Treatment in Mexico Lemus, F.
 2013
 16 7 p. A705-
1 p.
 artikel
75 A Flexible Multi-State Modelling Framework for the Simulation of Cancer Progression and Cancer Care van der Meijde, E.
 2013
 16 7 p. A616-
1 p.
 artikel
76 Aflibercept + FOLFIRI (AF) Versus. Placebo + FOLFIRI (PF) in Metastatic Colorectal Cancer (mCRC): Mean Overall Survival (OS) in a “Better Responders” Patient Population of the Velour Trial Joulain, F.
 2013
 16 7 p. A397-A398
nvt p.
 artikel
77 Aflibercept in Neovascular (Wet) Age-Related Macular Degeneration: An Analysis of the Payer Decision Landscape Brown, A.
 2013
 16 7 p. A511-
1 p.
 artikel
78 A Framework for the Cost-Equality Analysis of Health Care Programmes Asaria, M.
 2013
 16 7 p. A426-
1 p.
 artikel
79 Age and Gender Distribution of Outpatient Care Physiotherapy Services for Dorsopathia Diseases in Hungary Molics, B.
 2013
 16 7 p. A574-
1 p.
 artikel
80 Age and Gender Distribution of Outpatient Care Physiotherapy Services for Hip and Thigh Injuries in Hungary in 2009 Molics, B.
 2013
 16 7 p. A574-
1 p.
 artikel
81 Agranulocytosis Detection Outcome By Clozapine Treatment (Adoc Study) in Psychiatry: A Cost-Effectiveness Study Girardin, F.
 2013
 16 7 p. A725-
1 p.
 artikel
82 Agreement Between Child and Parent Symptom Diary Responses in Chronic Constipation (CC) and Irritable Bowel Syndrome with Constipation (IBS-C): Implications for the Measurement of Symptoms in Young Children Holloway, L.
 2013
 16 7 p. A499-
1 p.
 artikel
83 A Guide to Adjusting Survival Time Estimates to Account for Treatment Switching in Randomised Controlled Trials Latimer, N.R.
 2013
 16 7 p. A325-
1 p.
 artikel
84 A Health Economic Analysis of the Long-Term Outcomes and Costs Associated with Using Canagliflozin Versus Sitagliptin As an Add-On to Metformin (MET) in Mexico Teschemaker, A.R.
 2013
 16 7 p. A689-A690
nvt p.
 artikel
85 A Health Economic Evaluation of Fenofibric Acid in Combination with Statins in the Prevention of Cardiovascular Disease in Taiwanese Mixed Hyperlipidemia Patients Ramos, M.
 2013
 16 7 p. A526-
1 p.
 artikel
86 A Lei De Acesso À Informação Fortalece O Papel Da Avaliação De Tecnologias Em Saúde (ATS) De Fornecer Informações Sólidas E Transparentes Aos Usuários Do Sistema Único De Saúde Brito, G.V.
 2013
 16 7 p. A682-
1 p.
 artikel
87 A Lesson Learnt from Avastin®: - Bevacizumab Induced Hypertension as a Predictive Biomarker of Patient Response in Overcoming Regulatory and Health Technology Assessment (HTA) Hurdles Fowler, R.C.
 2013
 16 7 p. A393-
1 p.
 artikel
88 A Literature Review on the Humanistic and Economic Burden of Mineralocorticoid Excess Syndrome Langham, S.
 2013
 16 7 p. A392-
1 p.
 artikel
89 A Low Antiviral Treatment Rate in Chronic Heptitis C Patients in Taiwan- A Nationwide Physician-Based Survey Yu, M.L.
 2013
 16 7 p. A693-
1 p.
 artikel
90 Alternative High Level Disinfectants to Processing Flexible Endoscopes Passeri, L.A.
 2013
 16 7 p. A712-
1 p.
 artikel
91 A Mediação De Conflitos Na Ação Fiscalizatoria Do Setor De Saúde Suplementar Brasileiro Tanaka, F.H.R.
 2013
 16 7 p. A680-A681
nvt p.
 artikel
92 A Methodology for Predicting the Impact of Copayments on the Utilization of Health Technologies Sabatelli, L.
 2013
 16 7 p. A326-
1 p.
 artikel
93 A Micro-Costing of the Inpatient Management of Febrile Neutropenia in the Irish Health Care Setting McCullagh, L.
 2013
 16 7 p. A404-
1 p.
 artikel
94 A Mixed Treatment Comparison (MTC) to Compare Progression Free Survival (PFS) Associated with Different Chemotherapy Regimens for Platinum-Sensitive or Partially Platinum-Sensitive Recurrent Advanced Ovarian Cancer Edwards, S.J.
 2013
 16 7 p. A394-A395
nvt p.
 artikel
95 Amnog Benefit Assessment: Time Delay of Market Access for Pharmaceuticals in Germany? Neubauer, A.S.
 2013
 16 7 p. A475-
1 p.
 artikel
96 A Model of the Cost Effectiveness of Infliximab for the Treatment of Severely Active Ulcerative Colitis, in Children and Adolescents Aged 6 to 17 Years, Who Have Had an Inadequate Response to Conventional Therapy Farrell, J.
 2013
 16 7 p. A565-
1 p.
 artikel
97 A Model to Evaluate the Immunogenicity Costs of Tumour Necrosis Factor-Alpha Inhibitors in Patients with Rheumatoid Arthritis Heeg, B.
 2013
 16 7 p. A563-
1 p.
 artikel
98 A Multi-National Survey Assessing the Relationship Between Prophylaxis Treatment and Health-Related Quality of Life Among Severe Hemophilia a Patients in Latin America Perez Bianco, P.R.
 2013
 16 7 p. A671-A672
nvt p.
 artikel
99 Analyses Adjusting for Selective Crossover Show Improved Overall Survival with Decitabine Compared with Treatment Choice in DACO-016 Phase III Trial Tomeczkowski, J.
 2013
 16 7 p. A378-
1 p.
 artikel
100 Analysing the Access to Priority Health Services in the Adolescent Population in Six Provinces in Northern Argentina Maceira, D.
 2013
 16 7 p. A673-
1 p.
 artikel
101 Analysis and Classification of Risk-Sharing Schemes Proposed in Reimbursement Application Received by AHTAPol in 2012 Zawodnik, S.
 2013
 16 7 p. A488-
1 p.
 artikel
102 Analysis Cost Effectiveness of Pharmacological Prophylaxis of Contrast-Induced Nephropathy Alonso Herreros, J.
 2013
 16 7 p. A630-
1 p.
 artikel
103 Analysis of Adverse Reactions of Medicine in Ukraine Zalis’ka, O.
 2013
 16 7 p. A464-
1 p.
 artikel
104 Analysis of Brazilian Public Funding Process for New Biologic Drugs Rodrigues, T.
 2013
 16 7 p. A678-
1 p.
 artikel
105 Analysis of Causal Relations in Stroke Registry Data Jakubczyk, M.
 2013
 16 7 p. A590-
1 p.
 artikel
106 Analysis of Consumption of Antihypertensive Drugs in Serbia from 2007 to 2011 Milijasevic, B.
 2013
 16 7 p. A703-A704
nvt p.
 artikel
107 Analysis of Consumption of Diuretics in Serbia from 2006 to 2010 Tomic, Z.
 2013
 16 7 p. A703-
1 p.
 artikel
108 Analysis of Health Care Costs in Elderly Patients with Multiple Chronic Conditions Using a Finite Mixture of Generalized Linear Models Eckardt, M.
 2013
 16 7 p. A581-
1 p.
 artikel
109 Analysis of Mandibular Test Specimens Used to Evaluate Bone Fixation Systems Passeri, L.A.
 2013
 16 7 p. A700-A701
nvt p.
 artikel
110 Analysis of Public and Private Hospital Databases (PMSI) 2010 / 2011 to Estimate the Frequency and Associated Costs for Febrile Neutropenia in France Vainchtock, A.
 2013
 16 7 p. A406-
1 p.
 artikel
111 Analysis of Published Health Technology Assessments (HTA) in Russia and Its Place in Russian Reimbursement System Kalbasko, A.
 2013
 16 7 p. A481-
1 p.
 artikel
112 Analysis of Re-Hospitalisations for Stroke and Transient Ischemia Recurrence and Associated Costs in the Burgundy Region in France Marty, R.
 2013
 16 7 p. A538-A539
nvt p.
 artikel
113 Analysis of Spanish Generic Medicines Market: Recommendations to Enhance Long-Term Sustainability Dylst, P.
 2013
 16 7 p. A469-
1 p.
 artikel
114 Analysis of the IQWIG Comments on the Evidence Searches of Dossiers in the German Amnog Process Witt, B.
 2013
 16 7 p. A481-
1 p.
 artikel
115 Analysis of the Pricing and Market Access Landscape of Orphan Drugs in Latin America Senan Castellano, B.
 2013
 16 7 p. A673-
1 p.
 artikel
116 Analysis of the Reimbursed Psoriasis Market in Hungary Between 2007 and 2011 Ecseki, A.
 2013
 16 7 p. A390-
1 p.
 artikel
117 Analysis of Total Treatment Costs of Organophosphorous Poisoning in a Tertiary Care Hospital Pariti, B.
 2013
 16 7 p. A466-
1 p.
 artikel
118 Analysis of Transparency Amongst International Health Technology Assessment Organizations Jebrail, F.
 2013
 16 7 p. A481-A482
nvt p.
 artikel
119 Analyzing Costs Per Clinical Remission of Tocilizumab Monotherapy Versus Adalimumab Monotherapy in Rheumatoid Arthritis from a Public Perspective in Brazil Buschinelli, C.T.
 2013
 16 7 p. A716-
1 p.
 artikel
120 An Analysis of EQ-5D Quality of Life Data for a Cost-Effectiveness Analysis of Ivabradine Plus Standard Care Versus Standard Care Alone in Chronic HF Griffiths, A.
 2013
 16 7 p. A533-
1 p.
 artikel
121 An Analysis of How Not to Use Cost-Effectiveness Analysis for Price-Setting Standaert, B.
 2013
 16 7 p. A616-
1 p.
 artikel
122 An Analysis of Priscription and Reimbursement of Potentially Inappropriate Medication (PIM) in a German Practice Network Pohl-Dernick, K.
 2013
 16 7 p. A460-
1 p.
 artikel
123 An Analysis of the Cost Effectiveness of Left Atrial Appendage Closure for the Prevention of Stroke in Patients with Atrial Fibrillation and Absolute Contraindications to Warfarin Therapy Reddy, V.Y.
 2013
 16 7 p. A525-
1 p.
 artikel
124 An Analysis of the Cost of Switching Renal Transplant Patients from an Immediate-Release to a Prolonged-Release Formulation of Tacrolimus Based on Differences in Trough Concentration Variability in the United Kingdom Pollock, R.F.
 2013
 16 7 p. A631-
1 p.
 artikel
125 An Approach for Quantification of Patient Advocacy Group Input in the HTA Process Hicks, N.
 2013
 16 7 p. A614-
1 p.
 artikel
126 An Assessment of the Use of Utility Data in Long-Term Cost-Effectiveness Models of Lipid Lowering Therapies Kuan, R.K.
 2013
 16 7 p. A581-
1 p.
 artikel
127 An Assessment of Unemployment Among People Living with HIV/AIDS in Canada and Europe Cline, S.K
 2013
 16 7 p. A363-
1 p.
 artikel
128 A Nationwide Survey on Patient Safety Culture in Japan Hirose, M.
 2013
 16 7 p. A680-
1 p.
 artikel
129 An Economic Evaluation Alongside a Clinical Trial (EEACT) in Pelvic Floor Medicine Brennan, V.K.
 2013
 16 7 p. A334-
1 p.
 artikel
130 An Economic Evaluation Comparing ePTFE Covered Stent-Grafts Configured for Tips with Bare Metal Stents in Procedures for the Treatment of Portal Hypertension Complications Burke, M.
 2013
 16 7 p. A496-A497
nvt p.
 artikel
131 An Economic Evaluation of the Triple HCV Treatment Regimen for G1 Naïve Patients in the Greek Health Care System Athanasiadis, A.
 2013
 16 7 p. A497-
1 p.
 artikel
132 An Economic Model to Compare Linezolid and Vancomycin for the Treatment of Confirmed Methicillin-Resistant Staphylococcus aureus Nosocomial Pneumonia in Germany Patel, D.A.
 2013
 16 7 p. A354-
1 p.
 artikel
133 An Excel Calculator to Estimate Rheumatoid Arthritis Costs in Turkey Baser, O.
 2013
 16 7 p. A581-
1 p.
 artikel
134 An Exploratory Analysis of the Association Between EORTC-QLQ C30 Domains and Progression Free/Overall Survival in Advanced Melanoma After 12 Weeks of Treatment on Ipilimumab Compared to Gp100 in a Phase III Clinical Trial Lee, D.
 2013
 16 7 p. A422-
1 p.
 artikel
135 An Indirect Treatment Comparison of the Efficacy of Everolimus (Afinitor®) and Fulvestrant for the Treatment of Hormone Receptor Positive (HR+) HER2 Negative (HER2–) Advanced or Metastatic Breast Cancer Chandiwana, D.
 2013
 16 7 p. A393-A394
nvt p.
 artikel
136 An Innovative Method: Application of Negative Pressure Wound Therapy in the Treatment of Chronic Leg Ulcers – Medical and Health Economics Aspects Kovács, L.A.
 2013
 16 7 p. A505-
1 p.
 artikel
137 Análise Comparativa Dos Anticoncepcionais Orais Com Diferentes Concentraçoes De Etinilestradiol Em Relação Aos Perfis De Eficácia E De Adesão Freitas, M.G.
 2013
 16 7 p. A708-A709
nvt p.
 artikel
138 Análise Custo-Minimização (ACM) Do Cloridrato De Valganciclovir Comparado Com Ganciclovir Na Profilaxia Da Infecção Por CMV Em Transplantados Renais Alves Carvalho, L.
 2013
 16 7 p. A715-
1 p.
 artikel
139 Análise Das Potencialidades De Custo-Minimização Através Da Determinação Do Market Share Entre Os Quimioterápicos De Referência Que Possuem Genéricos Cadastrados Em Uma Operadora De Plano De Saúde Reis, H.P.L.C.
 2013
 16 7 p. A684-
1 p.
 artikel
140 Análise De Custo-Efetividade Para Utilização De Oclusores Septais No Fechamento De Comunicação Interatrial (CIA) Do Tipo Ostium Secundum Comparado Com a Cirurgia Convencional Costa, M.G.S.D.
 2013
 16 7 p. A706-
1 p.
 artikel
141 Análise De Impacto Orçamentário Do Oclusor Septal Percutâneo Para O Fechamento De Comunicação Interatrial (CIA) Do Tipo Ostium Secundum Senna, K.M.S.
 2013
 16 7 p. A704-
1 p.
 artikel
142 Análise De Impacto Orçamentário: Quanto Custaria Ao Sistema Público De Saúde Brasileiro Incrementar, Por Meio De Transplantes, O Tratamento Da Doença Renal Crônica Terminal? Alvares, J.
 2013
 16 7 p. A665-
1 p.
 artikel
143 Análisis Bibliométrico De La Producción Científica En Economía De La Salud En Latinoamérica Simbaqueba, E.
 2013
 16 7 p. A671-
1 p.
 artikel
144 Análisis Comparativo De Insulina Glargina Frente a Insulina Detemir: Modelo De Minimización De Costos Para Colombia Fragozo, A.
 2013
 16 7 p. A688-
1 p.
 artikel
145 Análisis Costo-Efectividad De Everolimus Más Exemestano Para Pacientes Con Cáncer De Mama Avanzado Con Receptores Hormonales Positivos (RE+), HER2–, Que Fallaron a Los Inhibidores De Aromatasa No Esteroideos (IANES) En México Zhang, J.
 2013
 16 7 p. A685-
1 p.
 artikel
146 Análisis Costo-Efectividad De Intervenciones Para El Manejo Del Trastorno Depresivo Mayor (TDM) En Pacientes Con Virus De La Inmunodeficiencia Humana (VIH+) Que Inician Tratamiento Antirretroviral De Gran Actividad (TARGA) Lemus, F.
 2013
 16 7 p. A668-
1 p.
 artikel
147 Análisis Costo-Efectividad De Linezolid Comparado Con Vancomicina En El Manejo De La Neumonía Asociada A La Ventilación Mecanica En Colombia Varon, F.A.
 2013
 16 7 p. A670-
1 p.
 artikel
148 Análisis Costo-Efectividad Del Tratamiento Farmacológico Para Las Manifestaciones Clínicas Mucocutáneas De La Enfermedad De Behcet Quirland Lazo, C.
 2013
 16 7 p. A726-A727
nvt p.
 artikel
149 Análisis Costo-Utilidad De Dos Alternativas Para El Tratamiento De Bebés Prematuros En Bogotá Castillo, M.
 2013
 16 7 p. A710-
1 p.
 artikel
150 Análisis De Costo Efectividad De Acido Gadoterico Frente a Otros Medios De Contrastes Basados En Gadolinio Simbaqueba, E.
 2013
 16 7 p. A692-
1 p.
 artikel
151 Análisis De Costo-Efectividad De Bevacizumab Para El Tratamiento De Primera Línea En Pacientes Con Cáncer Colorrectal Metastásico, Ccrm En Colombia parada Vargas, L.A.
 2013
 16 7 p. A686-
1 p.
 artikel
152 Análisis De Costo-Efectividad De Dos Formulaciones De Toxina Botulínica Tipo a (TBA) En Colombia Para El Tratamiento De La Parálisis Cerebral Infantil (PCI) Serizawa, E.
 2013
 16 7 p. A720-
1 p.
 artikel
153 Análisis De Costo-Efectividad De Erlotinib En El Tratamiento De Pacientes Con Cáncer Pulmonar De Células No Pequeñas, CPCNP, Con Mutación Del Gen EGFR+, En Colombia parada Vargas, L.A.
 2013
 16 7 p. A685-A686
nvt p.
 artikel
154 Análisis De Costo-Efectividad De Estrategias De Prevención Primaria Y Secundaria Para Cáncer De Cuello Uterino En Colombia Gamboa, O.A.
 2013
 16 7 p. A669-
1 p.
 artikel
155 Análisis De Costo-Efectividad De Ioxaglato Versus Iodixanol En Angiografía Coronaria Simbaqueba, E.
 2013
 16 7 p. A706-
1 p.
 artikel
156 Análisis De Costo-Efectividad De Las Vacunas Neumocócicas Conjugadas 10 Y 13 Valente Para Niños En Antioquía, Colombia Ordoñez Molina, J.E.
 2013
 16 7 p. A713-
1 p.
 artikel
157 Análisis De Costo-Efectividad De Las Vacunas Neumocócicas 13-Valente Y 23-Valente Para Adultos De Alto Riesgo En Colombia Ordoñez Molina, J.E.
 2013
 16 7 p. A667-
1 p.
 artikel
158 Análisis De Costo-Efectividad De Los Profesionales De Enfermeria Con Experiencia Laboral En Uci Versus Sin Experiencia Laboral En El Error De La Medicación Parenteral En Pacientes Adultos Hospitalizados En Uci Beiza, C.
 2013
 16 7 p. A676-A677
nvt p.
 artikel
159 Análisis De Costo-Efectividad Del Tratamiento Profiláctico Versus a Demanda En Adolescentes Con Hemofilia a Severa En Colombia Ordoñez Molina, J.E.
 2013
 16 7 p. A721-
1 p.
 artikel
160 Análisis De Costo-Efectividad Del Uso De Estatinas En La Prevención De Eventos Cardiovasculares En Colombia Mould, J.
 2013
 16 7 p. A666-
1 p.
 artikel
161 Análisis De Costo-Efectividad Dl Tratamiento Profiláctico Versus a Demanda En Adultos Jóvenes Con Hemofilia a Severa En Colombia Ordoñez Molina, J.E.
 2013
 16 7 p. A721-
1 p.
 artikel
162 Análisis De Costo-Efectividad Para El Manejo Farmacológico De La Hemofilia a Severa En 5 Entidades De Aseguramiento En Colombia Bryon, A.
 2013
 16 7 p. A727-
1 p.
 artikel
163 Análisis De Costos Mediante Un Modelo Lineal Generalizado De Pacientes Mexicanos Con Sindrome De West Pizarro, M.
 2013
 16 7 p. A720-
1 p.
 artikel
164 Análisis De Impacto Presupuestal Del Uso De Lng Siu Como Método De Contracepción En Colombia Acero, G.
 2013
 16 7 p. A709-
1 p.
 artikel
165 Análisis De Impacto Presupuestario De Linagliptina Adicionada a Metformina En El Tratamiento De Pacientes Con Diabetes Mellitus En Colombia Romero, M.
 2013
 16 7 p. A688-
1 p.
 artikel
166 Análisis De La Carga Financiera De Las Principales Enfermedades Reumatológicas Goycochea, M.
 2013
 16 7 p. A726-
1 p.
 artikel
167 Análisis Del Gasto Sanitario Español 1980-2010 Crespo, C.
 2013
 16 7 p. A675-
1 p.
 artikel
168 Análisis Del Impacto En La Demanda De Tecnologías Incluidas En El Plan De Beneficios Colombiano (POS) Posterior A Su Actualización En 2012 Romero, M.
 2013
 16 7 p. A670-
1 p.
 artikel
169 Análisis De Minimización De Costos De Iobitridol Versus Otros Medios De Contraste Iodados Iso E Hipo-Osmolales En Población General Simbaqueba, E.
 2013
 16 7 p. A675-
1 p.
 artikel
170 Análisis De Minimización De Costos Del Uso Del Aflibercept En Degeneracion Macular Relacionada Con La Edad En Colombia Romero, M.
 2013
 16 7 p. A697-
1 p.
 artikel
171 Análisis Economico De La Profilaxis Secundaria Versus El Tratamiento a Demanda De Una Cohorte De Pacientes Colombianos Con Hemofilia a Y B Severa Ruiz, A.F.
 2013
 16 7 p. A726-
1 p.
 artikel
172 Annual Expenditure on Anti-Tnf Treatment of Rheumatoid Arthritis for the Public Health System in Brazil Nobre, M.R.C.
 2013
 16 7 p. A561-
1 p.
 artikel
173 A Non-Interventional Retrospective Evaluation of Resources Consumed During the Provision of Care for Overactive Bladder Syndrome: A Real World Evaluation: German Perspective (The Reduce Study) Indig, M.
 2013
 16 7 p. A632-
1 p.
 artikel
174 A Novel Algorithm Using Claims Data to Identify Patients with Castration-Resistant Prostate Cancer (CRPC) Gorritz, M.
 2013
 16 7 p. A427-A428
nvt p.
 artikel
175 An Overview of Domestic Cancer Drugs in Turkey: 2008-2012 Vural, E.H.
 2013
 16 7 p. A417-
1 p.
 artikel
176 Antibacterial Treatment of Meticillin-Resistant Staphylococcus Aureus Complicated Skin and Soft Tissue Infections: A Budget Impact Analysis in the Greek Hospital Setting Karampli, E.
 2013
 16 7 p. A344-
1 p.
 artikel
177 Antibacterial Treatment of Meticillin-Resistant Staphylococcus aureus Complicated Skin and Soft Tissue Infections: A Cost-Effectiveness Analysis in Greece Karampli, E.
 2013
 16 7 p. A355-
1 p.
 artikel
178 Antibiotic Utilization in Complicated Urinary Tract Infection in a Tertiary Care Teaching Hospital in South India Nair, S.
 2013
 16 7 p. A635-A636
nvt p.
 artikel
179 Anticoagulant Use in Hospitalized Patients with Acute Venous Thromboembolism in the United States Liu, X.
 2013
 16 7 p. A515-A516
nvt p.
 artikel
180 Anticoagulation Treatment with VKA in France, Italy, Germany, Spain and United Kingdom. Results from the React AF Study Carrasco, J.
 2013
 16 7 p. A516-
1 p.
 artikel
181 Anti-Diabetic Medications Related Severe Hypoglycaemia Risk in Diabetes Type 1 and Type 2 – A Systematic Review of Observational Studies Paweska, J.
 2013
 16 7 p. A435-
1 p.
 artikel
182 Antithrombotic Strategies and Adverse Outcomes in Acute Coronary Syndrome and Atrial Fibrillation: A Community Study Chamberlain, A.M.
 2013
 16 7 p. A512-
1 p.
 artikel
183 A Parent-Administered But Child-Completed Patient-Reported Outcome (PRO) Provides a Measure with Content Validity That Is Valid and Reliable for Use in Children Aged 6 to 11 Years Arbuckle, R.
 2013
 16 7 p. A338-
1 p.
 artikel
184 Appetite Suppressants: A Drug Utilisation Study Truter, I.
 2013
 16 7 p. A389-A390
nvt p.
 artikel
185 Applicability of Japanese Health Care Database to Clinical Trial Planning for Dyslipidaemia Drug Yamamoto, Y.
 2013
 16 7 p. A585-
1 p.
 artikel
186 Application of a Data Visualization Tool: Treatment Patterns of Veteran Patients with Ankylosing Spondylitis Baser, O.
 2013
 16 7 p. A557-
1 p.
 artikel
187 Application of Behavioural Economics to the Understanding of Adherence: Does an Individual’s Time Preference Influence Adherence to Medications? Fargher, E.A.
 2013
 16 7 p. A327-A328
nvt p.
 artikel
188 Application of Copulas in Economic Evaluation Crespo, C.
 2013
 16 7 p. A609-
1 p.
 artikel
189 Application of Health Technology Assessment and Pharmacoeconomics in the Decision-Making Process in Selected Eu Member States Marusakova, E.
 2013
 16 7 p. A679-
1 p.
 artikel
190 Application of Logistic Regression for Signal Detection and Risk Assessment of Macrolide-Associated Torsade De Pointes Ali, A.K.
 2013
 16 7 p. A512-
1 p.
 artikel
191 Application of New French Guidelines for Economic Evaluations: A Cost-Effectiveness Analysis of Apixaban in Patients with Non-Valvular Atrial Fibrillation in France Durand-Zaleski, I.
 2013
 16 7 p. A523-
1 p.
 artikel
192 Applied Comparison of Meta-Analysis Techniques Wang, L.
 2013
 16 7 p. A701-
1 p.
 artikel
193 Approaches for Estimating Burden of Pneumococcal and Rotavirus Diseases: Conceptual Framework and Systematic Review Garcia Marti, S.
 2013
 16 7 p. A713-
1 p.
 artikel
194 Appropriate Evidence Sources for Populating Decision Analytic Models Within Health Technology Assessment (HTA): A Systematic Review of HTA Manuals and Health Economic Guidelines Zechmeister-Koss, I.
 2013
 16 7 p. A591-A592
nvt p.
 artikel
195 A Price Comparison Study of Recent Drugs in EU5, 2008-2012 Le Pen, C.
 2013
 16 7 p. A455-
1 p.
 artikel
196 A Proposed 6-Item Reduction for the European Organization for the Research and Treatment of Cancer-Quality of Core Questionnaire (EORTC QLQ-C30) - Cuban Group of Trialists on Epidermal Growth Factor (CGT-EGF) Viada, C.
 2013
 16 7 p. A422-
1 p.
 artikel
197 A Prospective Time and Motion Analysis Comparing Intravenous (IV) Vesus Subcutaneous (SC) Bortezomib in Patients with Multiple Myeloma (MM) Dranitsaris, G.
 2013
 16 7 p. A427-
1 p.
 artikel
198 A Quebec Economic Evaluation for 36 Months of Ranibizumab for the Treatment of Diabetic Macular Edema Haig, J.
 2013
 16 7 p. A507-
1 p.
 artikel
199 Are Conditionally Approved Therapies Successful in Gaining Market Access? Sweeney, N.
 2013
 16 7 p. A480-
1 p.
 artikel
200 Are “Dizzy” and “Lightheaded” the Same Concept or Separate Concepts? Challenges in Conceptual Equivalence of These Terms in 20 Languages Eremenco, S.
 2013
 16 7 p. A421-
1 p.
 artikel
201 Are Generic Drugs Defined and Classified Consistently Around the World? Alfonso-Cristancho, R.
 2013
 16 7 p. A672-
1 p.
 artikel
202 Are Head-To-Head Data Necessary to Gain Reimbursement in the French National Health Care System? Patel, A.
 2013
 16 7 p. A480-
1 p.
 artikel
203 Are ICER Threshold Values Malleable? The Case of Life-Extending Cancer Treatments at the End of Life Moïse, P.
 2013
 16 7 p. A424-A425
nvt p.
 artikel
204 Are Israeli Adults Willing to Pay Higher Health Taxes for a Wider Coverage of Life-Extending Medications? Greenberg, D.
 2013
 16 7 p. A338-
1 p.
 artikel
205 A Relationship Between Body Mass Index and Health-Related Quality of Life Among Koreans with Diabetes: The Korea National Health and Nutrition Examination Survey Lee, J.Y.
 2013
 16 7 p. A448-
1 p.
 artikel
206 Are Monoclonal Antibodies Still Considered as Innovative by the French Health Care System? A Retrospective Analysis 2000-2012 Conti, C.C.
 2013
 16 7 p. A483-
1 p.
 artikel
207 Are Patients’ Preferences for Osteoporosis Drug Treatment Transferable Between Countries? Results from a Discrete-Choice Experiment Conducted in Two European Countries Hiligsmann, M.
 2013
 16 7 p. A568-A569
nvt p.
 artikel
208 Are Public Subsidies Effective to Reduce Hospitalizations Rapp, T.
 2013
 16 7 p. A551-
1 p.
 artikel
209 Are the Biotechnology and Pharmaceutical Sectors Defensive Relative to the S&P 500? Furnback, W.
 2013
 16 7 p. A454-
1 p.
 artikel
210 A Retrospective Analysis of Drug Reimbursement Decisions in Ireland: A Multi Criteria Decision Analysis Approach Schmitz, S.
 2013
 16 7 p. A465-
1 p.
 artikel
211 A Retrospective Study Comparing Compliance, Persistence, and Blood Pressure Control Between Free-Drug and Single-Pill Combination Therapies in Korean Hypertensive Patients Hong, J.M.
 2013
 16 7 p. A534-A535
nvt p.
 artikel
212 A Review of Clinical Trial Simulation Methods Schuetz, C.A.
 2013
 16 7 p. A593-
1 p.
 artikel
213 A Review of Cognitive Interviewing Methodologies During Linguistic Validation of Clinical Outcome Assessments (COAs) Simon, M.
 2013
 16 7 p. A602-A603
nvt p.
 artikel
214 A Review of Cost-Effectiveness Evaluations as Part of National HTA Assessments of Biologic Dmards in the Treatment of Rheumatoid Arthritis Iannazzo, S.
 2013
 16 7 p. A571-
1 p.
 artikel
215 A Review of Methods Used in Health Economic Models of Chronic Myeloid Leukemia Interventions Marsh, K.
 2013
 16 7 p. A593-
1 p.
 artikel
216 A Review of the Application of International Reference Pricing in Ukraine’s Pilot Hypertension Reimbursement Scheme Rainova, K.
 2013
 16 7 p. A538-
1 p.
 artikel
217 Argentina’s Generic Drug Law: Was It Successful? Lee, B.
 2013
 16 7 p. A672-
1 p.
 artikel
218 Argentinian Survey in Cost of Illness and Unmet Needs in Multiple Sclerosis: Treatment Experience & the Costs of MS Patients in Argentina Kuperman, G.
 2013
 16 7 p. A721-
1 p.
 artikel
219 A Societal Perspective Cost-Utility Analysis of Rivaroxaban Compared with Enoxaparin Sodium in Patients Undergoing Total Hip or Total Knee Replacement Surgery Stollenwerk, B.
 2013
 16 7 p. A530-
1 p.
 artikel
220 Assesment of the Cost of Biological Therapy in Rheumatic Diseases: Economic Impact of Dosage Modification in Clinical Practice Manrique-Arija, S.
 2013
 16 7 p. A559-
1 p.
 artikel
221 Assessing Measurement Equivalence of Different Forms of Administration of the Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR) Using Rasch Analysis Twiss, J.
 2013
 16 7 p. A606-
1 p.
 artikel
222 Assessing Non-Inferiority of Aclidinium Bromide 400 mG Bid Versus Tiotropium 18 mG and 5 mG Qd in Patients with Chronic Obstructive Pulmonary Disease (COPD) by Means of a Network Meta-Analysis Karabis, A.
 2013
 16 7 p. A367-
1 p.
 artikel
223 Assessing Product Safety via Patient Based Active Surveillance (AS): A Study in 30.000 Women Using Hormone Replacement Therapy (HRT) Heinemann, K.
 2013
 16 7 p. A331-
1 p.
 artikel
224 Assessing Quality of Life in Adult Growth Hormone Deficiency: Further Development of the QoL-AGHDA Graham, J.E.
 2013
 16 7 p. A446-A447
nvt p.
 artikel
225 Assessing the Burden of Caregiving for Patients with Lung Cancer in Europe Goren, A.
 2013
 16 7 p. A403-
1 p.
 artikel
226 Assessing the Economic Burden and Health Care Utilizations of the United States Veteran Patients Diagnosed with Schizophrenia Wang, L.
 2013
 16 7 p. A553-
1 p.
 artikel
227 Assessing the Economic Burden and Health Care Utilizations of Veteran Patients Diagnosed with Chronic Kidney Disease in the United States Wang, L.
 2013
 16 7 p. A632-
1 p.
 artikel
228 Assessing the Economic Burden and Health Care Utilizations of Veteran Patients Diagnosed with Post-Traumatic Stress Disorder in the United States Xie, L.
 2013
 16 7 p. A544-A545
nvt p.
 artikel
229 Assessing the Economic Burden and Health Care Utilizations of Veteran Patients Diagnosed with the Hepatitis C Virus in the United States Wang, L.
 2013
 16 7 p. A346-
1 p.
 artikel
230 Assessing the Fiscal Consequences of Immunizing the Female and Male Population Against Human Papillomavirus (HPV) in Germany Kotsopoulos, N.
 2013
 16 7 p. A363-
1 p.
 artikel
231 Assessing the Future Burden of Renal Replacement Therapy in the United Kingdom McEwan, P.
 2013
 16 7 p. A578-
1 p.
 artikel
232 Assessing the Impact of Organized Screening for Abdominal Aorta Aneurysms in Austria – Following Eunethta Core Information Urach, C.
 2013
 16 7 p. A540-
1 p.
 artikel
233 Assessing the Relationship Between the Diabetes Health Profile and Diabetes Specific Clinical Indicators: Case for Tailored Therapeutics Mulhern, B.
 2013
 16 7 p. A448-
1 p.
 artikel
234 Assessing the Significance of HbA1c Durability in Cost Effectiveness Analysis of 2nd Line Oral Therapies in the Management of Type 2 Diabetes Foos, V.
 2013
 16 7 p. A589-
1 p.
 artikel
235 Assessment and Causal Link Between Vision-Related Quality of Life and General Health Related Quality of Life in Dry Eye Patients Ernst, F.
 2013
 16 7 p. A510-
1 p.
 artikel
236 Assessment of a Canadian Primary Care Electronic Medical Record Database for Use in Observational Studies Frise, S.
 2013
 16 7 p. A582-
1 p.
 artikel
237 Assessment of Adverse Events By Using Trigger Tools in Surgery Department of an Indian Tertiary Care Teaching Hospital Vilakkathala, R.
 2013
 16 7 p. A677-A678
nvt p.
 artikel
238 Assessment of Burden of Illness Due to Herpes Zoster in Argentina: A Prospective Observational Study Vujacich, C.
 2013
 16 7 p. A668-
1 p.
 artikel
239 Assessment of Cost-Effectiveness Models for Biologics in the Management of Psoriatic Arthritis Gokhale, S.
 2013
 16 7 p. A717-
1 p.
 artikel
240 Assessment of Cost-Effectiveness Models for Biologics in the Management of Severe Ankylosing Spondylitis Gokhale, S.
 2013
 16 7 p. A717-
1 p.
 artikel
241 Assessment of Generic Drug Policy Implementation by Measuring Persistence with Antihypertensive Drug Therapies After Patent Expiry Abonyi-Tóth, Z.
 2013
 16 7 p. A537-
1 p.
 artikel
242 Assessment of Methodological Quality of Economic Evaluations in Belgian Drug Reimbursement Applications Simoens, S.
 2013
 16 7 p. A474-
1 p.
 artikel
243 Assessment of Patient Population with NSCLC by Stage, ECOG-PS, EGFR Mutation Status and Line of Therapy in Germany Schmidt, U.
 2013
 16 7 p. A397-
1 p.
 artikel
244 Assessment of Real-World Usage of Lanreotide (Somatuline Autogel) 120 Mg in Polish Acromegalic Patients – Results from 1 Year Prospective Phase of Lanro-Study Orlewska, E.
 2013
 16 7 p. A438-
1 p.
 artikel
245 Assessment of the Budgetary Impact of Improving the Use of Evidence-Based Medicine in the Treatment of Patients with Heart Failure and Left Ventricular Dysfunction in England Underhill, S.M.
 2013
 16 7 p. A518-
1 p.
 artikel
246 Assessment of the Economic Impact of Belimumab for the Treatment of Systemic Lupus Erithematosus in the Italian Setting: A Cost-Effectiveness Analysis Turchetti, G.
 2013
 16 7 p. A564-
1 p.
 artikel
247 Assessment of the Key Drivers of Cost-Effectiveness in the Economic Modelling of Canagliflozin (CANA) Versus Glimepiride (GLIM) in the Treatment of Type 2 Diabetes Mellitus (T2DM) in the UK Setting Thompson, G.
 2013
 16 7 p. A441-
1 p.
 artikel
248 Assessment of the Perception and Practices with Respect to Antibiotic Usage in Public Through Social Media Priyendu, A.
 2013
 16 7 p. A724-
1 p.
 artikel
249 Association Between Cognitive Function and 3 Month Health Care Costs Among Patients Initiating an Antidepressant for Depressive Disorder in an Ambulatory Care Setting Kurlander, J.L.
 2013
 16 7 p. A544-
1 p.
 artikel
250 Association Between Non-Motor Symptoms and Health Care Utilization Among Patients with Parkinson’s Disease in the United States Makaroff, L.
 2013
 16 7 p. A629-
1 p.
 artikel
251 Associations Between Overall Care Experience Ratings and Utility and Psychological Well-Being in Men Recently Diagnosed with Prostate Cancer: Findings from a Population-Based Study Hennessy, M.
 2013
 16 7 p. A419-
1 p.
 artikel
252 Astrological Signs and Health Problems; Demonstrating the Multiple Comparisons Problem Vegter, S.
 2013
 16 7 p. A477-
1 p.
 artikel
253 A Study of A. Baumannii in a Tertiary Care Hospital with Consideration to Risk Factors of Infection and Resistance Pattern Sudhapalli, V.
 2013
 16 7 p. A343-
1 p.
 artikel
254 A Systematic Comparison of Market Access and Reimbursement Pathways for Diagnostic Tests in Germany, United Kingdom and the United States Walzer, S.
 2013
 16 7 p. A473-A474
nvt p.
 artikel
255 A Systematic Evaluation of Drug-Drug Interactions in Prescriptions; Facts and Comparisons Ahmad, M.
 2013
 16 7 p. A461-A462
nvt p.
 artikel
256 A Systematic Literature Review on the Epidemiology and Economic Burden of Anaemia Associated with Chronic Kidney Disease Rizzo, M.
 2013
 16 7 p. A381-A382
nvt p.
 artikel
257 A Systematic Review and Critical Appraisal of Economic Evaluations of Radiotherapy for Cancer Barbieri, M.
 2013
 16 7 p. A409-
1 p.
 artikel
258 A Systematic Review and Network Meta-Analysis of Second-Line Anti-Diabetes Treatments for Those with Type 2 Diabetes Mellitus Inadequately Controlled by Sulfonylurea Monotherapy Orme, M.E.
 2013
 16 7 p. A432-
1 p.
 artikel
259 A Systematic Review of Antidepressants in Irritable Bowel Syndrome: A Qualitative Analysis Lindner, L.
 2013
 16 7 p. A493-
1 p.
 artikel
260 A Systematic Review of Cost-Of-Illness Studies and Cost-Effectiveness Analyses in Borderline Personality Disorder Brettschneider, C.
 2013
 16 7 p. A546-
1 p.
 artikel
261 A Systematic Review of Economic Evidence in Hepatitis C: An Overview of Cost, Utility and Cost-Effectiveness Data Woods, M.S.
 2013
 16 7 p. A349-
1 p.
 artikel
262 A Systematic Review of Economic Evidence in Hepatitis C: Methods Used in Recent Economic Evaluations Woods, M.S.
 2013
 16 7 p. A579-
1 p.
 artikel
263 A Systematic Review of Patient Preferences for Subcutaneous Medications Ridyard, C.
 2013
 16 7 p. A335-A336
nvt p.
 artikel
264 A Systematic Review of Patient Reported Outcomes in Glaucoma Aggarwal, S.
 2013
 16 7 p. A509-
1 p.
 artikel
265 A Systematic Review of Patients’ Treatment Satisfaction and/or Preference Patient-Reported Oucomes Measures Used in Clinical Trials Pease, S.
 2013
 16 7 p. A596-
1 p.
 artikel
266 A Systematic Review of the Effectiveness of Taxes in Preventing Obesity Trends Maniadakis, N.
 2013
 16 7 p. A391-
1 p.
 artikel
267 A Systematic Review on the Effect of Behavioral Versus Surgical Intervention on Obese Patients’ Psychological Well-Being Fortier, K.J.
 2013
 16 7 p. A387-
1 p.
 artikel
268 A Systems-Thinking Approach for the Health Care Industry: Strategies and Insights for Biopharma, Payers and Providers Hoschander, S.
 2013
 16 7 p. A491-
1 p.
 artikel
269 Atención Intercultural Del Parto Vaginal En México: Costos Económicos, Determinantes Y Retos De La Implementación De Políticas Efectivas En Beneficio De Las Mujeres Indígenas Heredia, I.
 2013
 16 7 p. A711-A712
nvt p.
 artikel
270 A Time-Motion Comparison of Itemized Treatment Costs in First Versus Subsequent Cycles of in Vitro Fertilization (IVF): Treatments Can Optimized for Improving Outcomes While Increasing Patient Volumes in Cost-Constrained Regions Jones, C.
 2013
 16 7 p. A709-
1 p.
 artikel
271 Atopic Dermatitis: Evaluation of 2 Different Drug Related Managements Taieb, C.
 2013
 16 7 p. A502-
1 p.
 artikel
272 Atopic Dermatitis in Adults: Design and Validation of a Specific Burden Questionnaire Taieb, C.
 2013
 16 7 p. A508-
1 p.
 artikel
273 Atrial Fibrillation’s Burden of Disease in Portugal Gouveia, M.
 2013
 16 7 p. A539-
1 p.
 artikel
274 Attainment of Low-Density Lipoprotein Cholesterol Goals in Patients at Very High Cardiovascular Risk in the United Kingdom: Results from a General Practice Population Study Ray, K.K.
 2013
 16 7 p. A513-
1 p.
 artikel
275 Attitude of Parents Towards Obligatory and Recommended Childhood Vaccination Lehocká, L.
 2013
 16 7 p. A362-
1 p.
 artikel
276 Attitudes, Beliefs and Behaviours of General Practitioners Regarding Vaccination: Development of a Characterisation Tool – Qualitative Steps Tugaut, B.
 2013
 16 7 p. A365-
1 p.
 artikel
277 Attitudes of Physicians Toward Implementing Shared Medical Appointments at National Guard Family Medicine Centers in Riyadh Alhowimel, M.H.
 2013
 16 7 p. A538-
1 p.
 artikel
278 Audit of the Coverage Decision-Making Process in a Government Agency in Uruguay: From the Guidelines Till the Patients Garcia Marti, S.
 2013
 16 7 p. A674-
1 p.
 artikel
279 A UK Case Study of Societal and Herd-Effect Impact of Universal Mass Influenza Vaccination in the United Kingdom Meier, G.
 2013
 16 7 p. A353-
1 p.
 artikel
280 A Unified Methodological Framework for the Economic Evaluation of Therapeutic Medical Devices Iglesias, C.P.
 2013
 16 7 p. A702-
1 p.
 artikel
281 Australian Standard Costs and Consequences of Four Chemotherapy Adverse Events Pearce, A.M.
 2013
 16 7 p. A404-
1 p.
 artikel
282 Avaliação Do Impacto Orçamentário Com a Incorporação De Imunobiológicos Em Uma Operadora De Planos De Saúde – 2012 Reis, H.P.L.C.
 2013
 16 7 p. A715-A716
nvt p.
 artikel
283 A 10-Year Review of the Canadian Common Drug Review: Pharmaceutical Manufacturers’ Success Rate Shum, D.
 2013
 16 7 p. A464-
1 p.
 artikel
284 Barriers of Access to Elective Orthopedic Procedures in Rio De Janeiro, Brazil Fernandes, R.A.
 2013
 16 7 p. A719-
1 p.
 artikel
285 Barriers to Biologic Therapy Use for Autoimmune Disorders in Emerging Markets Gross, H.J.
 2013
 16 7 p. A389-
1 p.
 artikel
286 Barriers Underlying Limited Utilisation of Vaccines Throughout Life (Lifespan Immunisation) Ghosh, S.
 2013
 16 7 p. A364-
1 p.
 artikel
287 Baseline Characteristics and Vitreoretinal Interface Features in Patients with Vitreomacular Traction and Macular Hole from the MIVI-TRUST Clinical Program Lescrauwaet, B.
 2013
 16 7 p. A502-
1 p.
 artikel
288 Baseline Characteristics, Weight and Glycaemic Change Among Patients in the United Kingdom with Type 2 Diabetes Mellitus (T2DM) Prescribed a New Antidiabetic Treatment Class in a Real World Setting Blak, B.T.
 2013
 16 7 p. A432-
1 p.
 artikel
289 Baseline Patient, Ocular Features and Management of a Patient Population Diagnosed with Vitreomacular Traction: An Observational Study in Flanders Lescrauwaet, B.
 2013
 16 7 p. A502-
1 p.
 artikel
290 Basic Attitude Towards Health Care Resource Allocation Decision Making in Japanese People -Utilitarianism or Egalitarianism? Saito, S.
 2013
 16 7 p. A469-
1 p.
 artikel
291 Bayesian Analysis of Malformation Outcome in Selective Serotonin Reuptake Inhibitor (SSRI) Use During Pregnancy: An Indirect Comparison of Citalopram, Fluoxetine, Paroxetine, and Sertraline Ip, Q.
 2013
 16 7 p. A544-
1 p.
 artikel
292 Bayesian Calibration Method to Estimate Transition Probabilities for a Markov Model Based on a Continuous Outcome Measure: Application in Parkinson’s Disease Neine, M.
 2013
 16 7 p. A325-A326
nvt p.
 artikel
293 Bayesian Evidence Synthesis of Safety Data: A Robust Option? Amzal, B.
 2013
 16 7 p. A592-
1 p.
 artikel
294 Bayesian Network Meta-Analysis to Assess Relative Efficacy and Safety of Canagliflozin in Patients with Type 2 Diabetes Mellitus (T2DM) Inadequately Controlled with Metformin Pacou, M.
 2013
 16 7 p. A609-
1 p.
 artikel
295 Bayesian Network Meta-Analysis to Assess the Relative Efficacy and Safety of Canagliflozin in Patients with Type 2 Diabetes Mellitus (T2DM) Inadequately Controlled on Metformin and Sulphonylurea (MET+SU) Pacou, M.
 2013
 16 7 p. A431-
1 p.
 artikel
296 Benefit of Adding Panitumumab to FOLFOX4 in Patients with KRAS/NRAS Wild-Type (WT) Metastatic Colorectal Cancer (mCRC): A Number-Needed-To-Treat (NNT) Analysis Douillard, J.Y.
 2013
 16 7 p. A395-
1 p.
 artikel
297 Benefits of Vildagliptin Plus Metformin Combination Therapy in Type 2 Diabetes Mellitus (T2DM) from Patient’s Perspective: Quality of Life (QoL) and Hypoglycemia Burden Analysis Ionova, T.I.
 2013
 16 7 p. A447-
1 p.
 artikel
298 Beta-Thalassemia Patients Survey on Deferrization Therapy Xia, S.
 2013
 16 7 p. A727-
1 p.
 artikel
299 Beyond Patent Expiry: Development of a Model for Pricing Generic Drugs in South Africa Keele, M.G.
 2013
 16 7 p. A466-
1 p.
 artikel
300 ‘Big Data’ in Health Care. What Does It Mean and Will It Make a Difference? Velthuis, E.J.
 2013
 16 7 p. A479-
1 p.
 artikel
301 Biological Agents in the Treatment of Moderate to Severe Psoriasis: A Pharmacoeconomic Analysis Riveros, B.S.
 2013
 16 7 p. A726-
1 p.
 artikel
302 Biological Treatment Patterns and Associated Costs for Patients with Rheumatoid Arthritis in Taiwan Wu, C.H.
 2013
 16 7 p. A561-A562
nvt p.
 artikel
303 Biosimilar and Originator Biologic Pricing Dynamics in Emerging Markets Lockwood, C.
 2013
 16 7 p. A467-
1 p.
 artikel
304 Bisphosphonates-Associated Osteonecrosis of Jaw in Cancer Patients: A Meta-Analysis Lin, H.C.
 2013
 16 7 p. A392-
1 p.
 artikel
305 Bis Sensor Versus Conventional Anesthetic Monitoring: Systematic Review on Patient-Oriented Outcomes Nobre, M.R.C.
 2013
 16 7 p. A378-
1 p.
 artikel
306 Bivariate Indirect Comparison Meta-Analysis Model in Economic Evaluation of Cancer Treatments Tan, S.H.
 2013
 16 7 p. A594-
1 p.
 artikel
307 Boceprevir Use in France: A Markov Model of Disease Progression and Cost-Effectiveness for Chronic Hepatitis C (Virus G1) Ferrante, S
 2013
 16 7 p. A359-
1 p.
 artikel
308 Bone Evaluation Study (BEST): Prevalence and Treatment Rates of Male Patients with Osteoporosis (OP) in Germany Hadji, P.
 2013
 16 7 p. A574-
1 p.
 artikel
309 Breast Cancer Screening Program in the Basque Country: Costs and Health Benefits Assessment Through Discrete Event Simulation Arrospide, A.
 2013
 16 7 p. A399-A400
nvt p.
 artikel
310 Budget Impact Analisis of Switching from DPT and Monovalent Vaccines to DTaP–IPV-Hib Combined Vaccine into Russian Immunization Schedule Kulikov, A.
 2013
 16 7 p. A343-
1 p.
 artikel
311 Budget Impact Analysis for the Use of Vandetanib in Mexican Adult Patient Diagnosed with Advanced Unresectable Medullary Thyroid Cancer Ascencio, I.S.I.
 2013
 16 7 p. A683-
1 p.
 artikel
312 Budget Impact Analysis of Abiraterone Acetate in Metastatic Castration-Resistant Prostate Cancer Patients Previously Treated with Docetaxel from the Perspective of the Brazilian Private Health Care System Vitale, V.
 2013
 16 7 p. A665-
1 p.
 artikel
313 Budget Impact Analysis of a New Fixed-Dose Combination Inhaler for a Clinical Commissioning Group within the National Health Service in England Dunlop, W.
 2013
 16 7 p. A368-
1 p.
 artikel
314 Budget Impact Analysis of Apixaban for the Prevention of Venous Thrombo-Embolism in Patients Undergoing Orthopedic Replacement Surgery in Italy Mantovani, L.G.
 2013
 16 7 p. A518-
1 p.
 artikel
315 Budget Impact Analysis of Biologic Drugs for Treatment of Poliarticular Juvenile Rheumatoid Arthritis in Russia Ignatyeva, V.
 2013
 16 7 p. A559-
1 p.
 artikel
316 Budget Impact Analysis of Biosimilar Infliximab Treatment for Rheumatoid Arthritis in Six Central European Countries Brodszky, V.
 2013
 16 7 p. A558-
1 p.
 artikel
317 Budget Impact Analysis of Botulinum Toxin a Therapy for Upper Limb Spasticity in the United Kingdom Kurth, H.
 2013
 16 7 p. A620-
1 p.
 artikel
318 Budget Impact Analysis of Ceftaroline Versus Linezolid or Vancomycin on the Top of Standard Therapy in the Treatment of Complicated Skin and Soft Tissues Infections in Russian Federation Kulikov, A.
 2013
 16 7 p. A345-
1 p.
 artikel
319 Budget Impact Analysis of Deferasirox in the Treatment of Non Transfusion Dependent Thalassemia in Greece Masoura, P.
 2013
 16 7 p. A378-A379
nvt p.
 artikel
320 Budget Impact Analysis of Fentanyl Buccal Tablet for the Treatment of Cancer Breaktrough Pain Darba, J.
 2013
 16 7 p. A400-
1 p.
 artikel
321 Budget Impact Analysis of Ipilimumab for the Treatment of Advanced Melanoma in the Veneto Region, Italy Adami, S
 2013
 16 7 p. A399-
1 p.
 artikel
322 Budget Impact Analysis of Renal Post-Transplant Prophylaxis with Belatacept in Colombia Alfonso-Cristancho, R.
 2013
 16 7 p. A697-
1 p.
 artikel
323 Budget Impact Analysis of Rivaroxaban in the Prevention of Stroke in Non-Valvular Atrial Fibrillation Patients in Italy Capri, S.
 2013
 16 7 p. A519-
1 p.
 artikel
324 Budget Impact Analysis of Routine Gentamicin-Collagen Implants for the Prevention of Surgical Site Infection (SSI) in High Risk Cardiothoracic Surgery Patients Satherley, A.W.
 2013
 16 7 p. A518-
1 p.
 artikel
325 Budget Impact Analysis of Step-Down Strategy Versus Conventional Therapy in the Treatment of Nosocomial Pneumonia Caused by Gram Positive Bacteria in Mexico Peniche-Otero, G.
 2013
 16 7 p. A368-
1 p.
 artikel
326 Budget Impact and Thresholds: How Are Real Decisions Made? - Expected Utility or Prospect Theory? Adams, R.
 2013
 16 7 p. A490-
1 p.
 artikel
327 Budget Impact of an Individualized Approach in the Treatment of HBeAg-Negative CHB Patients Exploiting the Week-12 Peginterferon Alfa-2a Stopping Rule in Italy Iannazzo, S.
 2013
 16 7 p. A344-
1 p.
 artikel
328 Budget Impact of Dienogest in Treating Endometriosis Associated Pelvic Pain in Brazil: A Public Perspective Analysis Ferracini, M.
 2013
 16 7 p. A331-A332
nvt p.
 artikel
329 Budget Impact of Everolimus for Tuberous Sclerosis Complex (TSC) Related Angiomyolipoma (AML): United Kingdom Perspective Whalen, J.D.
 2013
 16 7 p. A620-
1 p.
 artikel
330 Budget Impact of HPV16/18 Genotyping Tests for the Management of Non-concordant Cotesting Cervical Cancer Screening Results: A United States Payer Perspective Huang, J.
 2013
 16 7 p. A331-
1 p.
 artikel
331 Budget Impact of Lipegfilgrastim for the Management of Chemotherapy-Induced Neutropenia Montouchet, C.
 2013
 16 7 p. A401-
1 p.
 artikel
332 Budget Impact of Metastatic Castrate-Resistant Prostate Cancer (CRPC) to German Payers Jensen, I.S.
 2013
 16 7 p. A398-
1 p.
 artikel
333 Budget Impact of Paliperidone Palmitate in Austria Ransmayr, S.
 2013
 16 7 p. A544-
1 p.
 artikel
334 Budget Impact of Switching from an Immediate-Release to a Prolonged-Release Formulation of Tacrolimus in Renal Transplant Recipients in the UK Based on Differences in Adherence Pollock, R.F.
 2013
 16 7 p. A631-
1 p.
 artikel
335 Budget Impact of Switching Pramipexole Immediate Release to Pramipexole Extended Release in Treatment of Parkinson’s Disease; Perspective of the Social Security Institution Kececioglu, S.
 2013
 16 7 p. A621-
1 p.
 artikel
336 Budget Impact of the Introduction of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir, the First Integrase Inhibitor-Based Single Tablet Antiretroviral Regimen for HIV Treatment, to Third Party Payers in the United States Brogan, A.
 2013
 16 7 p. A343-A344
nvt p.
 artikel
337 Budget Impacts of Probiotics in Controlling Upper Respiratory Tract Infections in France Berdeaux, G.
 2013
 16 7 p. A344-
1 p.
 artikel
338 Building a Real World Practice-Based Network Data Platform to Link Rare Disease Patients: Case Study of Myelofibrosis Patients in the United States Lee, A.
 2013
 16 7 p. A583-
1 p.
 artikel
339 Burden of Actinic Keratosis in Germany-Results of a Literature Research Pfiffner, C.
 2013
 16 7 p. A503-
1 p.
 artikel
340 Burden of Cystic Fibrosis in the Russian Federation Holownia, M.
 2013
 16 7 p. A384-
1 p.
 artikel
341 Burden of Disease of Cervical Dystonia in the United Kingdom Raluy, M.
 2013
 16 7 p. A573-
1 p.
 artikel
342 Burden of Dose Escalation with Biologics in Rheumatoid Arthritis: A Review of Frequency and Costs Moots, R.
 2013
 16 7 p. A573-
1 p.
 artikel
343 Burden of Herpes Zoster and Post-Herpetic Neuralgia in Sweden Nilsson, J.
 2013
 16 7 p. A347-
1 p.
 artikel
344 Burden of Hospitalization in Patients with Advanced Lung Cancer in the United States Taylor-Stokes, G.
 2013
 16 7 p. A424-
1 p.
 artikel
345 Burden of Informal Care in Relation to Disease Activity and Disability in Polish Patients with Rheumatoid Arthritis Szafraniec-Burylo, S.I.
 2013
 16 7 p. A567-
1 p.
 artikel
346 Burden of Infusion-Related Costs and Staff Time for Rheumatoid Arthritis in the Hospital Setting Ogden, K.
 2013
 16 7 p. A559-
1 p.
 artikel
347 Burden of L-Dopa-Induced Dyskinesia in Parkinson’s Disease Patients (PD-LID) in France – the Lidia Study Economic Analysis (Levodopa Induced Dyskinesia Impact Evaluation) Kryskowiak, P.
 2013
 16 7 p. A622-
1 p.
 artikel
348 Burden of Multiple Sclerosis and Unmet Needs in Brazil: Cost of Illness Study Silva, N.L.
 2013
 16 7 p. A720-A721
nvt p.
 artikel
349 Burden of Multiple Sclerosis and Unmet Needs in Brazil: Health Care Resource Utilization Silva, N.L.
 2013
 16 7 p. A722-
1 p.
 artikel
350 Burden of Multiple Sclerosis and Unmet Needs in Brazil: Measurement of Fatigue Using Modified Fatigue Impact Scale Silva, N.L.
 2013
 16 7 p. A722-
1 p.
 artikel
351 Burden of Multiple Sclerosis and Unmet Needs in Brazil: Measurement of Health-Related Quality of Life Using EQ-5D Silva, N.L.
 2013
 16 7 p. A722-
1 p.
 artikel
352 Burden of Varicella in Eastern Europe: A Systematic Review and Critical Analysis Yang, H.K.
 2013
 16 7 p. A342-A343
nvt p.
 artikel
353 Burden of Varicella in Latin America: A Systematic Review and Critical Analysis Yang, H.K.
 2013
 16 7 p. A712-
1 p.
 artikel
354 Calibration of a Cost-Effectiveness Model to Evaluate the Incorporation of a Quadrivalent HPV Types 6, 11, 16, 18 Vaccine in Argentina: Disease Burden Component Pichon-Riviere, A.
 2013
 16 7 p. A701-
1 p.
 artikel
355 Calidad De Prescripción De Antibióticos En El Servicio De Pediatria De Un Hospital General De Cardenas, Tabasco, México Zavala-González, M.A.
 2013
 16 7 p. A709-
1 p.
 artikel
356 Canadian Burden of Choroidal Neovascularization Secondary to Pathologic Myopia: Baseline Characteristics of Patients Zaour, N.
 2013
 16 7 p. A504-
1 p.
 artikel
357 Canadian Private Payers’ Perceptions and Expectations of Submission Requests for Drug Reimbursement Submitted by the Pharmaceutical Industry Charaan, M.
 2013
 16 7 p. A476-
1 p.
 artikel
358 Can Administrative Data Predict Chemotherapy Adverse Events? Pearce, A.M.
 2013
 16 7 p. A392-
1 p.
 artikel
359 Can a Multi-Criteria Decision (MCD) Optimisation Model Help Decision Makers in the Optimal Selection of Vaccines When Expanding Their Universal Mass Vaccination Programme? The Case of Poland Topachevskyi, O.
 2013
 16 7 p. A615-
1 p.
 artikel
360 Cancer Patients May Have a Different Point of View on Oncology Drug Coverage Decisions Than Non-Patients Foley, K.
 2013
 16 7 p. A423-
1 p.
 artikel
361 Can the Use of Social Media and Mobile Apps Improve Patient Knowledge of Disease and Health Outcomes? A Systematic Review Abogunrin, S.
 2013
 16 7 p. A326-
1 p.
 artikel
362 Can Variation in Hospital Procedure Rates Identify Candidates for Health Technology Reassessment and Disinvestment? Hollingworth, W.
 2013
 16 7 p. A470-
1 p.
 artikel
363 Can We Use the EQ-5D Only for Assessing the Quality of Life of Patients with Osteoporosis? Tadic, I.
 2013
 16 7 p. A601-
1 p.
 artikel
364 Características Socioeconómicas De Pacientes Con Enfermedad Vascular Cerebral Y Antecedentes De Tabaquismo Tratados En Un Hospital De Tercer Nivel De México Quintana Carrillo, R.H.
 2013
 16 7 p. A725-
1 p.
 artikel
365 Carbon Cost-Effectiveness of Cocooning Immunization Against Pertussis in England and Wales: An Ecological Perspective Terlinden, A.
 2013
 16 7 p. A578-
1 p.
 artikel
366 Caregiver Burden in Fragile X Syndrome as a Function of a Health State Utility Index in the United States Raspa, M.
 2013
 16 7 p. A625-
1 p.
 artikel
367 Catalogue of EQ-5D Scores for Chronic Conditions in Denmark Hvidberg, M.F.
 2013
 16 7 p. A595-
1 p.
 artikel
368 Catching the Low-Hanging Fruit in Medicines Optimisation Faria, R.
 2013
 16 7 p. A461-
1 p.
 artikel
369 Catheter-Associated Urinary Tract Infections: Cost Comparison Study from the Public Payer Perspective Tolentino, A.C.
 2013
 16 7 p. A698-
1 p.
 artikel
370 Causal Analysis of Longitudinal Patient Turnover Data at Hepatitis-C Lang, Z.
 2013
 16 7 p. A591-
1 p.
 artikel
371 Cell Therapies: Assessing the Patient Access Opportunities and Challenges That Lie Ahead Walker, R.
 2013
 16 7 p. A492-
1 p.
 artikel
372 Challenges in Modelling the Cost Effectiveness of Interventions in Cardiovascular Disease Burgers, L.T.
 2013
 16 7 p. A327-
1 p.
 artikel
373 Challenges of Conducting Economic Evaluations Using Linked Electronic Health Records - CPRD and HES in the United Kingdom Asaria, M.
 2013
 16 7 p. A580-
1 p.
 artikel
374 Change of Burden of Disease in German Rheumatoid Arthritis Patients Since the Uptake of TNF-Inhibitors: A Literature Review of German Real Life Data Wolff, M.
 2013
 16 7 p. A568-
1 p.
 artikel
375 Changes in Patient-Reported Outcomes Among Pediatric Leukemia and Lymphoma Patients During the First 2-Years Post Allogeneic Stem Cell Transplantation (alloSCT) Oberg, J.A.
 2013
 16 7 p. A421-
1 p.
 artikel
376 Characterising Preliminary Profile Paramaters for FDA Breakthrough Therapy Candidates Labban, M.
 2013
 16 7 p. A455-A456
nvt p.
 artikel
377 Characteristics of Children and Adolescents Using Proton Pump Inhibitors or Histamine-2-Receptor Antagonists: Analysis of Thin and Pharmo Databases Ruigómez, A.
 2013
 16 7 p. A494-
1 p.
 artikel
378 Characteristics of Hospitalizations Due to an Episode of Relapse in Multiple Sclerosis Brazilian Patients: A Retrospective Administrative Claims Analysis Under the Public Payer Perspective Takemoto, M.L.S.
 2013
 16 7 p. A721-
1 p.
 artikel
379 Characteristics of Patients with Chronic Obstructive Pulmonary Disease (COPD) Receiving Inhaled Corticosteroid/Long-Acting b2-ß2-agonist (ICS/LABA) Fixed Combination Products in English Primary Care Blak, B.T.
 2013
 16 7 p. A366-
1 p.
 artikel
380 Characterizing Disease Burden in an Ultra-Rare Disease in the United States: Transthyretin (TTR) Amyloidosis Patients & Caregivers Stewart, M.
 2013
 16 7 p. A386-
1 p.
 artikel
381 Chemotherapy Treatment Patterns, Health Care Costs, and Mortality of Lung Cancer Patients in Taiwan – A Longitudinal Study Between 2000 and 2008 Liang, F.W.
 2013
 16 7 p. A404-
1 p.
 artikel
382 Children with Atopic Dermatitis: Monitoring a French Cohort Over a Nine-Year Period Taieb, C.
 2013
 16 7 p. A502-A503
nvt p.
 artikel
383 Choosing Health States for Elicitation of Population Preferences for the EQ-5D Adams, R.
 2013
 16 7 p. A595-
1 p.
 artikel
384 Chronic Patients’ Access to Physicians Services in Times of Economic Crisis Kyriopoulos, I.I.
 2013
 16 7 p. A462-
1 p.
 artikel
385 Chronic Patients’ Perceptions About Generic Medicines in Greece: Findings from a Cross Sectional Survey Mylona, K.
 2013
 16 7 p. A469-
1 p.
 artikel
386 Chronic Patients Response to the Implementation of International Non-Proprietary Name (INN) Prescribing in Greece Mylona, K.
 2013
 16 7 p. A470-
1 p.
 artikel
387 Chronic Patients’ Willingness to Pay for an Alternative Drug with Innovative Characteristics Skroumpelos, A.
 2013
 16 7 p. A536-
1 p.
 artikel
388 Classification of Cognitive Dysfunction and Cognitive Normal Using Scores from Four Cognitive Assessments in Patients with Depressive Disorder Maruff, P.
 2013
 16 7 p. A578-
1 p.
 artikel
389 Clinical and Cost-effectiveness of a Procalcitonin Test as a Prompt Indicator of Prodomol Meningococcal Disease in Febrile Children: Cost-effectiveness Analysis Bell, J.M.
 2013
 16 7 p. A333-
1 p.
 artikel
390 Clinical and Cost-Effectiveness of Non-Pegylated Liposomal Doxorubicin for Non-Hodgkin Lymphoma: A Systematic Review Burda, A.
 2013
 16 7 p. A428-
1 p.
 artikel
391 Clinical and Economic Analysis of Mometasone Furoate Nasal Spray in the Treatment of Rhinosinusitis in Mexico Rely, K.
 2013
 16 7 p. A724-
1 p.
 artikel
392 Clinical and Health Economic Evidence Requirements for Obtaining Health Insurance Coverage for Innovative Medical Devices in Germany Schwander, B.
 2013
 16 7 p. A474-
1 p.
 artikel
393 Clinical Benefits of Immunosuppression Therapy in Renal Trasplant Patients. Systematic Review and Meta-Analysis Cerezo, O.
 2013
 16 7 p. A697-
1 p.
 artikel
394 Clinical Effectiveness Analysis of Deferasirox for the Treatment of Iron Overload Due to Frequent Blood Transfusions Walczak, J.
 2013
 16 7 p. A377-A378
nvt p.
 artikel
395 Clinical Effectiveness of Lacosamide and Its Impact on Concomitant Antiepileptic Drugs Consumption in the Czech Republic Klimes, J.
 2013
 16 7 p. A619-
1 p.
 artikel
396 Clinical, Epidemiological and Economic Metrics Difference Between HPV-Related and Traditional Head and Neck Cancers Coughlan, D.
 2013
 16 7 p. A489-
1 p.
 artikel
397 Clinical Guidelines Evidence as a Criterion for Changes in the Legislation Combating Tuberculosis Stepanenko, A
 2013
 16 7 p. A365-A366
nvt p.
 artikel
398 Clinical Outcome Assessments in FDA Oncology Labels Since 2010 Meyers, O.I.
 2013
 16 7 p. A420-
1 p.
 artikel
399 Clinical Outcomes and Health Care Costs Evaluation of Sulfonamides and Thiazolidinediones Compared with Dipeptidyl Peptidase 4 Inhibitors for the Treatment of Uncontrolled Diabetes Degli Esposti, L.
 2013
 16 7 p. A433-
1 p.
 artikel
400 Clinical Outcomes Assessments in Schizophrenia: A Systematic Literature Review Cooke, C.
 2013
 16 7 p. A575-
1 p.
 artikel
401 Clinical Outcomes in Schizophrenia Treated with Donepezil in Combination with Antipsychotics Ballesteros, J.
 2013
 16 7 p. A542-
1 p.
 artikel
402 Clinical Outcomes of Patients with Major Depressive Disorder Treated with Either Duloxetine or Selective Serotonin Reuptake Inhibitors in Mexico Hong, J.
 2013
 16 7 p. A694-
1 p.
 artikel
403 Clinical Practice Guideline Major Depressive Disorder for General Practitioners Kongsuk, T.
 2013
 16 7 p. A695-
1 p.
 artikel
404 Clinical Significance of Change in the Quality of Life-Assessment of Growth Hormone Deficiency in Adults (QoL-AGHDA) Score in Adult Growth Hormone Deficiency (AGHD) Wiid, Z.
 2013
 16 7 p. A449-
1 p.
 artikel
405 Co-administration of Antipsychotics and Anti-dementia Drugs in Austria Hinteregger, M.
 2013
 16 7 p. A331-
1 p.
 artikel
406 Cohort Analysis Assessing Health Care Costs Associated with Obesity at Various Places of Service in Employed Adults Abouzaid, S.
 2013
 16 7 p. A380-
1 p.
 artikel
407 Collaborative Care for Depression Management in Cancer: A Cost-Effectiveness Analysis Duarte, A.
 2013
 16 7 p. A412-
1 p.
 artikel
408 Comorbidities Associated to Atrial Fibrillation (AF) in Selected Latin America Countries Leyva-Bravo, V.
 2013
 16 7 p. A702-
1 p.
 artikel
409 Comorbidity Influence in the Control of Arterial Hypertension Sicras-Mainar, A.
 2013
 16 7 p. A512-
1 p.
 artikel
410 Comparación Del Trabajo En Equipo En Salas De Cirugía Entre Un Hospital Privado Y Uno Público De Bogotá, D.C Amaya Arias, A.C.
 2013
 16 7 p. A678-A679
nvt p.
 artikel
411 Comparación Indirecta De La Efectividad De La Combinación De Hipoglucemiantes Asociados a Metformina En Pacientes Diabéticos Tipo 2 Sanchez, O.
 2013
 16 7 p. A687-A688
nvt p.
 artikel
412 Comparative Analysis of the Cost and Metabolic Control in Diabetic Children Using Insulin Pumps Petkova, V.
 2013
 16 7 p. A437-
1 p.
 artikel
413 Comparative Cost-Consequence Analysis of the Bivalent and Quadrivalent Vaccines Against HPV in Spain López Belmonte, J.L.
 2013
 16 7 p. A408-
1 p.
 artikel
414 Comparative Costs Analysis of Conventional Strategy Versus Step-Down Strategy with Linezolid in the Treatment of Nosocomial Pneumonia Caused by Gram Positive Bacteria in Mexico Gryzbowski, E.
 2013
 16 7 p. A360-
1 p.
 artikel
415 Comparative Economic Analysis of Retreatment Strategies for HCV Genotype 1 Patients in Russia Ivakhnenko, O.
 2013
 16 7 p. A498-
1 p.
 artikel
416 Comparative Effectiveness of Active Versus Sham Acupuncture Versus Usual Care in the Management of Chronic, Non-Cancer Pain in Primary Care Saramago, P.
 2013
 16 7 p. A556-A557
nvt p.
 artikel
417 Comparative Effectiveness of Conservative Therapy Versus Cystectomy for Non-Muscle Invasive Bladder Cancer Patients Dinh, T.
 2013
 16 7 p. A408-
1 p.
 artikel
418 Comparative Effectiveness of Liraglutide Versus Sitagliptin in Type 2 Diabetes in the United Kingdom: A Retrospective Study in Primary Care Nyeland, M.E.
 2013
 16 7 p. A431-
1 p.
 artikel
419 Comparative Effectiveness of Peak and Trough Effects of Bimatoprost 0.03%/Timolol 0.5% Preservative-Free Fixed Combination for the Treatment of Open-Angle Glaucoma and Ocular Hypertension Harvey, B.
 2013
 16 7 p. A502-
1 p.
 artikel
420 Comparative Effectiveness of Triple Therapy Versus Dual Therapy for Chronic Hepatitis C Virus Infection in Kazakhstan Almadiyeva, A.
 2013
 16 7 p. A345-
1 p.
 artikel
421 Comparative Efficacy and Metabolic Side Effects of Lurasidone for the Management of Acute Schizophrenia: A Systematic Literature Review and Mixed Treatment Comparison with First and Second Generation Antipsychotics Guelfucci, F.
 2013
 16 7 p. A542-A543
nvt p.
 artikel
422 Comparative Efficacy of Blood Pressure Lowering Drugs in Primary Prevention for Elderly Patients Brouwers, F.
 2013
 16 7 p. A703-
1 p.
 artikel
423 Comparative Efficiency Research: Meta-Analysis of Cost-Effectiveness Studies Crespo, C.
 2013
 16 7 p. A617-
1 p.
 artikel
424 Comparative Evaluation of the Appropriateness of the Prescribing in Geriatrics Inpatients Using Beers Criteria 2012 and 2003 Bansal, D.
 2013
 16 7 p. A673-
1 p.
 artikel
425 Comparative Responsiveness of Direct and Mapped SF-6D Preference-Based Measures in Colorectal Cancer Wong, C.K.H.
 2013
 16 7 p. A420-
1 p.
 artikel
426 Comparative Study of the Cost-Effectiveness of Trastuzumab in the Treatment of Breast Cancer in Different Countries Rabbani, S.
 2013
 16 7 p. A411-
1 p.
 artikel
427 Compared Analysis of Inequalities in Health and Influence of Social Determinants of Health in Cuba and USA Diaz de León-Castañeda, C.
 2013
 16 7 p. A711-
1 p.
 artikel
428 Comparing Copd Costs By Exacerbation Frequency and Dyspnoea Level in a Primary Care Setting in the United Kingdom Punekar, Y.S.
 2013
 16 7 p. A723-
1 p.
 artikel
429 Comparing Costs and Consequences of Treating Chronic Obstructive Pulmonary Disease with Budesonide/Formoterol and Fluticasone/Salmeterol Roggeri, A.
 2013
 16 7 p. A371-
1 p.
 artikel
430 Comparing Costs Per Clinical Remission of Tocilizumab Monotherapy Versus Adalimumab Monotherapy in Patients with Rheumatoid Arthritis: A Brazilian Private Perspective Buschinelli, C.T.
 2013
 16 7 p. A716-
1 p.
 artikel
431 Comparing Health-Related Quality of Life Across Rheumatoid Arthritis, Psoriatic Arthritis and Axial Spondyloarthritis: Analyses from Certolizumab Pegol Clinical Trial Baseline Data Mease, P.J.
 2013
 16 7 p. A570-
1 p.
 artikel
432 Comparing Quality of Life and Clinical Variables for the Prediction of Future Medical Events Rendas-Baum, R.
 2013
 16 7 p. A676-
1 p.
 artikel
433 Comparing the Efficacy of First and Second Generation Disease-Modifying Therapies for Relapsing-Remitting Multiple Sclerosis: A Network Meta-Analysis Fogarty, E.
 2013
 16 7 p. A618-
1 p.
 artikel
434 Comparing the Health Care Costs and Utilizations Between Patients with Anxiety Versus Those Without Xie, L.
 2013
 16 7 p. A545-
1 p.
 artikel
435 Comparing the Performance of the EQ-5D-5L with the EQ-5D-3L in Stroke Patients in Japan Noto, S.
 2013
 16 7 p. A534-
1 p.
 artikel
436 Comparing the Potential Budget Impact of Novel Therapies for Advanced Melanoma in Second-Line Under Brazilian Private Health Care System Perspective Tsuchiya, C.T.
 2013
 16 7 p. A683-
1 p.
 artikel
437 Comparing the Value of Different HTA Decision Making Process: Evaluating the Evaluators Johannesen, K.M.
 2013
 16 7 p. A489-
1 p.
 artikel
438 Comparing Virtual Colonography with Conventional Colonoscopy for Colorectal Cancer Screening: What are the Drivers of Cost-effectiveness? Kriza, C.
 2013
 16 7 p. A328-
1 p.
 artikel
439 Comparison Between Everolimus (Afinitor®) and Chemotherapy Agents (Capecitabine, Docetaxel and Doxorubicin) for the Treatment of Hormone Receptor Positive (HR+) HER2 Negative (HER2–) Advanced or Metastatic Breast Cancer Vieira, J.
 2013
 16 7 p. A396-
1 p.
 artikel
440 Comparison of Alternative Methods of Resource-Use Data Collection for the Economic Evaluation of Health Care Interventions: A Case Study in Frail Older People Franklin, M.
 2013
 16 7 p. A578-
1 p.
 artikel
441 Comparison of Clinical Characteristics of Patients with Rheumatoid Arthritis Receiving Their First Biologic and Biologic-Naïve Patients Considered Biologic-Suitable in the United States Narayanan, S.
 2013
 16 7 p. A571-
1 p.
 artikel
442 Comparison of Clinical Characteristics of Patients with Rheumatoid Arthritis Receiving Their First Biologic in Europe Union and the United States Narayanan, S.
 2013
 16 7 p. A572-
1 p.
 artikel
443 Comparison of Dabigatran Etexilate Versus Warfarin, Asprin & No Treatment for Stroke Prevention in Atrial Fibrillation in England, United Kingdom, Over 5 Years Sunderland, T.J.
 2013
 16 7 p. A519-
1 p.
 artikel
444 Comparison of Dabigatran Etexilate Versus Warfarin for Stroke Prevention in Atrial Fibrillation in Ireland Over 5 Years McCarron, C.
 2013
 16 7 p. A519-
1 p.
 artikel
445 Comparison of Development Diagnosis Related Groups Base Rate in Hungary and Germany Ágoston, I.
 2013
 16 7 p. A454-
1 p.
 artikel
446 Comparison of Disease Status, Treatments and Outcomes of Patients with Psoriatic Arthritis Receiving Their First Biologic in the European Union and United States Narayanan, S.
 2013
 16 7 p. A571-
1 p.
 artikel
447 Comparison of Drug Assessments in France, Germany and the United Kingdom: Is European HTA a Reality? Troubat, A.
 2013
 16 7 p. A482-
1 p.
 artikel
448 Comparison of Elderly Adults by Number of Rx Medications Used: Results from the National Health and Wellness Survey Across 5EU Countries Annunziata, K.
 2013
 16 7 p. A336-
1 p.
 artikel
449 Comparison of Health Care Resource Utilization and Costs Among Children and Adolescents with Attention Deficit Hyperactivity Disorder in Germany Who Initiated Treatment with Atomoxetine or Long-Acting Methylphenidate Curtice, T.G.
 2013
 16 7 p. A549-A550
nvt p.
 artikel
450 Comparison of Markov and Discrete Event Simulation Modeling Techniques with Application to Cost Effectiveness Analyses Chrosny, W.(
 2013
 16 7 p. A587-
1 p.
 artikel
451 Comparison of Methods to Identify Stage IIIB or IV Metastatic Lung Cancer Patients from Electronic Medical Records Stafkey-Mailey, D.
 2013
 16 7 p. A582-
1 p.
 artikel
452 Comparison of the Health Care Costs and Utilizations Between Patients Diagnosed with the Hepatitis B Virus Versus Those Without Xie, L.
 2013
 16 7 p. A351-
1 p.
 artikel
453 Comparison of the Prices Used in the Manufacturers’ Budget Impact Analyses and the Prices from Reimbursed Drugs List Iwanczuk, T.
 2013
 16 7 p. A584-
1 p.
 artikel
454 Comparison of Treatment Satisfaction in Patients with Asthma Taking Leukotriene Modifiers Verus Those Taking Inhaled Corticosteroids Tomaszewski, E.L.
 2013
 16 7 p. A375-
1 p.
 artikel
455 Comparison Retail Prices of Drug Prices Between Turkey and European Countries Kockaya, G.
 2013
 16 7 p. A457-
1 p.
 artikel
456 Comparisons of the Clinical Effectiveness of Treatments for the Symptoms Associated with Overactive Bladder (OAB) Edwards, S.J.
 2013
 16 7 p. A630-
1 p.
 artikel
457 Comparisons of the Risk for Venous Thromboembolism Between Hip and Knee Arthroplasty Using Korea National Health Insurance Claims Database Kim, Y.J.
 2013
 16 7 p. A558-
1 p.
 artikel
458 Compliance Protects Against Fracture in Women with Postmenopausal Osteoporosis in Hungary Lakatos, P.
 2013
 16 7 p. A567-
1 p.
 artikel
459 Compliance with Preventive Recommendations in Primary Care and Rate of Potentially Avoided Hospitalizations by Diabetes, Chronic Heart Failure or Chronic Pulmonary Obstructive Disease Aizpuru, F.
 2013
 16 7 p. A537-
1 p.
 artikel
460 Comprehensive Overview: Efficacy, Tolerability and Cost- Effectiveness of Irbesartan Gialama, F.
 2013
 16 7 p. A527-
1 p.
 artikel
461 Conceptual and Practical Considerations when Dealing with Missing Utility Data in Longitudinal Trials, and Subsequent Use in Cost-Effectiveness Analyses Weston, A.R.
 2013
 16 7 p. A325-
1 p.
 artikel
462 Conditional Survival (CS) Probabilities for Advanced Melanoma Patients Treated with Ipilimumab: Model Based Analysis Lee, D.
 2013
 16 7 p. A398-
1 p.
 artikel
463 Confidential Patient Access Schemes in the United Kingdom – Do They Affect Prices in Other Markets? Nijhuis, T.
 2013
 16 7 p. A472-A473
nvt p.
 artikel
464 Confirmatory Factor Analysis and Evaluation of Clinically Important Differences in Menopause-Specific Quality of Life Associated with Bazedoxifene/Conjugated Estrogens in a Vulvar/Vaginal Atrophy Population Abraham, L.
 2013
 16 7 p. A337-
1 p.
 artikel
465 Confronting Heterogeneity: Using Systematic Review Effectively for Meta-Analysis Quigley, J.M.
 2013
 16 7 p. A612-
1 p.
 artikel
466 Considering Economic Analyses in the Revision of the Preventive Vaccination Law: A New Direction for Health Policy-Making in Japan? Akazawa, M.
 2013
 16 7 p. A364-
1 p.
 artikel
467 Consistency of Current Type 2 Diabetes (T2DM) Treatment Patterns in General Practice Versus the 2013 French Has T2DM Guidelines: A Transversal Study Based on the French IMS LifelinkTM Prospective Diabetes Cohort Larger, E.
 2013
 16 7 p. A449-
1 p.
 artikel
468 Construcción De Un Modelo De Priorización Aplicable a Latinoamérica – El Caso De Colombia Avila, A.
 2013
 16 7 p. A681-
1 p.
 artikel
469 Constructing an Index of International Pharmaceutical Prices. A Comparison of Pharmaceutical Prices in 56 Countries Davey, P.
 2013
 16 7 p. A458-A459
nvt p.
 artikel
470 Consumption of Biosimilar Drugs in Campania Region in the Years 2009-2012 Menditto, E.
 2013
 16 7 p. A457-
1 p.
 artikel
471 Consumption Patterns, Market Characteristics and Regulation in the Pharmaceutical Industry: Evidence from Two Therapeutic Groups in Insured Population in Argentina Maceira, D.
 2013
 16 7 p. A700-
1 p.
 artikel
472 Continued Improvements in Workplace and Household Productivity with Certolizumab Pegol Treatment in Axial Spondyloarthritis, Including Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis: 48-Week Results from the Rapid-axSpA Study van der Heijde, D.
 2013
 16 7 p. A570-
1 p.
 artikel
473 Continuos Renal Replacement Therapy Versus Intermittent Hemodialysis: Systematic Review on Patient-Oriented Outcomes Nobre, M.R.C.
 2013
 16 7 p. A630-
1 p.
 artikel
474 Contribution of Latin America to Mental Health in Pregnancy Lorenzo, L.S.
 2013
 16 7 p. A695-A696
nvt p.
 artikel
475 Copyright/Subscription 2013
 16 7 p. vi-
1 p.
 artikel
476 Coronary Artery Disease, Diabetes, and Health-Related Quality of Life: Findings of a Cohort Study from India Shah, B.S.
 2013
 16 7 p. A535-A536
nvt p.
 artikel
477 Correlación Entre Los Niveles De LDL-C Frente Al Riesgo De Presentación De Evento Cardiovascular Simbaqueba, E.
 2013
 16 7 p. A706-A707
nvt p.
 artikel
478 Correlating Cost Effectiveness Output with Patient Level Data Input Via the IMS Core Diabetes Model (CDM) McEwan, P.
 2013
 16 7 p. A587-
1 p.
 artikel
479 Correlation Between Montgomery-Asberg Depression Rating Scale (MADRS) and the Beck Depression Inventory II (BDI-II) in Patients with Focal Epilepsy Garcia, M.E.
 2013
 16 7 p. A627-
1 p.
 artikel
480 Correlation Between Prognostic Factors and Non Prosthetic Further Fracture Related Treatment After Femoral Neck Fracture Underwent Internal Fixation in Elderly Sebestyén, A.
 2013
 16 7 p. A558-
1 p.
 artikel
481 Correlations Between Changes in the Urticaria Activity Score (UAS7) and the Dermatology Life Quality Index (DLQI) from Baseline to 28 or 40 Weeks: Comparisons of Trajectories of Change in Patients with Chronic Spontaneous/Idiopathic Urticaria (CSU/CIU) Stull, D.E.
 2013
 16 7 p. A509-
1 p.
 artikel
482 Cost Analysis for Patients Hospitalised for Heart Failure in Germany Baierlein, J.
 2013
 16 7 p. A523-
1 p.
 artikel
483 Cost-Analysis in the Treatment of Patients Affected by Malignant Ascites in Italy Teruzzi, C.
 2013
 16 7 p. A407-
1 p.
 artikel
484 Cost Analysis of a Fibrin Sealant Patch for Mild, Moderate and Problematic Soft Tissue Surgical Bleeding: A Hospital Perspective Corral, M.
 2013
 16 7 p. A380-
1 p.
 artikel
485 Cost Analysis of Alprostadil (Prostavasin®) as Treatment for Patients with Peripheral Arterial Disease Stages III and IV Compared with Lumbar Sympathectomy in Mexico Carlos, F.
 2013
 16 7 p. A529-
1 p.
 artikel
486 Cost Analysis of an Intensive Care Unit Putignano, D.
 2013
 16 7 p. A468-
1 p.
 artikel
487 Cost Analysis of Anti-Migraine Prescribing Using a Claims Database Truter, I.
 2013
 16 7 p. A619-
1 p.
 artikel
488 Cost Analysis of Bypassing Agent Prophylaxis Treatment Versus On-Demand Therapy in Hemophilia a with Inhibitor in Spain Villarrubia, R.
 2013
 16 7 p. A380-
1 p.
 artikel
489 Cost Analysis of Proton Pump Inhibitors in the Treatment of Ulcer Duodenum in Ukraine Iakovlieva, L.
 2013
 16 7 p. A495-
1 p.
 artikel
490 Cost Analysis of Pulmonary Arterial Hypertension in a Tertiary Care Setting in Mexico City Rely, K.
 2013
 16 7 p. A704-A705
nvt p.
 artikel
491 Cost Analysis of the Use of an Operating Room with Full-Rotation 3-D Intraoperative Imaging and Navigation in Different Spine Surgeries Rodríguez, D.
 2013
 16 7 p. A560-
1 p.
 artikel
492 Cost Analysis of Vaccination for Children in Ukraine Antonchak, Z.
 2013
 16 7 p. A346-
1 p.
 artikel
493 Cost and Cost-Effectiveness Analyses for Moderate and Severe COPD Patients Treated Uniquely with Tiotropium 18 Mcg Od for Twenty-Four Months Povero, M.
 2013
 16 7 p. A369-
1 p.
 artikel
494 Cost and Cost-Effectiveness of Treating Urgency Stress Incontinence-Results from a Randomized Controlled Trial Kafri, R
 2013
 16 7 p. A632-A633
nvt p.
 artikel
495 Cost and Length of Stay Associated with Vancomycin-Induced Nephrotoxicity Stevens, V.
 2013
 16 7 p. A349-
1 p.
 artikel
496 Cost and Quality of Dying in Hospital: Results from the Argentine-Health Care Cost and Utilization Project (A-HCUP) Insua, J.T.
 2013
 16 7 p. A680-
1 p.
 artikel
497 Cost Assessment of Metastatic and Non-Metastatic Castration-Resistant Prostate Cancer Patient-Management in Spain Morote, J.
 2013
 16 7 p. A405-
1 p.
 artikel
498 Cost Associated with Adverse Events and Health Care Resources Utilization in Hepatitis C Virus Infection in Quebec, Canada Lachaine, J.
 2013
 16 7 p. A349-A350
nvt p.
 artikel
499 Cost/Benefit Analysis of First Line Chronic Lymphocytic Leukemia (CLL) Treatments in Mexico Wehler, E.
 2013
 16 7 p. A684-
1 p.
 artikel
500 Cost Burden of Rotavirus Gastro-enteritis Requiring Hospitalizations in the Czech Republic and in Slovakia Vitova, V.
 2013
 16 7 p. A332-
1 p.
 artikel
501 Cost-Comparison Between Different Treatment Regimens in Diabetes Mellitus in Germany Based on Long Acting Insulins Anderten, H.
 2013
 16 7 p. A435-
1 p.
 artikel
502 Cost-Consequence Analysis of a Treatment Strategy Including Ponatinib Compared to a Treatment Strategy Including Only the 2nd Generation Tyrosine Kinase Inhibitors (2g TKIs), Dasatinib or Nilotinib, in Resistant Patients with Philadelphia Chromosome-Positive (Ph+) Leukemia, in Italy Chiroli, S.
 2013
 16 7 p. A382-A383
nvt p.
 artikel
503 Cost-Effectiveness Analyses of Natalizumab for 2nd Line Versus Glatiramer Acetate in the Treatment of Relapsing-Remitting Multiple Sclerosis Patients in Brazil Nishikawa, A.M.
 2013
 16 7 p. A721-
1 p.
 artikel
504 Cost-Effectiveness Analyses of Natalizumab for 1st Line Versus Interferon Beta-1a 44 Mcg in the Treatment of Highly Active Relapsing-Remitting Multiple Sclerosis Patients in Brazil Nishikawa, A.M.
 2013
 16 7 p. A721-A722
nvt p.
 artikel
505 Cost-Effectiveness Analysis (CEA) of Linezolid Versus Vancomycin in the Treatment of Nosocomial Pneumonia Caused by Methicillin-Resistant Staphylococcus Aureus (MRSA-NP) Based on a Phase IV Clinical Trial: Results from Four Major Cities in China Wan, Y.
 2013
 16 7 p. A358-
1 p.
 artikel
506 Cost Effectiveness Analysis for the Use of Extended Release Quetiapine as Adjunctive Therapy in Mexican Adult Patients with Major Depressive Disorder Non-Responders to Antidepressant Treatment Polanco, A.C.
 2013
 16 7 p. A547-
1 p.
 artikel
507 Cost-effectiveness Analysis in the Treatment of Heavy Menstrual Bleeding in Spain Lete, I.
 2013
 16 7 p. A333-
1 p.
 artikel
508 Cost-Effectiveness Analysis of Abiraterone Acetate as Second Line Treatment for Metastatic Castration-Resistant Prostate Cancer After Docetaxel Treatment in Japan Shibahara, H.
 2013
 16 7 p. A415-A416
nvt p.
 artikel
509 Cost-Effectiveness Analysis of Alendronate Therapy for Secondary Prevention of Osteoporotic Fractures Moriwaki, K.
 2013
 16 7 p. A571-
1 p.
 artikel
510 Cost-Effectiveness Analysis of Apixaban in the Treatment of Atrial Fibrillation in Mexico Galindo-Suárez, R.M.
 2013
 16 7 p. A524-
1 p.
 artikel
511 Cost-Effectiveness Analysis of Apixaban Versus Dabigatran for Prevention of Stroke in Patients with Non-Valvular Atrial Fibrillation in Spain Betegón Nicolás, L.
 2013
 16 7 p. A523-
1 p.
 artikel
512 Cost-Effectiveness Analysis of Apixaban Versus Rivaroxaban for Prevention of Stroke in Patients with Non-Valvular Atrial Fibrillation in Spain Canal Fontcuberta, C.
 2013
 16 7 p. A523-
1 p.
 artikel
513 Cost-Effectiveness Analysis of Atorvastatin Compared to Simvastatin in the Prevention of Cardiovascular Diseases in the Czech Republic Klimes, J.
 2013
 16 7 p. A528-
1 p.
 artikel
514 Cost-Effectiveness Analysis of a Vaccination Programme for the Prevention of Herpes Zoster and Post-Herpetic Neuralgia in Adults Aged 50 and Over in Germany Largeron, N.
 2013
 16 7 p. A383-
1 p.
 artikel
515 Cost-Effectiveness Analysis of Biological Disease-Modifying Antirheumatic Drugs in the Treatment of Russian Patients with Rheumatoid Arthritis Who Failed Previous Anti-Tnf-Alfa Therapy Ryazhenov, V.V.
 2013
 16 7 p. A562-A563
nvt p.
 artikel
516 Cost Effectiveness Analysis of Boceprevir (BOC) Added to Pegifn/Ribavirin (P/R) Versus Pegifn/Ribavirin (Current Standard of Care) for the Treatment of Patients with Genotype 1 Chronic Hepatitis C in Greece Athanasakis, K.
 2013
 16 7 p. A352-
1 p.
 artikel
517 Cost-Effectiveness Analysis of 3 Candins and Fluconazole in the Treatment of Confirmed Invasive Candidiasis in Adult Non-Neutropaenic Patients in Spain Grau, S.
 2013
 16 7 p. A351-A352
nvt p.
 artikel
518 Cost-Effectiveness Analysis of Capsule Endoscopy in Screening for Colorectal Cancer in Japan Sakamaki, H.
 2013
 16 7 p. A414-
1 p.
 artikel
519 Cost-Effectiveness Analysis of Carbapenems in Treatment Nosocomian Pneumonia in Ukraine Iakovlieva, L.
 2013
 16 7 p. A372-
1 p.
 artikel
520 Cost-Effectiveness Analysis of Cysteamine in the Treatment of Patients with Cystinosis – a Rare Disease Walczak, J.
 2013
 16 7 p. A383-
1 p.
 artikel
521 Cost-Effectiveness Analysis of Dapaglifozin Versus Other T2DM Treatments in the Spanish Context Abad Paniagua, E.J.
 2013
 16 7 p. A439-
1 p.
 artikel
522 Cost-Effectiveness Analysis of Diagnostic Tests in the Work-Up of Patients with Intermediate Risk of Developing Rheumatoid Arthritis Buisman, L.R.
 2013
 16 7 p. A563-
1 p.
 artikel
523 Cost-Effectiveness Analysis of Empiric Liposomal Amphotericin B Versus Voriconazole in Turkey Turner, S.J.
 2013
 16 7 p. A356-
1 p.
 artikel
524 Cost-Effectiveness Analysis of Etanercept in the Treatment of Rheumatoid Arthritis in Institutional Market in Ecuador Albuja, M.F.
 2013
 16 7 p. A717-
1 p.
 artikel
525 Cost-Effectiveness Analysis of Glycopyrronium Bromide in the Treatment of Chronic Obstructive Pulmonary Disease in Spain Torres, C.
 2013
 16 7 p. A372-
1 p.
 artikel
526 Cost-Effectiveness Analysis of Incorporation of the HPV Vaccine to the National Immunization Program / NIP of Brazil Novaes, H.M.D.
 2013
 16 7 p. A685-
1 p.
 artikel
527 Cost-Effectiveness Analysis of Insulin Degludec Compared with Current Standard of Care in the Management of Type 1 and Type 2 Diabetes Mellitus in the Spanish Health System Ramirez de Arellano, A.
 2013
 16 7 p. A442-
1 p.
 artikel
528 Cost-Effectiveness Analysis of Ivabradine in Chronic Heart Failure in the Polish Setting Borowiec, L.
 2013
 16 7 p. A528-A529
nvt p.
 artikel
529 Cost-Effectiveness Analysis of Lacosamide Compared with Standard of Antiepileptic Care Based on Clinical Practice Data Vocelka, M.
 2013
 16 7 p. A623-A624
nvt p.
 artikel
530 Cost-Effectiveness Analysis of Linezolid and Vancomycin in Patients with Complicated Skin and Soft-Tissue Infections Caused by Methicilin-Resistant Staphylococcus in Portugal Inês, M.
 2013
 16 7 p. A506-
1 p.
 artikel
531 Cost-Effectiveness Analysis of Palivizumab as a Prophylaxis for Respiratory Syncytial Virus (RSV) Infection in High-Risk Late Preterm Infants in the Netherlands Langenfeld, M.K.
 2013
 16 7 p. A372-
1 p.
 artikel
532 Cost-Effectiveness Analysis of Rabbit Antithymocyte Globulin Compared to Basiliximab in the Induction of Renal Transplant Patients Escudero, P.
 2013
 16 7 p. A698-A699
nvt p.
 artikel
533 Cost-Effectiveness Analysis of Rivaroxaban in Secondary Prevention of ACS in Sweden Begum, N.
 2013
 16 7 p. A524-
1 p.
 artikel
534 Cost-Effectiveness Analysis of Stribild Compared to Similar Antiretroviral Therapies in a Specialty Retail Pharmacy Griggs, S.K.
 2013
 16 7 p. A355-
1 p.
 artikel
535 Cost-Effectiveness Analysis of Tocilizumab in Rheumatoid Arthritis, in Colombia Gamboa, O.
 2013
 16 7 p. A563-
1 p.
 artikel
536 Cost-Effectiveness and Cost-Utility Analysis of Belimumab for the Treatment of Patients with Systemic Lupus Erythematosus in Portugal Gouveia, M.
 2013
 16 7 p. A384-
1 p.
 artikel
537 Cost-Effectiveness and Cost-Utility Analysis of Mifamurtide Plus Combination Chemotherapy in Pediatric Patients with Osteosarcoma After Resection Surgery Vargas-Romero, J.A.
 2013
 16 7 p. A686-
1 p.
 artikel
538 Cost-Effectiveness Comparison of Genotype 1 Hepatitis C Virus (HCV) Treatments Using Telaprevir (TVR) in Patients with Mild Fibrosis Versus Patients with Bridging Fibrosis and Cirrhosis D’Angelo, E.R.
 2013
 16 7 p. A354-
1 p.
 artikel
539 Cost Effectiveness Evaluation of a Rotavirus Vaccination Program in Argentina Garcia Marti, S.
 2013
 16 7 p. A709-
1 p.
 artikel
540 Cost-Effectiveness Modelling of a 3-Month Tight Control Patient Management of Rheumatoid Arthritis with Certolizumab Pegol in France Fagnani, F.
 2013
 16 7 p. A562-
1 p.
 artikel
541 Cost-Effectiveness of an Interface Geriatric Intervention: Acute Medical Unit Comprehensive Geriatric Assessment Intervention Study (AMIGOS) Tanajewski, L.
 2013
 16 7 p. A465-A466
nvt p.
 artikel
542 Cost-Effectiveness of Antidepressant After 24 Months of Treatment Based on Discrete Event Simulation Modeling (DESM): Agomelatine Versus Matrix Comparator of Escitalopram, Sertraline and Venlafaxine in a Thai Setting Satra, T.
 2013
 16 7 p. A547-
1 p.
 artikel
543 Cost-Effectiveness of Antimicrobials as Treatment for Patients with Complicated Skin and Soft Tissues Infections: A Comparison Between Ceftaroline, Linezolid and Vancomycin in the Russian Health Care Kulikov, A.
 2013
 16 7 p. A355-
1 p.
 artikel
544 Cost Effectiveness of Anti-Oxidant Vitamin + Zinc Treatment to Prevent the Progression of Intermediate Age Related Macular Degeneration to Its Wet Form. A Singapore Perspective Saxena, N.
 2013
 16 7 p. A506-
1 p.
 artikel
545 Cost-Effectiveness of Anti-Rabies Prophylaxis After Exposure to Unobservable Dogs in Eradication Context: The French Case N’Diaye, D.S.
 2013
 16 7 p. A354-
1 p.
 artikel
546 Cost-Effectiveness of Apixaban Versus Other New Oral Anticoagulants for the Prevention of Stroke: An Analysis of Patients with Atrial Fibrillation in Greece Athanasakis, K.
 2013
 16 7 p. A525-
1 p.
 artikel
547 Cost-Effectiveness of Apixaban Versus Standard of Care for the Prevention of Stroke: An Analysis of Patients with Atrial Fibrillation in Greece Athanasakis, K.
 2013
 16 7 p. A524-A525
nvt p.
 artikel
548 Cost Effectiveness of Apomorphine in the Treatment of Advanced Parkinson Disease in the UK and Germany: Results from a Multicounty Decision Analytic Model Walter, E.
 2013
 16 7 p. A622-
1 p.
 artikel
549 Cost-Effectiveness of Asenapine in the Treatment of Bipolar Disorder I Patients with Mixed Episodes Azorin, J.M.
 2013
 16 7 p. A549-
1 p.
 artikel
550 Cost-Effectiveness of Asenapine Versus Atypical Antipsychotics Used in Turkey in the Treatment of Bipolar I Disorder Pala, M.
 2013
 16 7 p. A548-
1 p.
 artikel
551 Cost-Effectiveness of Asenapine Versus Atypical Antipsychotics Used in Turkey in the Treatment of Schizophrenia Pala, M.
 2013
 16 7 p. A548-
1 p.
 artikel
552 Cost-Effectiveness of a 13-Valent Conjugate Pneumococcal Vaccination Program in COPD Patients Aged ≥50 Years in Spain: Preliminary Results Menendez, R.
 2013
 16 7 p. A353-
1 p.
 artikel
553 Cost-Effectiveness of Basiliximab As Induction Therapy for Kidney Transplantation in Mexico Lemus, A.
 2013
 16 7 p. A699-
1 p.
 artikel
554 Cost-Effectiveness of Bendamustine-Rituximab in First-Line Indolent NHL: A Patient-Level Simulation Dewilde, S.
 2013
 16 7 p. A415-
1 p.
 artikel
555 Cost-Effectiveness of Bendamustine Versus Fludarabine for First-Line Treatment of Chronic Lymphocytic Leukemia (CLL) in Colombia Bertwistle, D.
 2013
 16 7 p. A413-
1 p.
 artikel
556 Cost-Effectiveness of Biologic Therapies for the Treatment of Moderate to Severe Psoriasis in the United Kingdom Betts, K.A.
 2013
 16 7 p. A505-A506
nvt p.
 artikel
557 Cost-Effectiveness of Boceprevir Add-On Treatment of Hepatitis C Virus Genotype 1 Patients in Denmark Ehlers, L.
 2013
 16 7 p. A354-
1 p.
 artikel
558 Cost-Effectiveness of Breast Cancer Surveillance by Lifetime Risk in Women Aged Less Than 50 Years Teljeur, C.
 2013
 16 7 p. A412-
1 p.
 artikel
559 Cost-Effectiveness of Cabazitaxel in mHRPC in Turkey Yesil, A.
 2013
 16 7 p. A413-
1 p.
 artikel
560 Cost-Effectiveness of Capsule Endoscopy (Pillcam®) in the Diagnosis of Small Bowel Crohn’s Disease Makino, K.
 2013
 16 7 p. A498-
1 p.
 artikel
561 Cost-Effectiveness of Caspofungin Versus Voriconazole for Empiric Therapy in Turkey Turner, S.J.
 2013
 16 7 p. A356-
1 p.
 artikel
562 Cost-Effectiveness of Childhood Rotavirus Vaccination in Germany Aidelsburger, P.
 2013
 16 7 p. A351-
1 p.
 artikel
563 Cost-Effectiveness of Cinacalcet Chronic Kidney Disease Patients on Dialysis with Secondary Hyperparathyroidism in Brazilian Public Health Care System (SUS) Nishikawa, A.M.
 2013
 16 7 p. A698-
1 p.
 artikel
564 Cost-Effectiveness of Cobas® EGFR Mutation Test Versus Sanger Sequencing in the Treatment of Locally Advanced or Metastatic NSCLC: A Payer Perspective in the United Kingdom Towse, A.
 2013
 16 7 p. A410-
1 p.
 artikel
565 Cost-Effectiveness of Combined Treatment of Metformin and Fenofibrate on Retinopathy Progression Hren, R.
 2013
 16 7 p. A438-
1 p.
 artikel
566 Cost-Effectiveness of Dabigatran Etexilate for the Secondary Prevention of Recurrent Deep Vein Thrombosis and Pulmonary Embolism in the United Kingdom Wolowacz, S.
 2013
 16 7 p. A526-
1 p.
 artikel
567 Cost-Effectiveness of Dapagliflozin as Add-On to Insulin for the Treatment of Type 2 Diabetes in the Netherlands van Haalen, H.G.M.
 2013
 16 7 p. A441-
1 p.
 artikel
568 Cost-Effectiveness of Drug-Eluting Stents Versus Bare Metal Stents in Egyptian Diabetic Patients ElSisi, G.
 2013
 16 7 p. A530-
1 p.
 artikel
569 Cost-Effectiveness of Early Versus Delayed Hepatitis C Virus (HCV) Treatment with Telaprevir/Pegylated Interferon Alpha/Ribavirin Triple Therapy in Adults Aged 40+ in France Lee, A.
 2013
 16 7 p. A497-
1 p.
 artikel
570 Cost-Effectiveness of EML4-ALK Fusion Testing and First-Line Crizotinib Treatment for Patients with Advanced ALK Positive Non-Small Cell Lung Cancer in a Publicly Funded System (Ontario, Canada) Djalalov, S.
 2013
 16 7 p. A410-
1 p.
 artikel
571 Cost-Effectiveness of Enzyme Replacement Therapy (ERT) with Alglucosidase Alfa in Classic-Infantile Patients with Pompe Disease Kanters, T.A.
 2013
 16 7 p. A384-
1 p.
 artikel
572 Cost-Effectiveness of Fesoterodine and Tolterodine for the Treatment of Overactive Bladder with Urge Urinary Incontinence in Spain and Finland Angulo, J.
 2013
 16 7 p. A633-
1 p.
 artikel
573 Cost-Effectiveness of First-Line Treatment of Advanced Metastatic Non Small Cell Lung Cancer- A Systematic Review of Economic Models Eijgelshoven, I.
 2013
 16 7 p. A414-A415
nvt p.
 artikel
574 Cost-Effectiveness of Fixed-Dose Combination (FDC) of Vildagliptin/Metformin for the Treatment of Diabetes Mellitus Type 2 in Mexico Lemus, A.
 2013
 16 7 p. A689-
1 p.
 artikel
575 Cost-Effectiveness of Gemcitabine Plus Cisplatin Versus Gemcitabine Alone for Treatment of Advanced Biliary Tract Cancer in Japan Arakawa, I.
 2013
 16 7 p. A416-
1 p.
 artikel
576 Cost-Effectiveness of Glatiramer Acetate and Interferon Beta-1a for Relapsing-Remitting Multiple Sclerosis, Based on the Combirx Study Darba, J.
 2013
 16 7 p. A623-
1 p.
 artikel
577 Cost-Effectiveness of Glycopyrronium Compared to Tiotropium in COPD Patients from a Swedish Societal Perspective Costa-Scharplatz, M.
 2013
 16 7 p. A371-A372
nvt p.
 artikel
578 Cost-Effectiveness of Hepatitis C Virus (HCV) Treatment with Telaprevir/Pegylated Interferon Alpha/Ribavirin Triple Therapy Versus Waiting for New Regimens in France Lee, A.
 2013
 16 7 p. A497-
1 p.
 artikel
579 Cost-Effectiveness of Increasing Statin Adherence for Primary and Secondary Prevention in Community Pharmacies Vegter, S.
 2013
 16 7 p. A528-
1 p.
 artikel
580 Cost Effectiveness of Induction Anesthetic Agents Nagappa, A.N.
 2013
 16 7 p. A383-
1 p.
 artikel
581 Cost-Effectiveness of Induction Treatment with Bortezomib Added to Thalidomide and Dexamethasone in Newly Diagnosed Multiple Myeloma Patients Eligible for Autologous Stem Cell Transplantation in Germany van Beurden-Tan, C.
 2013
 16 7 p. A409-A410
nvt p.
 artikel
582 Cost-effectiveness of Infant Pneumococcal Vaccination in the Netherlands Vemer, P.
 2013
 16 7 p. A334-
1 p.
 artikel
583 Cost-Effectiveness of Injectable Atypical Long-Acting Antipsychotics for Chronic Schizophrenia in Poland Hemels, M.
 2013
 16 7 p. A548-
1 p.
 artikel
584 Cost-Effectiveness of Insulin Degludec Compared with Insulin Glargine for Patients with Type 2 Diabetes Mellitus Initiating Insulin Therapy in the United Kingdom Evans, M.
 2013
 16 7 p. A442-
1 p.
 artikel
585 Cost-Effectiveness of Insulin Degludec Compared with Insulin Glargine in a Basal-Bolus Regimen in Patients with Type 1 Diabetes Mellitus in the United Kingdom Chubb, B.
 2013
 16 7 p. A442-
1 p.
 artikel
586 Cost-Effectiveness of Insulin Detemir in T2DM Patients Poorly Controlled with NPH Insulin in Poland Kaczor, M.P.
 2013
 16 7 p. A442-
1 p.
 artikel
587 Cost-Effectiveness of Intralesional Injection of Recombinant Human Epidermal Growth Factor for the Treatment of Severe Diabetic Foot Ulcers in Russian Health Care Setting Ignatyeva, V.
 2013
 16 7 p. A440-
1 p.
 artikel
588 Cost-Effectiveness of Intravitreal Aflibercept in Treating Neovascular Age-Related Macular Degeneration in Sweden Clements, K.M.
 2013
 16 7 p. A506-
1 p.
 artikel
589 Cost-Effectiveness of Linaclotide Compared to Antidepressants in the Treatment of Irritable Bowel Syndrome with Constipation in Scotland Fisher, M.
 2013
 16 7 p. A497-
1 p.
 artikel
590 Cost-Effectiveness of Linezolid Versus Vancomycin in the Treatment of Ventilator Associated Pneumonia in Jamaica Garita, M.
 2013
 16 7 p. A352-
1 p.
 artikel
591 Cost-effectiveness of Maternal Toxoplasma Screening in Austria: A Decision-analytic Model Prusa, A.R.
 2013
 16 7 p. A333-
1 p.
 artikel
592 Cost-Effectiveness of Medication Adherence Enhancing Interventions: A Systematic Review Oberjé, E.
 2013
 16 7 p. A335-
1 p.
 artikel
593 Cost-Effectiveness of Mirabegron Compared with Antimuscarinics for the Treatment of Patients with Overactive Bladder in the United Kingdom Maman, K.
 2013
 16 7 p. A633-A634
nvt p.
 artikel
594 Cost-Effectiveness of Mirabegron Compared with Tolterodine ER 4mg for the Treatment of Patients with Overactive Bladder in the United Kingdom: Results from a Trial-Based Model Aballéa, S.
 2013
 16 7 p. A633-
1 p.
 artikel
595 Cost-Effectiveness of Paliperidone Palmitate for the Treatment of Schizophrenia in Germany Zeidler, J.
 2013
 16 7 p. A547-
1 p.
 artikel
596 Cost Effectiveness of Paliperidone Palmitate in National Health Service (NHS) Wales: A Cost Utility Analysis Based on the National Institute for Health and Care Excellence (NICE) Core Model for the Management of Schizophrenia Lee, J.
 2013
 16 7 p. A549-
1 p.
 artikel
597 Cost Effectiveness of Paliperidone Palmitate Versus Risperidone Long-Acting Injectable, Quetiapine and Olanzapine for the Treatment of Patients with Schizophrenia in Colombia Casallas, C.
 2013
 16 7 p. A695-
1 p.
 artikel
598 Cost-Effectiveness of Paricalcitol in End Stage Chronic Kidney Disease Secondary Hyperparathyroidism Patients on Dialysis, in Brazil Menezes, F.G.
 2013
 16 7 p. A698-
1 p.
 artikel
599 Cost-Effectiveness of Paricalcitol Versus Parathyroidectomy for Secondary Hyperparathyroidism to Chronic Kidney Disease in Mexico Sanchez-Casillas, J.L.
 2013
 16 7 p. A689-
1 p.
 artikel
600 Cost-Effectiveness of Pazopanib as First Line Treatment for Metastatic Renal Cell Carcinoma in Brazil: Updated Analysis Pepe, C.
 2013
 16 7 p. A685-
1 p.
 artikel
601 Cost-Effectiveness of Peginterferon Alfa and Ribavirin for the Treatment of Children and Young People with Chronic Hepatitis C from the Perspective of the NHS in England and Wales Lion, M.
 2013
 16 7 p. A352-
1 p.
 artikel
602 Cost Effectiveness of Pharmacogenetic Screening Prior to Initiation of Carbamazepine Treatment for Epilepsy Plumpton, C.O.
 2013
 16 7 p. A624-
1 p.
 artikel
603 Cost-Effectiveness of Plerixafor (PXF) for Stem Cell Mobilization in Lymphoma (NHL/HL) and Multiple Myeloma (MM) Patients in Poland Kaczor, M.P.
 2013
 16 7 p. A384-A385
nvt p.
 artikel
604 Cost Effectiveness of Prepex Device and Dorsal–Slit Technique for Scaling-Up Adult Safe Medical Male Circumcision in HIV Prevention in Rural Central Uganda Kigenyi, O.
 2013
 16 7 p. A356-
1 p.
 artikel
605 Cost-Effectiveness of Ranibizumab for the Treatment of Visual Impairment Due to Choroidal Neovascularization Secondary to Pathologic Myopia in the United Kingdom Leteneux, C.
 2013
 16 7 p. A505-
1 p.
 artikel
606 Cost-Effectiveness of Rivaroxaban in the Prevention of Stroke in Non-Valvular Atrial Fibrillation Patients in Italy Capri, S.
 2013
 16 7 p. A525-A526
nvt p.
 artikel
607 Cost-Effectiveness of Routine Infant Vaccination Strategies in Russia: An Economic Evaluation Yagudina, R.I.
 2013
 16 7 p. A355-
1 p.
 artikel
608 Cost-Effectiveness of Sapropterin Versus Phenylalanine Free Diet in Patients with Phenylketonuria in Egypt ElSisi, G.
 2013
 16 7 p. A385-
1 p.
 artikel
609 Cost-Effectiveness of School-Based Health Promotion in Canada: A Life-Course Modeling Approach Tran, B.
 2013
 16 7 p. A391-
1 p.
 artikel
610 Cost-Effectiveness of Sequences of Biologic Treatments for Moderate-To-Severe Psoriasis in Finland Asseburg, C.
 2013
 16 7 p. A507-A508
nvt p.
 artikel
611 Cost-Effectiveness of Somatropin Administration with Increased Adherence Due to Monitoring Compared to Non-Monitored Administration in Patients with Growth Hormone Deficiency Vitova, V.
 2013
 16 7 p. A622-A623
nvt p.
 artikel
612 Cost-Effectiveness of Statins for Primary Prevention in Newly Diagnosed Type 2 Diabetes Patients in the Netherlands de Vries, F.M.
 2013
 16 7 p. A526-
1 p.
 artikel
613 Cost-Effectiveness of Sugammadex for Routine Reversal of Neuromuscular Blockade, with Extubation at a TOF Ratio of 0.9, in Anaesthetised Patients Undergoing Elective Surgery in England and Wales Praet, C.
 2013
 16 7 p. A383-
1 p.
 artikel
614 Cost-Effectiveness of Systematic Testing for Lynch Syndrome in Patients Newly Diagnosed with Colorectal Cancer in the United Kingdom Huxley, N.
 2013
 16 7 p. A414-
1 p.
 artikel
615 COST-EFFECTIVENESS OF TELAPREVIR COMBINATION THERAPY COMPARED TO PEGINTERFERON WITH RIBAVIRIN ALONE FOR NAIVE AND TREATMENT EXPERIENCED PATIENTS WITH GENOTYPE 1 CHRONIC HEPATITIS C IN POLAND Kaczor, M.P.
 2013
 16 7 p. A359-A360
nvt p.
 artikel
616 Cost-Effectiveness of Telaprevir in Genotype 1 Chronic Hepatitis C Virus (HCV) Infection in Argentina Garcia Marti, S.
 2013
 16 7 p. A692-
1 p.
 artikel
617 Cost-Effectiveness of Telaprevir in Genotype 1 Chronic Hepatitis C Virus (HCV) Infection in Chile Garcia Marti, S.
 2013
 16 7 p. A692-A693
nvt p.
 artikel
618 Cost-Effectiveness of Telaprevir in Genotype 1 Chronic Hepatitis C Virus (HCV) Infection in Colombia Garcia Marti, S.
 2013
 16 7 p. A693-
1 p.
 artikel
619 Cost-Effectiveness of Telaprevir in Genotype 1 Chronic Hepatitis-C Virus Infection in Venezuela Garcia Marti, S.
 2013
 16 7 p. A714-
1 p.
 artikel
620 Cost-Effectiveness of Telaprevir Plus Peginterferon/Ribavirin (TVR+PR) Versus Peginterferon/Ribavirin (PR) in Treatment-Naïve Genotype 1 Chronic Hepatitis C Patients with F2 Fibrosis in Brazil Morais, A.D.
 2013
 16 7 p. A354-
1 p.
 artikel
621 Cost-Effectiveness of the Optical Imaging Agent Hexaminolevulinate for Patients with Non-Muscle Invasive Bladder Cancer Marteau, F.
 2013
 16 7 p. A408-A409
nvt p.
 artikel
622 Cost-Effectiveness of the Systematic Identification and Treatment of Comorbid Major Depression for People with Chronic Diseases: The Example of Cancer Walker, S.
 2013
 16 7 p. A414-
1 p.
 artikel
623 Cost-Effectiveness of Transcatheter Aortic-Valve Implantation for Severe Symptomatic Aortic Stenosis in Inoperable Patients in the Brazilian Private Health Care System Nishikawa, A.M.
 2013
 16 7 p. A524-
1 p.
 artikel
624 Cost-Effectiveness of Transcatheter Aortic-Valve Implantation for Severe Symptomatic Aortic Stenosis in Inoperable Patients in the Brazilian Public Health Care System Nishikawa, A.M.
 2013
 16 7 p. A705-A706
nvt p.
 artikel
625 Cost-effectiveness of Universal Paediatric Rotavirus Vaccination with RIX4414 in Greece Karabela, P.
 2013
 16 7 p. A333-
1 p.
 artikel
626 Cost-Effectiveness of Universal Screening for Thyroid Disease in Pregnant Women in Spain Donnay, S.
 2013
 16 7 p. A438-
1 p.
 artikel
627 Cost-Effectiveness of Universal Vaccination Against Varicella in the Netherlands de Boer, P.T.
 2013
 16 7 p. A357-
1 p.
 artikel
628 Cost-effectiveness of Vaccination Against Herpes Zoster and Postherpetic Neuralgia: A Critical Review Kawai, K.
 2013
 16 7 p. A334-
1 p.
 artikel
629 Cost-Effectiveness of 13-Valent Versus 10-Valent Pneumococcal Conjugate Vaccine Use in the Czech National Immunization Program Tichopad, A.
 2013
 16 7 p. A352-A353
nvt p.
 artikel
630 Cost-Effectiveness of Various Combinations of Human Papillomavirus (HPV)-Based Primary Screening Testing, Including Genotyping for HPV 16/18, for Cervical Cancer Screening in Mexico Corro, A.
 2013
 16 7 p. A671-
1 p.
 artikel
631 Cost Effective Use of Urine Sampling and Dipstick Testing to Diagnose Urinary Tract Infections in Pre-School Children Presenting to Primary Care Busby, J.
 2013
 16 7 p. A630-
1 p.
 artikel
632 Cost-Minimization Analysis (CMA) of Different Strategies to Treat Newly Diagnosed Locally Confined Low-Risk Prostate Cancer (LCLRPC) in Germany: Results of the Harow Study Schädlich, P.K.
 2013
 16 7 p. A415-
1 p.
 artikel
633 Cost-minimization Analysis of Dienogest Versus Gonadotrophin-releasing Hormone Analogues or Dydrogesterone for Endometriosis Treatment in Russia Avxentyeva, M.
 2013
 16 7 p. A334-
1 p.
 artikel
634 Cost-Minimization Analysis of Ferumoxytol in the Management of Anemia in Patients with Chronic Kidney Disease in Belgium Vandekerckhove, S.
 2013
 16 7 p. A634-
1 p.
 artikel
635 Cost-Minimization Analysis of Intravitreal Aflibercept (IVT-AFL) for Neovascular Age-Related Macular Degeneration in Spain Garcia-Layana, A.
 2013
 16 7 p. A507-
1 p.
 artikel
636 Cost-Minimization Analysis of Maraviroc Versus Darunavir Raltegravir and Enfuvirtide for CCR5-Tropic Treatment-Experienced Patients with HIV Infection in Russia Pyadushkina, E.
 2013
 16 7 p. A358-A359
nvt p.
 artikel
637 Cost-Minimization Analysis of Multifocal and Monofocal Intraocular Lenses in Cataract Surgery in the Czech Republic Kruntoradova, K.
 2013
 16 7 p. A507-
1 p.
 artikel
638 Cost-Minimization Analysis of Subcutaneous Abatacept in the Treatment of Rheumatoid Arthritis in Spain Ariza-Ariza, R.
 2013
 16 7 p. A564-
1 p.
 artikel
639 Cost Minimization Analysis of the Dienogest Use in Patients with Endometris under Brazilian Public and Private Perspective Ferracini, M.
 2013
 16 7 p. A334-A335
nvt p.
 artikel
640 Cost-Minimization Analysis of Treatment of Spasticity with Botulinum Toxin Type A Tapias, G.
 2013
 16 7 p. A624-
1 p.
 artikel
641 Cost-Minimization of Mabthera Intravenous Versus Subcutaneous Administration Bax, P.
 2013
 16 7 p. A390-A391
nvt p.
 artikel
642 Costo Del Automonitoreo Glucémico En Pacientes En Tratamiento Combinado Oral Y Con Insulina En Argentina Elgart, J.
 2013
 16 7 p. A691-
1 p.
 artikel
643 Costo-Efectividad De Carbetocina En Comparación Con Oxitocina Para Prevenir Hemorragia Posparto Por Atonía Uterina En Pacientes Con Factores De Riesgo En Colombia Rueda, C.
 2013
 16 7 p. A709-A710
nvt p.
 artikel
644 Costo-Efectividad De Clopidogrel Versus Ticagrelor, Ambos En Combinación Con Asa, Para El Manejo Del Síndrome Coronario Agudo, Desde La Perspectiva Del Sistema De Salud Privado En México Reyes, A.
 2013
 16 7 p. A706-
1 p.
 artikel
645 Costo Efectividad Del Antibiótico Oral Vs. Local En Mujeres No Gestantes Con Flujo Vaginal Sugestivo De Vaginosis Bacteriana En Colombia Diaz, J.A.
 2013
 16 7 p. A713-
1 p.
 artikel
646 Costo-Efectividad De Las Cintas De Uretra Media Comparadas Con El Tratamiento Convencional De La Incontinencia Urinaria Femenina De Esfuerzo En Colombia Lopez-Ramos, H.E.
 2013
 16 7 p. A710-
1 p.
 artikel
647 Costo-Efectividad De Las Pruebas Para La Tamización De Bacteriuria Asintomática Durante La Gestación Chicaiza, L.
 2013
 16 7 p. A698-
1 p.
 artikel
648 Costo-Efectividad Del Diagnostico Etiológico Con Pruebas Rapidas Vs. Sindromico En Mujeres No Gestantes Con Sintomas De Infección Cervical En Colombia Diaz, J.A.
 2013
 16 7 p. A714-
1 p.
 artikel
649 Costo-Efectividad Del Screening Y Tratamiento De Hipoacusia Bilateral En Recién Nacidos (Rn) En Chile Castillo-Laborde, C.
 2013
 16 7 p. A696-A697
nvt p.
 artikel
650 Costo-Efectividad Del Trasplante Renal Comparado Con La Diálisis En Colombia Rosselli, D.
 2013
 16 7 p. A699-
1 p.
 artikel
651 Costo-Efectividad Del Uso De Pruebas Treponémicas Rápidas Para La Detección Y Tratamiento Temprano De Sífilis Gestacional En Colombia Castañeda Guerrero, C.
 2013
 16 7 p. A668-
1 p.
 artikel
652 Costo-Efectividad De Tres Estrategias Diagnosticas Para La Identificación De Infección Bacteriana Severa En Lactantes Febriles Sin Foco Buendia, J.A.
 2013
 16 7 p. A668-
1 p.
 artikel
653 Costo E Impacto Presupuestal Del Tratamiento De La Artritis Reumatoide Moderada Y Severa Considerando El Uso De Terapias Biológicas En México Aguirre, A.
 2013
 16 7 p. A665-
1 p.
 artikel
654 Costo E Impacto Presupuestal Del Tratamiento Del Cáncer De Púlmon De Celulas No Pequeñas Del Tipo Adenocarcinoma Con Grado Ecog 0,1,2 En Estadio Iv Con Mutación + (EGFR O ALK) Con Terapias Blanco En México Peniche-Otero, G.
 2013
 16 7 p. A684-
1 p.
 artikel
655 Cost of Achieving Relevant Composite Endpoint of HbA1c<7%, No Hypoglycaemia and Weight Loss of ≥3% in a 52 Week Post-Hoc Analysis of Dapagliflozin Versus Glipizide Bergenheim, K.
 2013
 16 7 p. A439-
1 p.
 artikel
656 Cost of Adults> 50 Years Community-Acquired Pneumonia in Argentina Giglio, N.D.
 2013
 16 7 p. A713-
1 p.
 artikel
657 Cost of Adverse Events During Treatment with Everolimus Plus Exemestane or Single-Agent Chemotherapy in Patients with Advanced Breast Cancer Campone, M.
 2013
 16 7 p. A401-A402
nvt p.
 artikel
658 Cost of Cancer in the Austrian Hospital Setting Walter, E.
 2013
 16 7 p. A407-
1 p.
 artikel
659 Cost of Care with Everolimus Versus Axitinib for Second-Line Metastatic Renal Cell Carcinoma Patients in Canada Perrin, A.
 2013
 16 7 p. A402-
1 p.
 artikel
660 Cost of End of Life Pharmacotherapy in Cancer Patients: Where Does the Budget Go To? Hammerman, A.
 2013
 16 7 p. A427-
1 p.
 artikel
661 Cost of Illness of Neuropathic Pain in Spain in 2012 from a Societal Perspective Ruiz, L.
 2013
 16 7 p. A381-
1 p.
 artikel
662 Cost-Of-Illness Study of Patients Subjected to Cardiac Rhythm Management Devices Implantation: Results from a Single Tertiary Centre Fanourgiakis, J.
 2013
 16 7 p. A705-
1 p.
 artikel
663 Cost of Influenza in Germany Anastassopoulou, A.
 2013
 16 7 p. A348-
1 p.
 artikel
664 Cost of Inpatient Management of Hypoglycaemia in France Torreton, E.
 2013
 16 7 p. A436-
1 p.
 artikel
665 Cost of Intensive Care Stay in Turkey: In the View of Payer and Health Care Provider Daylan Kockaya, P.
 2013
 16 7 p. A466-
1 p.
 artikel
666 Cost of Microvascular and Macrovascular Complications in Peoples with Diabetes Type 1 and Type 2 in Bulgaria Dimitrova, M.
 2013
 16 7 p. A437-
1 p.
 artikel
667 Cost of Obesity and Economic Value of Obesity Surgery for Turkey (CEVOS-T) Kockaya, G.
 2013
 16 7 p. A381-
1 p.
 artikel
668 Cost of Treatment After Renal Transplantation in Iran: Should Government Continue Paying for New Expensive Immunosuppressive Drugs? Foroutan, N.
 2013
 16 7 p. A632-
1 p.
 artikel
669 Costos Asociados a Eventos Cardiovasculares En Pacientes Con Artritis Reumatoide Afiliados Al Régimen Subsidiado En Colombia Urrego Novoa, J.R.
 2013
 16 7 p. A716-
1 p.
 artikel
670 Costos Asociados a Neumonía Severa Y Tuberculosis En Pacientes Con Artritis Reumatoide Que Han Recido Tratamiento Con Terapia Biologica Anti-TNF Varon, F.A.
 2013
 16 7 p. A716-
1 p.
 artikel
671 Costos Económicos Asociados A Secuelas De Meningitis En Colombia Alvis-Guzmán, N.
 2013
 16 7 p. A712-A713
nvt p.
 artikel
672 Cost-Outcome Description of Clinical Pharmacist Interventions in a University Teaching Hospital Gallagher, J.
 2013
 16 7 p. A467-
1 p.
 artikel
673 Costo-Utilidad De Colágena-Polivinilpirrolidona En El Tratamiento De Osteartrosis De Rodilla I-Ii Frente Al Cuidado Estandar Establecido En Los Protocolos Vigentes De Las Instituciones Publicas En México Burbano-Levy, X.
 2013
 16 7 p. A718-
1 p.
 artikel
674 Costo-Utilidad De Intervenciones Preventivas Contra El Cáncer De Cuello Uterino En Mujeres Peruanas Gutiérrez-Aguado, A.
 2013
 16 7 p. A686-
1 p.
 artikel
675 Cost Per Cure of Telaprevir and Boceprevir in Treatment-Naïve Genotype 1 Hepatitis C Patients with F2 Fibrosis in Brazil Morais, A.D.
 2013
 16 7 p. A352-
1 p.
 artikel
676 Cost-Per-Responder Analysis of Biological Agents for the Treatment of Active Ankylosing Spondylitis in Germany Betts, K.A.
 2013
 16 7 p. A562-
1 p.
 artikel
677 Cost Reduction Associated with Use of Subglottic Aspiration to Reduce Ventilator-Associated Pneumonia in Turkey Kockaya, G.
 2013
 16 7 p. A344-
1 p.
 artikel
678 Costs and Consequences of Oral Anticoagulation in Atrial Fibrillation in Colombia Rosselli, D.
 2013
 16 7 p. A702-
1 p.
 artikel
679 Costs and Effectiveness of Non-Smoking Clinic Laine, J.
 2013
 16 7 p. A371-
1 p.
 artikel
680 Costs and Outcomes Associated with Multidrug Resistant Staphylococcus Aureus Bacteremia Singh, S.
 2013
 16 7 p. A712-
1 p.
 artikel
681 Costs Associated with Cold Chain Used to Store and Transport Thermally Unstable Antiretroviral Drugs Omelyanovsky, V.
 2013
 16 7 p. A360-
1 p.
 artikel
682 Costs Associated with the Impact of Progressive Multiple Sclerosis: Insights from a Three Year Clinical Trial (The Cupid Trial) Green, C.
 2013
 16 7 p. A624-
1 p.
 artikel
683 Cost Saving After Sutureless Replacement in Aortic Valve Stenosis: Results from a Propensity-Matched Score Analysis in Germany Santarpino, G.
 2013
 16 7 p. A520-
1 p.
 artikel
684 Cost Savings in the Hungarian Care Managing Programme Ágoston, I.
 2013
 16 7 p. A486-
1 p.
 artikel
685 Costs Comparison of Cutaneous Drug Reactions Treatment Divided by Diagnosis Groups Wisniewska, N.
 2013
 16 7 p. A504-
1 p.
 artikel
686 Costs Evaluations of Ready-To-Use Propofol Syringes Versus Syringes Drawn from Vials in Critically Ill Devaud, J.C.
 2013
 16 7 p. A356-
1 p.
 artikel
687 Costs in Patients Along First Year Poststroke in Spain Álvarez Sabín, J.
 2013
 16 7 p. A522-
1 p.
 artikel
688 Costs of Acute Heart Failure in France Bouee, S.
 2013
 16 7 p. A521-
1 p.
 artikel
689 Costs of Alternative Methods of Child Delivery in Serbia Odalovic, M.
 2013
 16 7 p. A332-
1 p.
 artikel
690 Costs of Best Supportive Care in the Treatment of Moderate-To-Severe Psoriasis in the United States Tencer, T.
 2013
 16 7 p. A504-A505
nvt p.
 artikel
691 Costs of COPD in France: A National Database Analysis Laurendeau, C.
 2013
 16 7 p. A370-
1 p.
 artikel
692 Costs of Dengue Control and Prevention Program in Brazil Santos, S.M.
 2013
 16 7 p. A678-
1 p.
 artikel
693 Costs of Formal and Informal Home Care and Quality of Life of Patients with Multiple Sclerosis in Sweden Svensson, M.
 2013
 16 7 p. A629-
1 p.
 artikel
694 Costs of HER 2 Negative, Hormonal Receptor Positive, Metastatic Breast Cancer (MBC-HR+) Treated with Everolimus (EVE) + Exemestane (EXE) in the Brazilian Private System (BPS): A Real World (RW) and Published Literature Analysis Clark, O.A.C.
 2013
 16 7 p. A405-
1 p.
 artikel
695 Costs of Hormonal Receptor Positive, Her 2 Negative Metastatic Breast Cancer (MBC-HR+) in Brazilian Private System (BPS): A Real World and Published Literature Analysis Clark, O.A.C.
 2013
 16 7 p. A685-
1 p.
 artikel
696 Costs of Incidence-Based Central Retinal Vein Occlusion in France Girmens, J.F.
 2013
 16 7 p. A504-
1 p.
 artikel
697 Costs of Management of Pregnancy in Obese Women Across Europe: The Dali Experience Diaz-Cuervo, H
 2013
 16 7 p. A636-
1 p.
 artikel
698 Costs of Pilot Programs Employing Allied Health Professionals Within the Centers for Population Health and Health Disparities Walton, S.
 2013
 16 7 p. A402-A403
nvt p.
 artikel
699 Costs of Prevalence-Based Central Retinal Vein Occlusion (CRVO) in the United Kingdom Priaulx, J.
 2013
 16 7 p. A504-
1 p.
 artikel
700 Costs of Primary Biliary Cirrhosis Treatment with Ursodeoxycholic Acid in Brazil Lemos, L.L.P.
 2013
 16 7 p. A692-
1 p.
 artikel
701 Cost-Utility Analyses of Cognitive-Behavioral Therapy for Major Depressive Disorder – A Systematic Review Brettschneider, C.
 2013
 16 7 p. A549-
1 p.
 artikel
702 Cost-Utility Analyses of Natalizumab Versus Interferon Beta-1a 44 Mcg for Rapidly Evolving Severe Relapsing-Remitting Multiple Sclerosis (RESRRMS) Patients in Brazil Nishikawa, A.M.
 2013
 16 7 p. A624-
1 p.
 artikel
703 Cost-Utility Analysis (CUA) of Belimumab (BEL) in the Treatment of Adult Patients with Active, Autoantibody-Positive Systemic Lupus Erythematosus (SLE) Walczak, J.
 2013
 16 7 p. A385-
1 p.
 artikel
704 Cost-Utility Analysis (CUA) of Different Strategies to Treat Newly Diagnosed Locally Confined Low-Risk Prostate Cancer (LCLRPC) in Germany: Results of the Harow Study Schädlich, P.K.
 2013
 16 7 p. A416-
1 p.
 artikel
705 Cost-Utility Analysis of Coronary Artery Calcium Score to Guide Statin Therapy in Patients with Elevated C-Reactive Protein and Low LDL Cholesterol Levels Silva Miguel, L.
 2013
 16 7 p. A530-A531
nvt p.
 artikel
706 Cost-Utility Analysis of Deferasirox for the Treatment of Iron Overload Due to Frequent Blood Transfusions in the Children and Adolescents Walczak, J.
 2013
 16 7 p. A385-
1 p.
 artikel
707 Cost-Utility Analysis of Disease-Modifying Drugs in Relapsing-Remitting Multiple Sclerosis in Iran Imani, A.
 2013
 16 7 p. A624-
1 p.
 artikel
708 Cost Utility Analysis of Everolimus in the Treatment of Metastatic Renal Cell Cancer in the Netherlands Mihajlović, J.
 2013
 16 7 p. A416-
1 p.
 artikel
709 Cost-Utility Analysis of Linaclotide in the Treatment of Irritable Bowel Syndrome with Constipation in Belgium Gerlier, L.
 2013
 16 7 p. A498-
1 p.
 artikel
710 Cost-Utility Analysis of Lisdexamfetamine in the Treatment of Children and Adolescents with Attention-Deficit/Hyperactivity Disorder in the United Kingdom Zimovetz, E.
 2013
 16 7 p. A549-
1 p.
 artikel
711 Cost-Utility Analysis of Posaconazole Versus Fluconazole for Prevention of Invasive Fungal Infections in Patients with Graft-Versus-Host Disease in Sweden Lundberg, J.G.
 2013
 16 7 p. A359-
1 p.
 artikel
712 Cost Utility Analysis of Screening and Treatment of Hyperlipidemia in Chinese Adults Aged 45 and Above Zhang, X.G.
 2013
 16 7 p. A530-
1 p.
 artikel
713 Cost-Utility Analysis of Telaprevir in Combination with Peginterferon Alpha and Ribavirin in Previously Untreated Patients with Chronic Hepatitis in a Romanian Setting Paveliu, M.S.
 2013
 16 7 p. A499-
1 p.
 artikel
714 Cost-Utility Analysis of Tocilizumab in Combination with Methotrexate Versus Standard of Care for the Treatment of Rheumatoid Arthritis in Greece Athanasakis, K.
 2013
 16 7 p. A565-
1 p.
 artikel
715 Cost-Utility Analysis of Tocilizumab Monotherapy Versus Standard of Care for the Treatment of Rheumatoid Arthritis in Greece Athanasakis, K.
 2013
 16 7 p. A565-
1 p.
 artikel
716 Cost-Utility of Active Surveillance for the Treatment of Localized Prostate Cancer in the Context of the German Health Care System Koerber, F.
 2013
 16 7 p. A417-
1 p.
 artikel
717 Cost-Utility of Apixaban Compared to Warfarin for Stroke Prevention in Patients with Atrial Fibrillation in Colombia Rosselli, D.
 2013
 16 7 p. A706-
1 p.
 artikel
718 Cost-Utility of Dagibatran for Chronic Atrial Fibrillation in Argentina Ferrante, D.
 2013
 16 7 p. A706-
1 p.
 artikel
719 Cost-Utility of First-Line Adalimumab and Tocilizumab Monotherapies in Rheumatoid Arthritis Based on Head-To-Head Data Soini, E.J.
 2013
 16 7 p. A566-
1 p.
 artikel
720 Cost-Utility of Granulocyte-Colony Stimulating Factors (G-CSFs) for Primary Prophylaxis (PP) of Chemotherapy Induced Febrile Neutropenia (FN) in Breast Cancer Patients in the Netherlands Somers, L.
 2013
 16 7 p. A415-
1 p.
 artikel
721 Cost-Utility of Pediatric Cochlear Implantation in Hungary Hashim, M.S.
 2013
 16 7 p. A508-
1 p.
 artikel
722 Cost-Utility of Rheumatoid Arthritis Monotherapy with Tocilizumab in Spain Benito Ruiz, P.
 2013
 16 7 p. A565-
1 p.
 artikel
723 Counting the Cost of Meningococcal Disease in France Faivre, P.
 2013
 16 7 p. A346-A347
nvt p.
 artikel
724 Coverage with Evidence Development in Sweden – Formality or Effective Way to Reduce Uncertainty? Kornfeld, A.
 2013
 16 7 p. A487-A488
nvt p.
 artikel
725 Covering the PASS: Development of Protocol Template Language (PTL) for Data Collection and Data Management (DM) in Post-Authorization Safety Studies (PASS) Oberthur Johnson, L.
 2013
 16 7 p. A583-
1 p.
 artikel
726 C-Quality: A Cost and Quality of Life Pharmacoeconomic Analysis of Antidepressants in Major Depressive Disorder in Italy Katz, P.
 2013
 16 7 p. A549-
1 p.
 artikel
727 Crescimento De Óbitos Pós Partos Cesarianos No Brasil Versus Partos Normais Drago, S.
 2013
 16 7 p. A675-A676
nvt p.
 artikel
728 Croatia’s EU Accession in the Context of International Reference Pricing: What Will Be the Wider Impact for Pricing and Reimbursement? Melck, B.
 2013
 16 7 p. A460-
1 p.
 artikel
729 Crohn’s Disease: An Economic Assessment of Biological Drugs in Italy Cicchetti, A.
 2013
 16 7 p. A497-A498
nvt p.
 artikel
730 Cross-Country Comparison of Prescribing Patterns Versus Portugal and Potential Cost-Savings Costa, S.
 2013
 16 7 p. A537-A538
nvt p.
 artikel
731 Cross-Markets Variability of Innovation Benefit’s Evaluations. How Italy Compares to France, Germany and the United States Savi, L.
 2013
 16 7 p. A482-
1 p.
 artikel
732 Crossover Adjustment in Oncology Trials Using a Rank Preserving Structural Failure Time Model (RPSFTM): Wrapping Bootstraps Around Estimates of Life Expectancy for CE Models Ray, J.
 2013
 16 7 p. A594-
1 p.
 artikel
733 Cross (-Walk) at Your Own Peril! Comparing and Contrasting Cea Results When Individual-Level Utilities Are Derived from External Mapping Algorithms Rather Than Actually Observed Responses Patton, T.
 2013
 16 7 p. A599-
1 p.
 artikel
734 Cultural Adaptation and Validation to Spanish of the “MS Treatment Concerns Questionnaire-MSTCQ” Galera, J.
 2013
 16 7 p. A625-A626
nvt p.
 artikel
735 Current and Future Strategy for Osteoporosis Screening and Diagnostics: Cost-Effectiveness of Frax with or without Pulse-Echo Ultrasound Measurement of Bone Mineral Density and DXA on Demand Asseburg, C.
 2013
 16 7 p. A564-A565
nvt p.
 artikel
736 Current Characteristics, Treatment and Health Care Consumption of Patients with Asthma or COPD in the Netherlands Overbeek, J.A.
 2013
 16 7 p. A367-
1 p.
 artikel
737 Current Situation of Oral Anticancer Treatments Use in France: The Actor Study (Analysis of Cancer Treatments Given Orally) Benjamin, L
 2013
 16 7 p. A425-
1 p.
 artikel
738 Current Status and Evidence of Effects of E-Prescribing Implementation in United Kingdom, Italy, Germany, Denmark, Poland and United States Hermanowski, T.R.
 2013
 16 7 p. A462-A463
nvt p.
 artikel
739 Custo-Efetividade Do Tratamento Para Osteoporose Na Pos-Menopausa No Brasil Brandão, C.M.R.
 2013
 16 7 p. A717-
1 p.
 artikel
740 Custos Das Fraturas Osteoporóticas No Sistema Público De Saúde Brasileiro Brandão, C.M.R.
 2013
 16 7 p. A716-A717
nvt p.
 artikel
741 Custos De Pneumonias Hospitalizadas No Brasil: Análise Comparativa Por Diferentes Métodos De Custeio Nunes, S.
 2013
 16 7 p. A724-
1 p.
 artikel
742 Dabigatran Etexilate in Prevention of Stroke for Nonvalvular Atrial Fibrillation Patients in Turkish Health Care Setting; A Study on Cost Containment of Social Security Institution (SSI) Kececioglu, S.
 2013
 16 7 p. A520-
1 p.
 artikel
743 Dealing with Zero Cells in Sparse Networks in Bayesian Network Meta-Analysis Ivanescu, C.
 2013
 16 7 p. A614-
1 p.
 artikel
744 Decision Analytic Models Used in Estimating the Cost-Effectiveness of Drug-Eluting Stents Versus Bare-Metal Stents: A Systematic Review Burgers, L.T.
 2013
 16 7 p. A588-
1 p.
 artikel
745 Decision Making in HIRA for 5 Years of Positive List System MiHai, P.
 2013
 16 7 p. A426-
1 p.
 artikel
746 Decison Making Under Uncertainty: Coverage with Evidence Development in the Context of Medical Devices Sorenson, C.
 2013
 16 7 p. A328-
1 p.
 artikel
747 Defining Eligible Patient Population in São Paulo State Based on Cleopatra Trial Inclusion Criteria: A Retrospective Analysis of Fundação Oncocentro (FOSP) Cancer Patient Registry (Registro Hospitalar Do Câncer – RHC) Tobaruella, F.S.
 2013
 16 7 p. A430-
1 p.
 artikel
748 Defining Standards of Clinician Qualifications for the Linguistic Validation of Clinical Outcome Assessments (COAs) Sweeney, E.
 2013
 16 7 p. A603-
1 p.
 artikel
749 Defining the Patient Journey via Claims Analysis in an Orphan Ophthalmic Condition: Is There a Standard of Care? Gavaghan, M.
 2013
 16 7 p. A510-
1 p.
 artikel
750 Defining the Proper Methodology to Use in a Data-Peek for Power (DPP) Eisenberg, D.
 2013
 16 7 p. A608-
1 p.
 artikel
751 Delay of Total Hip Replacement (THR) Using HA Viscosupplementation: Is Cost Effective? Migliore, A.
 2013
 16 7 p. A562-
1 p.
 artikel
752 Demineralised Bone Matrix (DBM) Versus Iliac Crest Bone Graft (ICBG) for Lumbar Spinal Fusion Procedures in the United Kingdom; A Budget-Impact Analysis Carlqvist, P.
 2013
 16 7 p. A558-
1 p.
 artikel
753 Derivation of Severity Index for Rheumatoid Arthritis Baser, O.
 2013
 16 7 p. A577-
1 p.
 artikel
754 Desarrollo De Una Escala De Estructuras Y Proceso Para La Evaluación De Los Centros De Hemodiálisis Scarpitta, C.
 2013
 16 7 p. A701-
1 p.
 artikel
755 Descripción De Una Cohorte De Pacientes Con Artritis Reumatoide Tratados Con Etanercept (Enbrel®) Dentro De Un Programa De Atención En Un Centro Especializado En Colombia Jauregui, E.
 2013
 16 7 p. A719-
1 p.
 artikel
756 Description of Treatment Pathways in Chronic Diseases Using Large General Practitioner Longitudinal Data: The Example of Pharmaco-Therapy in Parkinson’s Disease in the United Kingdom Guelfucci, F.
 2013
 16 7 p. A583-
1 p.
 artikel
757 Design of a Randomized Controlled Trial (RCT) Evaluating Outcome and Cost-Effectiveness of a Local Case Management Intervention of Patients Suffering from Chronic Obstructive Pulmonary Disease (COPD) Sørensen, S.S.
 2013
 16 7 p. A576-
1 p.
 artikel
758 Design of Lupus Impact Tracker (LIT) Validation Study in Five European Clinical Practice Settings Schneider, M.
 2013
 16 7 p. A605-
1 p.
 artikel
759 Desigualdad En Salud Relativa Al Ingreso En Chile: Análisis De Descomposición Del Índice De Concentración En Hipertensión, Diabetes Y Depresión Cabieses, B.
 2013
 16 7 p. A708-
1 p.
 artikel
760 Determinantes De Los Costos De Accidentes De Tránsito Ocurridos En Medellín (Colombia) 2009-2010 García García, H.I.
 2013
 16 7 p. A674-
1 p.
 artikel
761 Determinants of Non-Adherence to Medications Among Chronic Patients in Maccabi Health Care Services Simon Tuval, T.
 2013
 16 7 p. A335-
1 p.
 artikel
762 Determinants of Prompt Access to Health Care in CHPS Programme in Rural Communities of Bawjiase, Ghana Nuamah Buruwaa, G.
 2013
 16 7 p. A477-
1 p.
 artikel
763 DETERMINING THE MAGNITUDE OF A DETECTABLE AND A RELEVANT TREATMENT BENEFIT IN AESTHETIC MEDICINE USING A PHOTOGUIDE AND THE INTERNET Pleil, A
 2013
 16 7 p. A603-
1 p.
 artikel
764 Developing an Individualized E-Health Decision Support System for Dementia Treatment and Care: The FP7 EU-Project E-Health Monitor (EHM) Schaller, S.U.
 2013
 16 7 p. A551-A552
nvt p.
 artikel
765 Developing a Population-Based Dementia Registry Focusing on Patients and Carer Needs: Methodological Challenges Gobin, J.
 2013
 16 7 p. A554-
1 p.
 artikel
766 Developing a Publication Strategy in the Context of Outcome Research: A Review of the Literature Laloyaux, C.
 2013
 16 7 p. A584-
1 p.
 artikel
767 Developing Personalized Medicine Drugs - Incentives for Pharmaceutical Companies Noweski, M.
 2013
 16 7 p. A424-
1 p.
 artikel
768 Developing Realistic Pathways in Cost-Effectiveness Models for Psoriasis: What to Do When a Biologic Fails Mauskopf, J.A.
 2013
 16 7 p. A588-
1 p.
 artikel
769 Development of an Interviewer-Administered Version of the Asthma Control Questionnaire (ACQ-IA) for 6-10 Year Old Patients in 11 Languages Juniper, E.
 2013
 16 7 p. A598-
1 p.
 artikel
770 Development of a Questionnaire to Evaluate Food-Related Well-Being Guillemin, I.
 2013
 16 7 p. A605-A606
nvt p.
 artikel
771 Development of Novel Imaging Tests to Select Patients for Individualized Therapies: Are They Worth Further Investment? Buisman, L.R.
 2013
 16 7 p. A526-
1 p.
 artikel
772 Development of the Scharr HUD (Health Utilities Database) Rees, A.
 2013
 16 7 p. A580-
1 p.
 artikel
773 Development of the Schizophrenia Caregiver Questionnaire: Modification of the Zarit Burden Interview Informed by Qualitative Insights Gater, A.
 2013
 16 7 p. A577-
1 p.
 artikel
774 Diabetic Patients in Primary Care: Self-Perception and Satisfaction. Comparative Study Spain Versus Europe Sánchez-Piedra, C.
 2013
 16 7 p. A446-
1 p.
 artikel
775 Diagnosis of Pancreatic Exocrine Insufficiency in Chronic Pancreatitis, Pancreatic Cancer and Gastrointestinal or Pancreatic Surgery Patients: A Systematic Literature Review and Expert Consensus on the Accuracy of Diagnostic Test Used in Spain De Madaria, E.
 2013
 16 7 p. A493-
1 p.
 artikel
776 Diferencias En La Consecución De Información Sobre Costos Del Manejo De La Diabetes Mellitus En Colombia Alfonso-Cristancho, R.
 2013
 16 7 p. A700-
1 p.
 artikel
777 Difference in Interdialytic Intervals Leading to Hospital Admission and Mortality in Hemodialysis Patients Kumar, P.
 2013
 16 7 p. A636-
1 p.
 artikel
778 Differences in Approach to Biosimilars: Nice Versus SMC Recommendations Izmirlieva, M.
 2013
 16 7 p. A323-
1 p.
 artikel
779 Differences in Health Care Resource Utilization and Expenditures Among Schizophrenic Patients in the United States by Health Insurance Status, 2007-2008 Rohwer, R.
 2013
 16 7 p. A553-
1 p.
 artikel
780 Differences in Medical Cost and Survival Between Trial and Non-Trial Patients with Acute Myeloid Leukaemia – A UK Population-Based Propensity Analysis Wang, H.I.
 2013
 16 7 p. A394-
1 p.
 artikel
781 Differences in the Weighted Average Daily Doses of Statins in Latin America and Their Potential Impact on Cardiovascular Outcomes Mould-Quevedo, J.F.
 2013
 16 7 p. A703-
1 p.
 artikel
782 Different Discounting Approaches and Their Impact in Economic Evaluation: A Practical Example Using Hepatitis B Vaccination Cure, S.
 2013
 16 7 p. A355-A356
nvt p.
 artikel
783 Differential Diagnosis of Leg Ulcers – Medical and Health Economics Aspects Kovács, L.A.
 2013
 16 7 p. A505-
1 p.
 artikel
784 Differential Discouting: Capturing the Value of Living Longer and Better Ralston, S.
 2013
 16 7 p. A467-
1 p.
 artikel
785 Differential Item Functioning in a Satisfaction Item Bank Campillo-Álvarez, Á
 2013
 16 7 p. A606-A607
nvt p.
 artikel
786 Differential Resource Use and Costs Among Inpatients and Outpatients with Schizophrenia in Tianjin, China Liu, L.L.
 2013
 16 7 p. A545-
1 p.
 artikel
787 Different Injection Frequencies of Basal Insulins in Type 2 Diabetes Patients Under Real-Life Conditions: A Retrospective Database Analysis Kostev, K.
 2013
 16 7 p. A450-
1 p.
 artikel
788 Diffusion of the Efficiency Frontier Approach Within Health Economic Evaluation: Current and Future Applications Sandmann, F.G.
 2013
 16 7 p. A473-
1 p.
 artikel
789 Diminishing Marginal Disutility of Hypoglycaemic Events Lauridsen, J.T.
 2013
 16 7 p. A445-
1 p.
 artikel
790 Direct and Indirect Burden Associated with Parents Whose Infant Has Been Hospitalized for a Lower Respiratory Tract Infection (LRTI) in Greece Tsolia, M.
 2013
 16 7 p. A376-
1 p.
 artikel
791 Direct and Indirect Costs of MS in Ireland Fogarty, E.
 2013
 16 7 p. A621-
1 p.
 artikel
792 Direct Cost of Diabetes Mellitus and Its Complications in Spain. Seccaid Study: Spain Estimated Cost Ciberdem-Cabimer in Diabetes Crespo, C.
 2013
 16 7 p. A436-
1 p.
 artikel
793 Direct Costs of Type 2 Diabetes from the Brazilian Public Health Care Sector Perspective Hnoosh, A.
 2013
 16 7 p. A689-
1 p.
 artikel
794 Direct Costs of Type 2 Diabetes in Mexico from the Public Health Care Sector Perspective Chatzitheofilou, I.
 2013
 16 7 p. A688-A689
nvt p.
 artikel
795 Direct Health Care Costs of Patients Switching Biologic Therapies in Chronic Plaque Psoriasis Qureshi, A.
 2013
 16 7 p. A727-
1 p.
 artikel
796 Direct Medical Costs and Health Care Resource Utilization Associated with Selected Antibiotic Treatment Pathways in Acute Bacterial Skin and Skin Structure Infections in the United States Fan, W
 2013
 16 7 p. A351-
1 p.
 artikel
797 Direct Medical Costs (DMC) of Treating Chronic Lymphoid Leukemia (CLL) Patients in the Private Health Care System in Brazil: Results from a 12-Month Retrospective Analysis of an Administrative Database Paloni, E.D.M.P.
 2013
 16 7 p. A684-A685
nvt p.
 artikel
798 Direct Medical Costs (DMC) of Treating Chronic Lymphoid Leukemia (CLL) Patients in the Public Health Care System in Brazil: Results from a Retrospective Analysis of an Administrative Database Asano, E.
 2013
 16 7 p. A403-
1 p.
 artikel
799 Direct Medical Costs of Treating Diabetes-Related Complications in Argentina Elgart, J.
 2013
 16 7 p. A688-
1 p.
 artikel
800 Direct-To-Patient Contact and Proactive Pharmacovigilance System: A Case Study Wiederkehr, S.
 2013
 16 7 p. A512-
1 p.
 artikel
801 Discrete Event Simulation Model of Primary Prevention of Stroke: Benefits of Increasing Coverage to Unserved Patients Urbina-Valdespino, E.
 2013
 16 7 p. A520-
1 p.
 artikel
802 Disease Becomes Social. Health Research Conducted On, or Using, Web 2.0 Media: A Systematic Review Martin, A.
 2013
 16 7 p. A479-
1 p.
 artikel
803 Disease Burden Among Patients with Multiple Sclerosis Not Receiving Disease Modifying Treatments in Europe and the United States Narayanan, S.
 2013
 16 7 p. A628-
1 p.
 artikel
804 Disease Burden Among Patients with Psoriatic Arthritis Who Have Experienced First Line Tumor Necrosis Factor Inhibitor Regimen Failure in the European Union Narayanan, S.
 2013
 16 7 p. A572-
1 p.
 artikel
805 Disease Burden Among Patients with Secondary Progressive Multiple Sclerosis Currently Using Disease Modifying Treatments in Europe Union and the United States Narayanan, S.
 2013
 16 7 p. A628-
1 p.
 artikel
806 Disease Burden in Epilepsy Associated with Tuberous Sclerosis Complex: Systematic Review Blieden, M.
 2013
 16 7 p. A618-
1 p.
 artikel
807 Disease Burden of Ischemic Stroke Along First Year Post-Stroke in Spain Álvarez Sabín, J.
 2013
 16 7 p. A521-
1 p.
 artikel
808 Disease-Modifying Therapies (DMT) for Multiple Sclerosis (MS): Analysis of Its Evolution in Spain Between 2004 and 2012 Villoro, R.
 2013
 16 7 p. A629-
1 p.
 artikel
809 Disease Status, Treatments and Outcomes of Patients with Ankylosing Spondylitis Receiving Their First Biologic in the United States and European Union Narayanan, S.
 2013
 16 7 p. A389-
1 p.
 artikel
810 Disentangling Effects on Fatal and Non-Fatal Cardiovascular Events Over Time Thurston, S.
 2013
 16 7 p. A590-
1 p.
 artikel
811 Dispensation Channels of Anti-TNFs in Inflammatory Bowel Disease Thivolet, M.
 2013
 16 7 p. A501-
1 p.
 artikel
812 Disponibilidad Y Fuentes De La Información Para La Toma De Decisiones En Reumatología: Uso De Los Estudios Económicos Guzman Vazquez, S.
 2013
 16 7 p. A701-A702
nvt p.
 artikel
813 Disposición a Pagar Y Análisis De Conjoint Para Determinar Las Preferencias Por Los Productos Medley En México Camacho, A.
 2013
 16 7 p. A707-
1 p.
 artikel
814 Divergence of HTA Decisions Across Countries: Case Analysis of Ivabradine Thivolet, M.
 2013
 16 7 p. A540-A541
nvt p.
 artikel
815 Do EMA and FDA Have Different Opinions/Requirements in Terms of Pediatric Studies for Sitagliptin (Alone or in Combination)? Caron, M.
 2013
 16 7 p. A340-
1 p.
 artikel
816 Does Europe Reward Reformulations? A Data Driven Analysis of Value Preservation Through Reformulation Hughes, A.L.H.
 2013
 16 7 p. A458-
1 p.
 artikel
817 Does HTA Process Help to Achieve the Health Objectives of the Millennium? A South American Analysis Sansone, D.
 2013
 16 7 p. A490-
1 p.
 artikel
818 Does It Matter? Discounting and Its Role in Analysing the Cost-Effectiveness of Preventative Interventions Starkie Camejo, H.J.
 2013
 16 7 p. A585-
1 p.
 artikel
819 Does Personalised Health Care (PHC) in Oncology Require New Approaches to Clinical Development, Regulatory Assessment, and Economic Evaluation? Teale, C.W.
 2013
 16 7 p. A423-
1 p.
 artikel
820 Do Fixed-Dose Combinations Improve Antidiabetic Treatment Compliance? A Study Based on French IMS Lifelink Disease Analyzer Database Grandfils, N.
 2013
 16 7 p. A444-A445
nvt p.
 artikel
821 Do Nice Evidence Review Groups (ERG) Focus on Different Aspects of Manufacturer Submissions in Oncology? Heemstra, L.
 2013
 16 7 p. A429-
1 p.
 artikel
822 Don’t Make Me Wait: The Variance Reduction Technique for Faster Monte Carlo Simulations in Cost Effectiveness Models on Web Kutepov, G.
 2013
 16 7 p. A615-
1 p.
 artikel
823 Do Policy Measures Impact on Cost Consciousness of Health Care Professionals? Jakovljevic, M.
 2013
 16 7 p. A542-
1 p.
 artikel
824 Doubling of Health Care Costs Among Asthma Patients with COPD Diagnosis and Its Associated Co-Morbidities in a Claims Database in the United States Andersson, M.
 2013
 16 7 p. A369-
1 p.
 artikel
825 Draft Versus Final Guidance in Nice’s Drug Technology Appraisal Process McGee, M.A.
 2013
 16 7 p. A484-
1 p.
 artikel
826 Drivers of Clinician Prescribing Decisions and the Economics of Information Parkinson, B.
 2013
 16 7 p. A471-
1 p.
 artikel
827 Driving After Drinking: Hospitalization, Mortality Rate, and Costs Pre and Post Prohibition in Rio De Janeiro, Brazil Fernandes, R.A.
 2013
 16 7 p. A719-
1 p.
 artikel
828 Drug Compliance and Persistence in Patients with Parkinson’s Disease Treated in Primary Care in the United Kingdom: A CPRD-Based Study Bineau, S.
 2013
 16 7 p. A628-A629
nvt p.
 artikel
829 Drug Distribution Strategies Cost in Brazil Carraro, W.H.
 2013
 16 7 p. A675-
1 p.
 artikel
830 Drug Treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in Austria Hinteregger, M.
 2013
 16 7 p. A543-
1 p.
 artikel
831 Dual Back Translation Versus Single Back-Translation Methodology When Translating Patient Reported Outcomes (PRO) Talbert, M.
 2013
 16 7 p. A596-
1 p.
 artikel
832 Dynamic Modeling of Vector-Borne Diseases (VBD): The Example of Malaria Snedecor, S.J.
 2013
 16 7 p. A712-
1 p.
 artikel
833 Dynamic Modeling to Estimate the Economic Impact of Increasing Influenza Vaccination in the United States Inocencio, T.J.
 2013
 16 7 p. A348-
1 p.
 artikel
834 Dynamic Network Model of Clostridium Difficile Infection to Evaluate Treatment Interventions and Costs Zowall, H.
 2013
 16 7 p. A363-
1 p.
 artikel
835 Dynamics of Quality of Life in Children with Cystic Fibrosis Aged 5-16 Years Simonova, O.
 2013
 16 7 p. A625-
1 p.
 artikel
836 Early Life Determinants of Metabolic Syndrome and Diabetes Mellitus in South Asian Population Living in Europe: A Systematic Review Callejo, D.
 2013
 16 7 p. A434-A435
nvt p.
 artikel
837 Early Response to Certolizumab Pegol in Rheumatoid Arthritis Predicts Outcome at One Year Berenbaum, F.
 2013
 16 7 p. A556-
1 p.
 artikel
838 Early-Stage Economic Evaluation of Stratified Medicine in Multiple Myeloma Gaultney, J.G.
 2013
 16 7 p. A417-
1 p.
 artikel
839 Easing Decision-Making by Expanding Methods of Multiple Treatment Comparison Meta-Analysis – Incorporating Non-Comparative Studies Via Informative Priors Thorlund, K.
 2013
 16 7 p. A577-
1 p.
 artikel
840 Economic Activity of Cancer Survivors in Poland Macioch, T.
 2013
 16 7 p. A417-A418
nvt p.
 artikel
841 Economical Justification of the Innovation Method of Laboratory Diagnostic of the Structural and Functional Changes of Serum Albumin in Septic Complications (Ata-Test) Vorobiev, P.
 2013
 16 7 p. A364-
1 p.
 artikel
842 Economical Losses Due to Disablementparents Carring for Children with Oncohematological Diseases Ganieva, D.
 2013
 16 7 p. A429-A430
nvt p.
 artikel
843 Economic Analysis of Protease Inhibitors in First-Line Haart in Adult Patients with HIV Avxentyeva, M.
 2013
 16 7 p. A356-A357
nvt p.
 artikel
844 Economic Analysis of the Prevention of Medical Sharps Injuries with Safety-Engineered Devices: A Systematic Review Barnett, G.S.
 2013
 16 7 p. A455-
1 p.
 artikel
845 Economic Analysis of Use of Harmonic Devices in Inpatient Laparoscopic Cholecystectomy in the United States Cheng, H.
 2013
 16 7 p. A495-
1 p.
 artikel
846 Economic and Quality-Of-Life Burden of Moderate to Severe Irritable Bowel Syndrome with Constipation (IBS-C) in Spain: Interim Analysis of the IBIS-C Study Mearin, F.
 2013
 16 7 p. A500-
1 p.
 artikel
847 Economic Burden in Direct Costs of Chronic Obstructive Pulmonary Disease (COPD) in Turkey: A Payor Perspective Malhan, S.
 2013
 16 7 p. A370-
1 p.
 artikel
848 Economic Burden of Axial Spondyloarthritis Related to Paid Work and Household Productivity at Baseline in the Rapid-axSpA Study: Differences and Similarities Between Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis van der Heijde, D.
 2013
 16 7 p. A566-
1 p.
 artikel
849 Economic Burden of Coronary Heart Disease in the Patients Attending National Heart Center, Kathmandu, Nepal Dangi, A.
 2013
 16 7 p. A705-
1 p.
 artikel
850 Economic Burden of Inpatient Post-Admission Dehydration – Retrospective Database Analysis in Us Pash, E.
 2013
 16 7 p. A675-
1 p.
 artikel
851 Economic Burden of Patients with Painful Diabetic Neuropathy in Europe: A Systematic Literature Review Alleman, C.J.M.
 2013
 16 7 p. A381-
1 p.
 artikel
852 Economic Burden of Toxicities Associated with Advanced Melanoma Treatments in France, Italy, the Netherlands, and Spain Bilir, S.P.
 2013
 16 7 p. A405-A406
nvt p.
 artikel
853 Economic Burden of Toxicities Associated with Advanced Melanoma Treatments in the United States Bilir, S.P.
 2013
 16 7 p. A406-
1 p.
 artikel
854 Economic Burden of Venous Thromboemoblism Across Patient Populations: A Literature Review Claflin, A.B.
 2013
 16 7 p. A519-
1 p.
 artikel
855 Economic Consequences of Nonalcoholic Steatohepatitis in the United States Lin, F.
 2013
 16 7 p. A496-
1 p.
 artikel
856 Economic Evaluation of an Electrical Impedance Spectroscopy (EIS) Device Used as an Adjunct to Colposcopy Bessey, A.
 2013
 16 7 p. A407-
1 p.
 artikel
857 Economic Evaluation of an Urine Closed Collection System Versus a Traditional Open Device in Non-Pregnant Women Cardona, D.P.
 2013
 16 7 p. A670-
1 p.
 artikel
858 Economic Evaluation of Apixaban for the Prevention of Stroke in Atrial Fibrillation in the Netherlands Stevanovic, J.
 2013
 16 7 p. A529-A530
nvt p.
 artikel
859 Economic Evaluation of Ceftobiprole Compared to a Combination of Linezolid with Ceftazidime in the Management of Hospitalised Pneunomia in Scotland van der Scheer, F.W.
 2013
 16 7 p. A358-
1 p.
 artikel
860 Economic Evaluation of Collagenase Versus Hydrogel Dressings for Chronic-Wound Treatment from the Public Payer Perspective Tolentino, A.C.
 2013
 16 7 p. A704-
1 p.
 artikel
861 Economic Evaluation of Direct Acting Antiviral (DAA) Treatments for Hepatitis C Virus (HCV) Infection in Previously Treated Patients from the Peruvian Health Care System Perspective Ariza, J.G.
 2013
 16 7 p. A693-
1 p.
 artikel
862 Economic Evaluation of Enhanced Asthma Management: A Systematic Review Yong, Y.V.
 2013
 16 7 p. A377-
1 p.
 artikel
863 Economic Evaluation of Epoetin Alfa Hexal (Binocrit) Compared to Darbepoetin Alfa (Aranesp) in the Treatment of Chemotherapy Induced Anemia (CIA) in Germany Turner, M.
 2013
 16 7 p. A399-
1 p.
 artikel
864 Economic Evaluation of Epoetin Alfa Hexal (Binocrit) Compared to Darbepoetin Alfa (Aranesp) in the Treatment of Chronic Haemodialysis (CKD5) Patients in Germany Turner, M.
 2013
 16 7 p. A631-
1 p.
 artikel
865 Economic Evaluation of Fidaxomicin for the Treatment of Clostridium Difficile Infections (CDI) also known as C. Difficile-Associated Diarrhoea (CDAD) in Ireland Van Engen, A.
 2013
 16 7 p. A353-
1 p.
 artikel
866 Economic Evaluation of Fluoroquinolone-Based Regimens for the Treatment of Community-Acquired Pneumonia in a Multi-Field Hospital in Russia Kozlov, R.S.
 2013
 16 7 p. A358-
1 p.
 artikel
867 Economic Evaluation of Fulvestrant 500 Mg Versus Generic Non-Steroidal Aromatase Inhibitors in Patients with Advanced Breast Cancer in Norway Ekman, M.
 2013
 16 7 p. A414-
1 p.
 artikel
868 Economic Evaluation of HPV Vaccination Program in South Korea Kim, J.
 2013
 16 7 p. A416-
1 p.
 artikel
869 Economic Evaluation of Insulin Lispro Mix 25 with Glargine in the Treatment of Type 2 Diabetes Mellitus Patients in the Mexican Public Health Care System in Mexico Carlos, F.
 2013
 16 7 p. A690-
1 p.
 artikel
870 Economic Evaluation of Intravenous Iodinated Contrast Media in Italy Iannazzo, S.
 2013
 16 7 p. A468-
1 p.
 artikel
871 Economic Evaluation of Ivabradine for Chronic Heart Failure NYHA II to IV Class with Systolic Dysfunction in Ireland Lacey, L.
 2013
 16 7 p. A527-
1 p.
 artikel
872 Economic Evaluation of Ivabradine in Chronic Heart Failure in Greece Kourlaba, G.
 2013
 16 7 p. A524-
1 p.
 artikel
873 Economic Evaluation of Liraglutide for Treatment of Type 2 Diabetes Mellitus in the Russian Federation Yagudina, R.
 2013
 16 7 p. A443-
1 p.
 artikel
874 Economic Evaluation of Mandibular Advancement Device to Treat Obstructive Sleep Apnea Giannopoulou, A.
 2013
 16 7 p. A373-
1 p.
 artikel
875 Economic Evaluation of Nasogastric Hydration Versus Intravenous Hydration for Infants with Bronchiolitis: A Randomised Trial Murphy, B.
 2013
 16 7 p. A710-
1 p.
 artikel
876 Economic Evaluation of Pharmacological Treatments for Overactive Bladder Posnett, J.
 2013
 16 7 p. A633-
1 p.
 artikel
877 Economic Evaluation of Ranibuzumab for the Treatment of Myopic Choroidal Neovascularization in Canada Lee, A.
 2013
 16 7 p. A506-
1 p.
 artikel
878 Economic Evaluation of Sitagliptin in Diabetes Mellitus Treatment in China Chen, W.
 2013
 16 7 p. A443-
1 p.
 artikel
879 Economic Evaluation of the Impact of New Treatment Alternatives on Market Dynamics in Respiratory Diseases; A Case Study in Turkish Health Care System Kececioglu, S.
 2013
 16 7 p. A377-
1 p.
 artikel
880 Economic Evaluation of the Treatment Compliance in Patients with Parkinson’s Disease Received Different Preparations of Levodopa Ryazhenov, V.V.
 2013
 16 7 p. A623-
1 p.
 artikel
881 Economic Evaluation of Tips Compared to Large Volume Paracentesis in Patients with Refractory Ascites Burke, M.
 2013
 16 7 p. A496-
1 p.
 artikel
882 Economic Evaluation of Treatments for Chronic Hepatitis B Wiens, A.
 2013
 16 7 p. A715-
1 p.
 artikel
883 Economic Evaluation of Universal Antenatal HIV Screening Compared with Current “At Risk” Policy in Israel Chowers, M.
 2013
 16 7 p. A359-
1 p.
 artikel
884 Economic Evaluations of Varicella and Herpes Zoster Vaccination Programmes: A Systematic Review Damm, O.
 2013
 16 7 p. A358-
1 p.
 artikel
885 Economic Evidence of Surgical Procedures in Cancer: A Systematic Literature Review Ara, R.
 2013
 16 7 p. A411-
1 p.
 artikel
886 Economic Impact Associated with a Biological Therapy Prioritization Protocol in Rheumatoid Arthritis Patients in the Hospital of Sagunto Borrás-Blasco, J.
 2013
 16 7 p. A572-
1 p.
 artikel
887 Economic Impact Model of Lipegfilgastrim to Prevent Neutropenia in Cancer Patients in Spain Sánchez-de la Rosa, R.
 2013
 16 7 p. A402-
1 p.
 artikel
888 Economic Impact of a Smoking Cessation Program in Mexico: Enrolling Employees and Employers Huicochea-Bartelt, J.L.
 2013
 16 7 p. A373-
1 p.
 artikel
889 Economic Impact of Denosumab for Skeletal Related Event Prevention in Patients with Breast Cancer and Bone Metastasis from a United State Managed Care Organization Perspective Chen, K.
 2013
 16 7 p. A400-
1 p.
 artikel
890 Economic Impact of Denosumab for Skeletal Related Event Prevention in Patients with Prostate Cancer and Bone Metastasis from a United State Managed Care Organization Perspective Arellano, J.
 2013
 16 7 p. A398-A399
nvt p.
 artikel
891 Economic Impact of Improving the Accuracy of Blood Glucose Self-Monitoring on the Spanish Health Service Sanz-Granda, Á
 2013
 16 7 p. A432-
1 p.
 artikel
892 Economic Impact of Including Sequential Bevacizumab for the Treatment of Patients with Kirsten Ras Wild Type Unresectable Metastatic Colorectal Cancer in Four Latin American Countries Rautenberg, T.
 2013
 16 7 p. A684-
1 p.
 artikel
893 Economic Impact of Pruritus Among End-Stage Renal Disease Patients Receiving Hemodialysis Ramakrishnan, K
 2013
 16 7 p. A632-
1 p.
 artikel
894 Economic Impact of Stroke Episode in Patients Previous Diagnosed with Atrial Fibrillation in Private Health System in Brazil Araújo, G.
 2013
 16 7 p. A522-
1 p.
 artikel
895 Economic Impact of the Use of an Absorbable Adhesion Barrier in Preventing Adhesions Following Open Gynecologic Surgeries Roy, S.
 2013
 16 7 p. A331-
1 p.
 artikel
896 Economic Implications of Alternative Treatments and Care Locations for Acute Bacterial Skin and Skin Structure Infections with Suspected MRSA LaPensee, K.
 2013
 16 7 p. A350-
1 p.
 artikel
897 Economics of Dialysis Dependence Following Acute Kidney Injury (AKI) in the Intensive Care Unit (ICU) Ethgen, O.
 2013
 16 7 p. A631-
1 p.
 artikel
898 Editorial Board 2013
 16 7 p. IFC-
1 p.
 artikel
899 Efectividad Y Costo-Efectividad De La Fluoración Del Agua En La Prevención De Caries Dental Zaror, C.
 2013
 16 7 p. A696-
1 p.
 artikel
900 Efecto De La Determinación De La Concentración Capilar De Proteína C Reactiva En La Tasa De Prescripción De Antibióticos Para El Tratamiento De Infección De Vías Respiratorias Altas (Análisis De Costo-Efectividad) Mendez, G.F.
 2013
 16 7 p. A714-
1 p.
 artikel
901 Efecto Del Seguro Popular Salud Sobre La Demanda De Servicios Prenatales En El Contexto De La Cobertura Universal, México 2012 Servan-Mori, E.
 2013
 16 7 p. A670-A671
nvt p.
 artikel
902 Effectiveness and Cost Analysis of the Smoking Cessation Program in the Public Health System in Brazil Mendes, A.C.R.
 2013
 16 7 p. A724-
1 p.
 artikel
903 Effectiveness of Different Dosage Regimen of Pralidoxime in Organophosphorus Poisoning in Tertiary Care Hospital Thunga, G.
 2013
 16 7 p. A678-
1 p.
 artikel
904 Effectiveness of Montelukast on Asthma Control in Infants: Methodology of a Claims Data Study Belhassen, M.
 2013
 16 7 p. A367-
1 p.
 artikel
905 Effectiveness of the Early Psychosocial Intervention on Institutionalization of Patients with Mild Alzheimer’s Disease and Caregivers’ Quality of Life – An Alsova Study Martikainen, J.A.
 2013
 16 7 p. A618-A619
nvt p.
 artikel
906 Effect of Antiviral Treatment Rates on the Predicted Future Burden of Genotype-1 Chronic Hepatitis C in the United Kingdom Westerhout, K.Y.
 2013
 16 7 p. A342-
1 p.
 artikel
907 Effect of Health Spending, Income Inequality and Margination Index on the Efficiency of the Health System in Mexico Pinzon Florez, C.E.
 2013
 16 7 p. A666-A667
nvt p.
 artikel
908 Effect of Ivabradine on Thai Chronic Stable Angina Pectoris Patients Rojkajornnaphalai, S.
 2013
 16 7 p. A515-
1 p.
 artikel
909 Effect of Nurse-Led Medication Reviews in Psychiatric Patients – An Interventional Study Soerensen, A.L.
 2013
 16 7 p. A554-
1 p.
 artikel
910 Effect of Smoking Status on Health Care Costs and Resource Utilization in Patients with Chronic-Obstructive-Pulmonary-Disease in Clinical Practice: A Retrospective Nested Case-Control Economic Study Sicras-Mainar, A.
 2013
 16 7 p. A371-
1 p.
 artikel
911 Effects of Changing Health Policy on Pharmacoeconomics and Health Outcome Studies from 2000 to 2012 in Turkey Kockaya, G.
 2013
 16 7 p. A478-A479
nvt p.
 artikel
912 Effects of Claims-Based Rheumatoid Arthritis Severity on Biologic Therapy Use and Health Care Costs in Turkey Baser, O.
 2013
 16 7 p. A555-
1 p.
 artikel
913 Effects of Excess Use of Coronary Angiography and Its Association with Mortality Rates, Health Care Costs and Hospital Quality in Turkey Baser, O.
 2013
 16 7 p. A515-
1 p.
 artikel
914 Effects of the Occurrence of a First Cardiovascular Event on Statin Adherence in Type 2 Diabetes: A Matched Cohort Design de Vries, F.M.
 2013
 16 7 p. A532-A533
nvt p.
 artikel
915 Efficacy and Safety of Agomelatine in Depressed Thai Patients Including the Elderly Depressed Population Suraaroonsamrit, B.
 2013
 16 7 p. A542-
1 p.
 artikel
916 Efficacy and Safety of Belimumab for the Treatment of Systemic Lupus Erythematosus Borba, H.H.L.
 2013
 16 7 p. A725-A726
nvt p.
 artikel
917 Efficacy and Safety of New Anticoagulants in the Treatment of Atrial Fibrillation: A Health Technology Assessment Buehler, A.M.
 2013
 16 7 p. A667-
1 p.
 artikel
918 Efficacy and Safety of Pulmonary Veins Isolation with Cryo Technique Curnis, A.
 2013
 16 7 p. A699-
1 p.
 artikel
919 Efficacy and Safety of Treatments of Type 2 Diabetes Mellitus (T2DM): A Systematic Review (Slr) Pettré, S.
 2013
 16 7 p. A433-
1 p.
 artikel
920 Efficacy and Tolerability of CT-Guided Epidural Steroid Injections and Pharmacotherapy for Managing Chronic Low Back Ache with Radiculopathy Bansal, D.
 2013
 16 7 p. A727-
1 p.
 artikel
921 Efficacy of Brentuximab Vedotin and Other Treatments in Patients with Relapsed or Refractory (RR) Systemic Anaplastic Large-Cell Lymphoma (SALCL): A Systematic Review Bonthapally, V.
 2013
 16 7 p. A395-
1 p.
 artikel
922 Efficacy of Fingolimod in Delaying Confirmed Disability Progression in Patients Failing Prior Treatment: A Markov Model Application to Estimate Time to Disability Health States Bergvall, N.
 2013
 16 7 p. A618-
1 p.
 artikel
923 Efficacy of Inhaled Antibiotics in CF Patients with Chronic P. Aeruginosa Infection: A Network Meta-Analysis Janssen, K.J.
 2013
 16 7 p. A619-
1 p.
 artikel
924 Efficacy of Long-Acting Injectable Antipsychotic Therapies in Maintenance Treatment of Schizophrenia: A Mixed Treatment Comparison (MTC) of Double-Blind Randomized Clinical Trials Majer, I.M.
 2013
 16 7 p. A541-
1 p.
 artikel
925 Eficácia E Segurança De Ranibizumabe E Bevacizumabe No Tratamento De Degeneração Macular Relacionada a Idade Saturnino, L.T.M.
 2013
 16 7 p. A667-A668
nvt p.
 artikel
926 Eighty-Nine Local Roche Sponsored French Studies Performed in the Past 10 Years Were Evaluated to Determine How Patient Reported Outcomes Were Used Pau, D.
 2013
 16 7 p. A337-
1 p.
 artikel
927 Elicitation of Health-Related Quality of Life Concepts Associated with Overactive Bladder Hawken, N.A.
 2013
 16 7 p. A635-
1 p.
 artikel
928 Eliciting Patients’ Preferences for Epilepsy Diagnostics: A Discrete Choice Experiment Wijnen, B.F.M.
 2013
 16 7 p. A626-
1 p.
 artikel
929 Eliciting the Relative Importance of Key Elements for Benefit-Risk Assessment: A Comparison Among General Population, Health Authority and Medical Doctors Ha, J.H.
 2013
 16 7 p. A487-
1 p.
 artikel
930 EMA Approval of Drugs on the Basis of Pivotal Non-Comparative Phase II Trial Data Macaulay, R.
 2013
 16 7 p. A324-
1 p.
 artikel
931 Emerging Cardiovascular Events Associated with Targeted Anticancer Drugs. Preliminary Results of a Care Line’s Program Based on Audit Vigilance in a Private Health Care in Brazil Tanaka, E.
 2013
 16 7 p. A669-
1 p.
 artikel
932 Empirical Evidence for the Validity and Reliability of Resource-Use Measures Based on Patient Recall: A Systematic Review Thorn, J.
 2013
 16 7 p. A579-A580
nvt p.
 artikel
933 Empirical Therapy for Respiratory Tract Infections in an Era of Increasing Antimicrobial Resistance: A Decision and Cost Analysis Babela, R.
 2013
 16 7 p. A372-A373
nvt p.
 artikel
934 Enteral Diets (ED): A Cost-Comparison Analysis for In-Hospital Preparations Based on Real World Observation Clark, O.A.C.
 2013
 16 7 p. A495-
1 p.
 artikel
935 Epidemiological and Economic Impact of Chronic Kidney Disease in Patients with Hypertension and Diabetes in Colombia Carrasquilla-Sotomayor, M.
 2013
 16 7 p. A671-
1 p.
 artikel
936 Epidemiology and Economic Studies on Patients Diagnosed with Insomnia: A Review of the Literature Greene, N.
 2013
 16 7 p. A720-
1 p.
 artikel
937 Epidemiology for Oncological Drugs Regarding the Benefit Dossier Preparation in Germany Kürschner, N.
 2013
 16 7 p. A429-
1 p.
 artikel
938 Epidemiology, Treatment Outcomes and Costs of Treating Hepatitis C in Routine Care – Results from a Large Multicenter Trial Stahmeyer, J.T.
 2013
 16 7 p. A341-A342
nvt p.
 artikel
939 ePRO Migration and Usability Testing of Patient-Reported Outcome (PRO) Measures Wilkins, G.
 2013
 16 7 p. A597-
1 p.
 artikel
940 EQ-5D-5L Crosswalk Value Set for Poland Golicki, D.
 2013
 16 7 p. A599-
1 p.
 artikel
941 EQ-5D Utility Weights Associated with Response to Treatment with Matrix Applied Autologous Cultured Chondrocytes (MACI) Implant and Microfracture for Cartilage Defects of the Knee Saris, D.
 2013
 16 7 p. A556-
1 p.
 artikel
942 Essential Medicine List (Cuadro Básico) in México. Is It a Guideline for Decision Making on the Current and Future Health Needs? Lemus, A.
 2013
 16 7 p. A669-
1 p.
 artikel
943 Estimación De La Costo-Efectivadad Del Uso De Daptomicina Vs Vancomicina En Pacientes Con Bacteriemia Y/O Endocarditis Por S. Aureus Resistente a Meticilina Paula Micone, P.M.
 2013
 16 7 p. A714-
1 p.
 artikel
944 Estimación De La Prevalencia De Artritis Reumatoide En México Galindo-Suárez, R.M.
 2013
 16 7 p. A719-
1 p.
 artikel
945 Estimación Epidemiologica Del Cácer De Pulmón De Celulas No Pequeñas En México Peniche-Otero, G.
 2013
 16 7 p. A683-
1 p.
 artikel
946 Estimated Cost Effectiveness of Lower-Dose Submicron Diclofenac Compared with Traditional Diclofenac in Brazil Mladsi, D.M.
 2013
 16 7 p. A717-A718
nvt p.
 artikel
947 ESTIMATED COSTS OF HER2-POSITIVE METASTATIC BREAST CANCER FOR PATIENTS INITIATING AN ORAL ANTICANCER TREATMENT: RESULTS FROM A FRENCH PROSPECTIVE OBSERVATIONAL STUDY Woronoff-Lemsi, M.C.
 2013
 16 7 p. A405-
1 p.
 artikel
948 Estimated Osteoporotic Population and the Related Medication Consumption in Municipality Level – Discrepancies Observed Through Data Visualization Approach Säävuori, N.
 2013
 16 7 p. A557-
1 p.
 artikel
949 Estimates of Price and Income Elasticity in Greece: Greek Debt Crisis Transforming Cigarettes into a Luxury Good Tarantilis, F.
 2013
 16 7 p. A377-
1 p.
 artikel
950 Estimating and Modeling Long Term Survival in Lung Cancer Using Mixture Parametric Models Sánchez, L.
 2013
 16 7 p. A398-
1 p.
 artikel
951 Estimating Chronic Disease PREVALENCE from Claims Data: Reducing Bias by Accounting for Diseased Individuals Who Do Not Generate Claims Signorovitch, J.
 2013
 16 7 p. A609-
1 p.
 artikel
952 Estimating Health State Utilities for Patients with Relapsed/Refractory (R/R) Hodgkin Lymphoma (HL) and Systemic Anaplastic Large-Cell Lymphoma (sALCL) in Mexico and Brazil Shingler, S.
 2013
 16 7 p. A419-
1 p.
 artikel
953 Estimating Market Potential for Biosimilar Introduction Paglia, R.
 2013
 16 7 p. A472-
1 p.
 artikel
954 Estimating Prevalence of Prostate Cancer Clinical States Using a Dynamic Patient Progression Model Dass, R.N.
 2013
 16 7 p. A397-
1 p.
 artikel
955 Estimating the Association Between the Oxford Hip Score (OHS) and EQ-5D Utility Values Using Direct and Response Mapping Methods Rivero-Arias, O.
 2013
 16 7 p. A600-
1 p.
 artikel
956 Estimating the Budget Impact in Brazilian Public Health Care System of Tocilizumab Reimbursement As a Rheumatoid Arthritis First-Line Biological Therapy Tsuchiya, C.T.
 2013
 16 7 p. A715-
1 p.
 artikel
957 Estimating the Budget Impact of Adding Avastin (Bevacizumab) to Front Line Treatment for Advanced Ovarian Cancer in Brazilian Supplementary Health Care System Tsuchiya, C.T.
 2013
 16 7 p. A400-
1 p.
 artikel
958 Estimating the Budget Implications of Radium Ra 223 Dichloride in Castration-Resistant Prostate Cancer Patients with Non-Visceral Bone Metastases Treated in Infusion Centers in the United States Hansen, R.N.
 2013
 16 7 p. A400-
1 p.
 artikel
959 Estimating the Cardiovascular Benefits of DPP-4 Inhibitors: A Simulated Study Schuetz, C.A.
 2013
 16 7 p. A514-
1 p.
 artikel
960 Estimating the Cost Impact of Switching from a Vial to a Pre-Filled Syringe Mode of Administration for the DTaA-IPV-Hib ‘5-In-1’ Vaccine in Infants Kumar, G.
 2013
 16 7 p. A345-
1 p.
 artikel
961 Estimating the Cost of HPV-Related Diseases in Turkey: A Delphi Approach Bakir, M.
 2013
 16 7 p. A404-A405
nvt p.
 artikel
962 Estimating the Health Outcome of Treating Type 2 Diabetic Population to Target in Local Municipality Level Säävuori, N.
 2013
 16 7 p. A434-
1 p.
 artikel
963 Estimating the Impact of Endogenous Substance Abuse on Self-Reported Health Status Gu, N.Y.
 2013
 16 7 p. A607-
1 p.
 artikel
964 Estimating the Impact of Statin Therapy on Direct and Societal Costs in Mexico: A Comparison to Sweden Semilla, A.P.
 2013
 16 7 p. A707-A708
nvt p.
 artikel
965 Estimating the Social Distribution of Health in England Asaria, M.
 2013
 16 7 p. A602-
1 p.
 artikel
966 Estimation of Generic Utilities in Spanish Chronic Obstructive Pulmonary Disease Patients Miravitlles, M.
 2013
 16 7 p. A374-
1 p.
 artikel
967 Estimation of the Cost-Effectiveness of Apixaban in Non-Valvular Atrial Fibrillation in Argentina Giorgi, M.A.
 2013
 16 7 p. A666-
1 p.
 artikel
968 Estimation of the Cost of Complications Related to Glycated Hemoglobin in the Italian Diabetes Type 1 Population Nicolucci, A.
 2013
 16 7 p. A435-
1 p.
 artikel
969 Estimation of the Epidemiological and Economic Impact of the Quadrivalent HPV Vaccination in Girls and Boys in Spain Bosch, X.
 2013
 16 7 p. A407-A408
nvt p.
 artikel
970 Estimation of the Number of Cases of Nosocomial Pneumonia in Adults Caused by Gram-Positive Bacteria in Public Hospitals in Mexico Gryzbowski, E.
 2013
 16 7 p. A367-A368
nvt p.
 artikel
971 Estimation of the Number of Cases of Nosocomial Skin and Soft Tissue Infection in Adults Caused by Gram-Positive Bacteria in Public Hospitals in Mexico Gryzbowski, E.
 2013
 16 7 p. A342-
1 p.
 artikel
972 Estudio De Costo/Utilidad Del Tratamiento Habitual De La Artritis Reumatoidea Mas Etanercept Versus Tratamiento Habitual Más Otros Biológicos Del Mercado Chileno Y Versus Tratamiento Habitual Sin Biológicos Biagini, L.
 2013
 16 7 p. A718-
1 p.
 artikel
973 Estudios Del Coste De La Enfermedad Crespo, C.
 2013
 16 7 p. A699-A700
nvt p.
 artikel
974 Estudio Transversal Del Proceso De Actualización De Medicamentos En El Cuadro Básico Y Catálogo De Insumos Del Sector Salud Rizo Ríos, P.
 2013
 16 7 p. A670-
1 p.
 artikel
975 Etanercept 25 Mg Once Weekly Could Be a Cost-Effective Option for Rheumatology Patients in Sustained Clinical Remission Borrás-Blasco, J.
 2013
 16 7 p. A573-
1 p.
 artikel
976 Etanercept Provides Improved Quality of Life Regardless of the Presence of Psoriatric Arthritis in Moderate/Severe Psoriasis Subjects from Central and Eastern Europe, Latin America and Asia Kemeny, L.
 2013
 16 7 p. A509-
1 p.
 artikel
977 EU Payer and Decision Maker Use of Observational Studies for Health Care Reimbursement Decisions Hogue, S.
 2013
 16 7 p. A459-A460
nvt p.
 artikel
978 Evaluación Costo-Efectividad Y De Valor Social De Un Programa De Intervención En Población Infantil En Situación De Vulnerabilidad, Rezago O Déficit En El Desarrollo Integral - Chile 2012 Vallejos, C.
 2013
 16 7 p. A710-
1 p.
 artikel
979 Evaluación De Costo-Efectividad De Certolizumab Pegol Comparado Con Etanercept En El Tratamiento De Artritis Reumatoidea En Colombia Guzman, R.
 2013
 16 7 p. A717-
1 p.
 artikel
980 Evaluación De Costo-Efectividad De La Trabeculoplastia Láser Selectiva Como Primera Opción De Tratamiento En Glaucoma Primario De Ángulo Abierto En Colombia Bernal, M.M.
 2013
 16 7 p. A696-
1 p.
 artikel
981 Evaluación Económica Del Uso De Dos Tratamientos Farmacológicos En Degeneración Macular Relacionada Con La Edad De Tipo Exudativa (Dmre) Para Venezuela Romero, M.
 2013
 16 7 p. A697-
1 p.
 artikel
982 Evaluación Económica Del Uso De La Perfusión Aislada De Extremidad Con Tasonermia En Pacientes Con Sarcoma De Tejido Blando Irresecable Gay, J.G.
 2013
 16 7 p. A686-
1 p.
 artikel
983 Evaluate the Status of Pharmacoeconomic Research Development in China from 2002 to 2013 Chen, C.I.
 2013
 16 7 p. A471-
1 p.
 artikel
984 Evaluating Different Modes of Radiotherapy Based on a Patient-Level Simulation Model Quik, E.H.
 2013
 16 7 p. A580-
1 p.
 artikel
985 Evaluating Economic Burden of Tick-Borne Encephalitis. Evidence from Russia Avxentev, N.
 2013
 16 7 p. A347-A348
nvt p.
 artikel
986 Evaluating Fatigue in Fibromyalgia: Development and Validation of the Daily Diary of Fatigue Symptoms in Fibromyalgia (DFS-Fibro) Burbridge, C.
 2013
 16 7 p. A626-
1 p.
 artikel
987 Evaluating Overall Survival in Oncology Trials with Subsequent Therapies: A Methodological Review and Application in Non-Small Cell Lung Cancer Jonsson, L.
 2013
 16 7 p. A610-
1 p.
 artikel
988 Evaluating Patient Adherence Rates to Approved Disease Modifying Therapies (DMT) for Relapsing-Remitting Ms (RRMS): Operational Setup for a Multi-Country, Multi-Center Study Apecechea de Scheffer, M.
 2013
 16 7 p. A626-A627
nvt p.
 artikel
989 Evaluating the Burden of Bone Metastases (BM) on Patients with Castration-Resistant Prostate Cancer (CRPC) and Their Treating Physicians: Findings from a Routine Practice Study in 13 Medium-Sized European Countries Hechmati, G.
 2013
 16 7 p. A422-
1 p.
 artikel
990 Evaluating the Cost Effectiveness of Gene Expression Profiling and Immunohistochemistry Tests Rafia, R.
 2013
 16 7 p. A413-
1 p.
 artikel
991 Evaluating the Cost-Utility of Fenofibrate Treatment of Diabetic Retinopathy in Australia Valentine, W.J.
 2013
 16 7 p. A442-
1 p.
 artikel
992 Evaluating the Economic Impact of Technological Advances in Diagnostics: The Case of High Throughput Sequencing for Hereditary Breast Cancer Jacob, I.
 2013
 16 7 p. A617-
1 p.
 artikel
993 Evaluating the Efficacy of Biosimilar Infliximab with the ACR50 Response in Patients with Rheumatoid Arthritis; A Meta-Analysis in Bayesian Framework Brodszky, V.
 2013
 16 7 p. A556-
1 p.
 artikel
994 Evaluating Whether Inconsistencies Are Present in a Mixed Treatment Comparison of Trough Forced Expiratory Volume in 1 Second at 12 Weeks Buckley, F.
 2013
 16 7 p. A575-
1 p.
 artikel
995 Evaluating Willingness-To-Pay Threshold for Sugammadex Reversal of Rocuronium-Induced Neuromuscular Blockade: A Contingent Valuation Survey Song, H.J.
 2013
 16 7 p. A388-
1 p.
 artikel
996 Evaluation of Acute Pancreatitis Signals with Incretin Enhancers: Revisiting Disproportionality Analysis of the Adverse Event Reporting System Ali, A.K.
 2013
 16 7 p. A431-
1 p.
 artikel
997 Evaluation of a Process of Care Model for Open Intravesical Ureteral Reimplantation from a Contemporary Health Care Perspective Ellsworth, P.
 2013
 16 7 p. A636-
1 p.
 artikel
998 Evaluation of Associations Among Biomarkers, Correlates and Treatment Efficacy in Clinical Studies in Patients Diagnosed with Non-Psychotic Major Depressive Disorder: A Literature Review Greene, N.
 2013
 16 7 p. A694-
1 p.
 artikel
999 Evaluation of Dissemination of Brazilian Network for Health Technology Assessment (REBRATS) Gonçalves, L.
 2013
 16 7 p. A582-A583
nvt p.
 artikel
1000 Evaluation of Factors Affecting Treatment Response and Risk Factors for Patients Diagnosed with Non-Psychotic Major Depressive Disorder: A Literature Review Greene, N.
 2013
 16 7 p. A693-A694
nvt p.
 artikel
                             2104 gevonden resultaten
 
   volgende >>
 
 Koninklijke Bibliotheek - Nationale Bibliotheek van Nederland